Urea-containing agonists of orexin receptor type 2
Urea-containing compounds targeting Orexin receptor type 2 address the limitations of current treatments for narcolepsy and related disorders by providing high selectivity and improved drug-like properties, effectively treating conditions mediated by Ox2R signaling.
Patent Information
- Application Number
- PCT/US2024/036648
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-05
- Filing Date
- 2024-07-03
- Publication Date
- 2025-01-09
AI Technical Summary
Current treatments for narcolepsy and related sleep disorders, such as idiopathic hypersomnia and sleep apnea syndrome, lack effective compounds that selectively target orexin receptor type 2 (Ox2R) with high potency and favorable drug-like properties, including central nervous system penetration and pharmacokinetic profiles.
Development of urea-containing compounds with specific structural formulas that act as agonists or antagonists of Orexin receptor type 2, demonstrating high selectivity and improved drug-like properties, such as central nervous system penetration and favorable pharmacokinetic profiles, to treat conditions mediated by Ox2R signaling.
The described compounds effectively prevent or treat narcolepsy, idiopathic hypersomnia, and other hypersomnia-related disorders by selectively targeting Orexin receptor type 2, offering improved potency and drug-like properties that enhance treatment efficacy.
Smart Images

Figure IMGF000003_0001 
Figure IMGF000018_0001 
Figure IMGF000021_0001
Abstract
Description
UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority from U.S. Provisional Application No. 63 / 525,043, filed July 5, 2023, which is herein incorporated by reference in their entirety. FIELD OF THE INVENTION
[0002] This invention generally relates to compounds that function as agonists of orexin receptor type 2 (Ox2R), particularly urea-containing agonist compounds thereof, as well as methods of using such compounds for treating conditions or disorders associated with a deficiency in Ox2R signaling, e.g., narcolepsy, idiopathic hypersomnia, hypersomnia, and sleep apnea syndrome. BACKGROUND
[0003] Orexins are hypothalamic neuropeptides that are implicated in, for example, sleep / wake control and body weight homeostasis. The peptides act on two G protein-coupled receptors termed Orexin receptor type 1 (Ox1R) and Orexin receptor type 2 (Ox2R). Orexin producing neurons are exclusively localized in the lateral hypothalamic area, but their receptors are expressed in many areas of the brain.
[0004] Narcolepsy is a socially debilitating disorder characterized by an inability to properly maintain wakefulness (excessive daytime sleepiness, sleep attacks), and a pathological intrusion of signs of REM sleep into wakefulness (cataplexy, hypnagogic hallucination, sleep paralysis, etc). Narcolepsy affects an estimated 1 in every 2,000 individuals, and is a non-progressive, life- long condition. A deficiency in orexin / OX2R signaling causes the sleep disorder narcolepsy in humans, mice and dogs. A vast majority (>90%) of human narcoleptics lacks detectable levels of orexin peptides in the cerebrospinal fluid due to a highly specific (probably autoimmune) degeneration of orexin neurons, indicating that human narcolepsy is an “orexin deficiency syndrome.”SUMMARY
[0005] One aspect of the invention provides compounds, compositions, and methods useful for preventing or treating a disease which is at least partially mediated by orexin receptor 2, such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, and hypersomnia associated with dementia with Lewy body. It was surprisingly discovered that the compounds disclosed and claimed herein demonstrate, among other things, high potency and selectivity for Ox2R, and improved drug-like properties, such as central nervous system penetration (e.g., as determined by a MDR1-MDCK permeability assay) and a favorable pharmacokinetic profile.
[0006] Accordingly, provided herein is a compound having the structure of Formula (I): , or a deuteratedor prodrug thereof, wherein: A is phenyl or 5- or 6-membered heteroaryl; R1is halo, cyano, —(C═O)NR5R6, —NR5R6, — NR5(C═O)—R7,—(C═O)O—R7,(C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, or 4-7 membered heterocycloalkyl; wherein (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, and 4-7 membered heterocycloalkyl are optionally substituted with one or more of R9; n is 0, 1, or 2; R2is independently for each occurrence selected from halo, cyano, —(C═O)NR5R6, —(C═O)O—R7, —SO2—R7, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, and 4-7 membered heterocycloalkyl; wherein (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6- C10)aryl, and 4-7 membered heterocycloalkyl are optionally substituted with one or more of R10; or R1and an adjacent R2taken together form a fused carbocyclic or heterocyclic ring optionally substituted with one or more of R10;X and Y are each independently a bond, —NR8—, —C(═O)—, —OC(═O)—, —SO—, —SO2—, —S—, —O—, or methylene optionally substituted with one or more (C1-C6)alkyl; where (C1-C6)alkyl is optionally substituted with one or more R11; R3is hydrogen, hydroxy, halo, cyano, or (C1-C6)alkyl optionally substituted with one or more R12, R4is (C6-C10)aryl, 5- to 10-membered heteroaryl, (C3-C8)cycloalkyl, 4- to 7-membered heterocycloalkyl, or cyano; wherein (C6-C10)aryl, 5- to 10-membered heteroaryl (C3- C8)cycloalkyl, 4- to 7-membered heterocycloalkyl, and 5- to 10-membered heteroaryl are optionally substituted with one or more R13, or when Y is a bond, R3and R4together with the carbon to which they are attached form a (C3-C6) spirocarbocylic ring or a 4- to 10-membered saturated heterospirocyclic ring; wherein each is optionally substituted with optionally substituted with one or more R12; R5to R7are each independently hydrogen, halogen, or (C1-C6)alkyl optionally substituted with one or more R14; R8is hydrogen or (C1-C6)alkyl optionally substituted with one or more R15; R9is independently for each occurrence selected from halo, hydroxy, (C1-C6)alkyl optionally substituted with one or more R16, (C3-C8)cycloalkyl optionally substituted with one or more R16, and (C1-C6)alkoxy optionally substituted with one or more R16; or in the case where R1is cycloalkyl or heterocycloalkyl substituted with two R9groups, the two R9groups together with the atom or atoms to which they are attached taken together form a 3- to 8-membered carbocyclic or 3- to 8-membered heterocyclic ring, wherein each 3- to 8-membered carbocyclic or 3- to 8-membered heterocyclic ring is optionally substituted with one or more R16; R10to R15are independently for each occurrence selected from halo, hydroxy, (C1- C6)alkyl optionally substituted with one or more R16, (C3-C8)cycloalkyl optionally substituted with one or more R16, and (C1-C6)alkoxy optionally substituted with one or more R16; R16is independently for each occurrence halo, hydroxy, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkylalkyl, or (C1-C6)alkoxy; Z1is oxygen or sulfur; Z2is oxygen or —NH—; Z3is —CH—, a nitrogen, or a carbon; and represents a single bond or a double bond.
[0007] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
[0008] Other features, objects, and advantages of the invention will be apparent from the detailed description, and from the claims. DETAILED DESCRIPTION
[0009] Definitions
[0010] For convenience, before further description of the present invention, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and understood as by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.
[0011] In order for the present invention to be more readily understood, certain terms and phrases are defined below and throughout the specification.
[0012] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
[0013] The phrase “and / or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and / or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specificallyidentified by the “and / or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and / or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
[0014] As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating items in a list, “or” or “and / or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.
[0015] As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and / or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
[0016] It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
[0017] In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.
[0018] Certain compounds contained in compositions of the present invention may exist in particular geometric or stereoisomeric forms. In addition, polymers of the present invention may also be optically active. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
[0019] “Geometric isomer" means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon- carbon double bond may be in an E (substituents are on opposite sides of the carbon- carbon double bond) or Z (substituents are oriented on the same side) configuration. "R," "S," "S*," "R*," "E," "Z," "cis," and "trans," indicate configurations relative to the core molecule. Certain of the disclosed compounds may exist in “atropisomeric” forms or as “atropisomers.” Atropisomers are stereoisomers resulting from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers. The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from a mixture of isomers. Conventional resolution techniques include forming the salt of a free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization andregeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either a starting material or a final product using various well known chromatographic methods.
[0020] If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
[0021] Percent purity by mole fraction is the ratio of the moles of the enantiomer (or diastereomer) or over the moles of the enantiomer (or diastereomer) plus the moles of its optical isomer. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least about 60%, about 70%, about 80%, about 90%, about 99% or about 99.9% by mole fraction pure relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least about 60%, about 70%, about 80%, about 90%, about 99% or about 99.9% by mole fraction pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least about 60%, about 70%, about 80%, about 90%, about 99% or about 99.9% by mole fraction pure.
[0022] When a disclosed compound is named or depicted by structure without indicating the stereochemistry, and the compound has at least one chiral center, it is to be understood that the name or structure encompasses either enantiomer of the compound free from the corresponding optical isomer, a racemic mixture of the compound or mixtures enriched in one enantiomer relative to its corresponding optical isomer. When a disclosed compound is named or depicted bystructure without indicating the stereochemistry and has two or more chiral centers, it is to be understood that the name or structure encompasses a diastereomer free of other diastereomers, a number of diastereomers free from other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers in which one diastereomer is enriched relative to the other diastereomer(s) or mixtures of diastereomers in which one or more diastereomer is enriched relative to the other diastereomers. The invention embraces all of these forms.
[0023] Structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds produced by the replacement of a hydrogen with deuterium or tritium, or of a carbon with a13C- or14C-enriched carbon are within the scope of this invention.
[0024] The term “prodrug” as used herein encompasses compounds that, under physiological conditions, are converted into therapeutically active agents. A common method for making a prodrug is to include selected moieties that are hydrolyzed under physiological conditions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the host animal.
[0025] The phrase “pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ or portion of the body, to another organ or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, not injurious to the patient, and substantially non- pyrogenic. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol;(12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer’s solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations. In certain embodiments, pharmaceutical compositions of the present invention are non-pyrogenic, i.e., do not induce significant temperature elevations when administered to a patient.
[0026] The term “pharmaceutically acceptable salts” refers to the relatively non-toxic, inorganic and organic acid addition salts of the compound(s). These salts can be prepared in situ during the final isolation and purification of the compound(s), or by separately reacting a purified compound(s) in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like. (See, for example, Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19.)
[0027] In other cases, the compounds useful in the methods of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term “pharmaceutically acceptable salts” in these instances refers to the relatively non-toxic inorganic and organic base addition salts of a compound(s). These salts can likewise be prepared in situ during the final isolation and purification of the compound(s), or by separately reacting the purified compound(s) in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al., supra).
[0028] The term “pharmaceutically acceptable cocrystals” refers to solid coformers that do not form formal ionic interactions with the small molecule.
[0029] A “therapeutically effective amount” (or “effective amount”) of a compound with respect to use in treatment, refers to an amount of the compound in a preparation which, when administered as part of a desired dosage regimen (to a mammal, preferably a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, e.g., at a reasonable benefit / risk ratio applicable to any medical treatment.
[0030] The term “prophylactic or therapeutic” treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, (i.e., it protects the host against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
[0031] The term “patient” or “subject” refers to a mammal in need of a particular treatment. In certain embodiments, a patient is a primate, canine, feline, or equine. In certain embodiments, a patient is a human.
[0032] An aliphatic chain comprises the classes of alkyl, alkenyl and alkynyl defined below. A straight aliphatic chain is limited to unbranched (linear) carbon chain moieties. As used herein, the term “aliphatic group” refers to a straight chain, branched-chain, or cyclic aliphatic hydrocarbon group and includes saturated and unsaturated aliphatic groups, such as an alkyl group, an alkenyl group, or an alkynyl group.
[0033] “Alkyl” refers to a fully saturated cyclic or acyclic, branched or unbranched carbon chain moiety having the number of carbon atoms specified, or up to 30 carbon atoms if no specification is made. For example, alkyl of 1 to 8 carbon atoms refers to moieties such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl, and those moieties which are positional isomers of these moieties. Alkyl of 10 to 30 carbon atoms includes decyl, undecyl,dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, heneicosyl, docosyl, tricosyl and tetracosyl. In certain embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chains, C3-C30 for branched chains), and more preferably 20 or fewer. Alkyl groups may be substituted or unsubstituted.
[0034] As used herein, the term “heteroalkyl” refers to an alkyl moiety as hereinbefore defined which contain one or more oxygen, sulfur, nitrogen, phosphorus, or silicppon atoms in place of carbon atoms.
[0035] As used herein, the term “haloalkyl” refers to an alkyl group as hereinbefore defined substituted with at least one halogen.
[0036] As used herein, the term “hydroxyalkyl” refers to an alkyl group as hereinbefore defined substituted with at least one hydroxyl.
[0037] As used herein, the term “alkylene” refers to an alkyl group having the specified number of carbons, for example from 2 to 12 carbon atoms, that contains two points of attachment to the rest of the compound on its longest carbon chain. Non-limiting examples of alkylene groups include methylene -(CH2)-, ethylene -(CH2CH2)-, n-propylene -(CH2CH2CH2)-, isopropylene -(CH2CH(CH3))-, and the like. Alkylene groups can be cyclic or acyclic, branched or unbranched carbon chain moiety, and may be optionally substituted with one or more substituents.
[0038] "Cycloalkyl" means mono- or bicyclic or bridged or spirocyclic, or polycyclic saturated carbocyclic rings, each having from 3 to 12 carbon atoms. Preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 3-6 carbons in the ring structure. Cycloalkyl groups may be substituted or unsubstituted.
[0039] As used herein, the term “halocycloalkyl” refers to a cycloalkyl group as hereinbefore defined substituted with at least one halogen.
[0040] Unless the number of carbons is otherwise specified, “lower alkyl,” as used herein, means an alkyl group, as defined above, but having from one to ten carbons, more preferablyfrom one to six carbon atoms in its backbone structure such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. Likewise, “lower alkenyl” and “lower alkynyl” have similar chain lengths. Throughout the application, preferred alkyl groups are lower alkyls. In certain embodiments, a substituent designated herein as alkyl is a lower alkyl.
[0041] “Alkenyl” refers to any cyclic or acyclic, branched or unbranched unsaturated carbon chain moiety having the number of carbon atoms specified, or up to 26 carbon atoms if no limitation on the number of carbon atoms is specified; and having one or more carbon-carbon double bonds in the moiety. Alkenyl of 6 to 26 carbon atoms is exemplified by hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodenyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl, nonadecenyl, eicosenyl, heneicosoenyl, docosenyl, tricosenyl, and tetracosenyl, in their various isomeric forms, where the unsaturated bond(s) can be located anywhere in the moiety and can have either the (Z) or the (E) configuration about the double bond(s).
[0042] “Alkynyl” refers to any cyclic or acyclic, branched or unbranched unsaturated carbon chain moiety having the number of carbon atoms specified, or up to 26 carbon atoms if no limitation on the number of carbon atoms is specified, and having one or more carbon-carbon triple bonds in the moiety.
[0043] The term “aryl,” as used herein, includes 3- to 12-membered substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon (i.e., carbocyclic aryl). Preferably, aryl groups include 5- to 12-membered rings, more preferably 6- to 10-membered rings. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Some examples of aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
[0044] The term “heteroaryl,” as used herein, includes substituted or unsubstituted aromatic 3- to 12-membered ring structures, more preferably 5- to 12-membered rings, more preferably 5- to 10-membered rings, whose ring structures include one to four heteroatoms. Heteroaryl groups include, for example, pyrrole, imidazole, pyrazole, isothiazole, oxazole, isoxazole, pyridine,pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, thiophene, thiazole, triazole, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, and the like. Aryl and heteroaryl can be monocyclic, bicyclic, or polycyclic.
[0045] The term “halo”, “halide”, or “halogen” as used herein means halogen and includes, for example, and without being limited thereto, fluoro, chloro, bromo, iodo and the like, in both radioactive and non-radioactive forms. In a preferred embodiment, halo is selected from the group consisting of fluoro, chloro and bromo.
[0046] The terms “heterocyclyl” or “heterocyclic group” or “heterocycloalkyl” or “heterocyclic ring” or “cycloheteroalkyl” are herein considered synonymous and refer to saturated 3- to 12-membered ring structures, more preferably 5- to 12-membered rings, more preferably 5- to 10-membered rings, or more typically 4- to 8-membered rings, 4- to 7- membered, or 4- to 6-membered rings, whose ring structures include one, two, three, or four heteroatoms, wherein the heteroatoms typically include one or more of oxygen, sulfur, nitrogen, phosphorus, and / or silicon atoms (in place of carbon atoms). Heterocycles can be monocyclic, bicyclic, spirocyclic, or polycyclic. Heterocyclic groups include, for example, pyrrolidine, oxolane, thiolane, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring can be unsubstituted or substituted at one or more positions with such substituents as described above, such as, for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, sulfamoyl, sulfinyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF3, -CN, and the like.
[0047] The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound,e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxy, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. In preferred embodiments, the substituents on substituted alkyls are selected from C1-6 alkyl, C3-6 cycloalkyl, halogen, carbonyl, cyano, or hydroxyl. In more preferred embodiments, the substituents on substituted alkyls are selected from fluoro, carbonyl, cyano, or hydroxyl. It will be understood by those skilled in the art that substituents can themselves be substituted, if appropriate. Unless specifically stated as “unsubstituted,” references to chemical moieties herein are understood to include substituted variants. For example, reference to an “aryl” group or moiety implicitly includes both substituted and unsubstituted variants.
[0048] As used herein, the definition of each expression, e.g., alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
[0049] As used herein, “small molecules” refers to small organic or inorganic molecules of molecular weight below about 3,000 Daltons. In general, small molecules useful for the invention have a molecular weight of less than 3,000 Daltons (Da). The small molecules can be, e.g., from at least about 100 Da to about 3,000 Da (e.g., between about 100 to about 3,000 Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100 to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250 Da, about 100 to about 1,000 Da, about 100 toabout 750 Da, about 100 to about 500 Da, about 200 to about 1500, about 500 to about 1000, about 300 to about 1000 Da, or about 100 to about 250 Da).
[0050] In some embodiments, a “small molecule” refers to an organic, inorganic, or organometallic compound typically having a molecular weight of less than about 1000. In some embodiments, a small molecule is an organic compound, with a size on the order of 1 nm. In some embodiments, small molecule drugs of the invention encompass oligopeptides and other biomolecules having a molecular weight of less than about 1000.
[0051] An “effective amount” is an amount sufficient to effect beneficial or desired results. For example, a therapeutic amount is one that achieves the desired therapeutic effect. This amount can be the same or different from a prophylactically effective amount, which is an amount necessary to prevent onset of disease or disease symptoms. An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a composition depends on the composition selected. The compositions can be administered from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and / or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the compositions described herein can include a single treatment or a series of treatments.
[0052] The terms “decrease,” “reduce,” “reduced”, “reduction”, “decrease,” and “inhibit” are all used herein generally to mean a decrease by a statistically significant amount relative to a reference. However, for avoidance of doubt, “reduce,” “reduction” or “decrease” or “inhibit” typically means a decrease by at least 10% as compared to a reference level and can include, for example, a decrease by at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, up to and including, for example, the complete absence of the given entity or parameter ascompared to the reference level, or any decrease between 10-99% as compared to the absence of a given treatment.
[0053] The terms “increased”, “increase” or “enhance” or “activate” are all used herein to generally mean an increase by a statically significant amount; for the avoidance of any doubt, the terms “increased”, “increase” or “enhance” or “activate” means an increase of at least 10% as compared to a reference level, for example an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% increase or any increase between 10-100% as compared to a reference level, or at least about a 2-fold, or at least about a 3-fold, or at least about a 4-fold, or at least about a 5-fold or at least about a 10- fold increase, or any increase between 2-fold and 10-fold or greater as compared to a reference level.
[0054] As used herein, the term “modulate” includes up-regulation and down-regulation, e.g., enhancing or inhibiting a response.
[0055] A “radiopharmaceutical agent,” as defined herein, refers to a pharmaceutical agent which contains at least one radiation-emitting radioisotope. Radiopharmaceutical agents are routinely used in nuclear medicine for the diagnosis and / or therapy of various diseases. The radiolabelled pharmaceutical agent, for example, a radiolabelled antibody, contains a radioisotope (RI) which serves as the radiation source. As contemplated herein, the term “radioisotope” includes metallic and non-metallic radioisotopes. The radioisotope is chosen based on the medical application of the radiolabeled pharmaceutical agents. When the radioisotope is a metallic radioisotope, a chelator is typically employed to bind the metallic radioisotope to the rest of the molecule. When the radioisotope is a non-metallic radioisotope, the non-metallic radioisotope is typically linked directly, or via a linker, to the rest of the molecule.
[0056] For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.
[0058] Compounds of the Invention
[0059] One aspect of the invention relates to a compound of Formula (I): , or a deuteratedsalt, or a prodrug thereof, wherein: A is phenyl or 5- or 6-membered heteroaryl; R1is halo, cyano, —(C═O)NR5R6, —NR5R6, —NR5(C═O)—R7,— (C═O)O—R7, (C1- C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, or 4-7 membered heterocycloalkyl; wherein (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, and 4-7 membered heterocycloalkyl are optionally substituted with one or more of R9; n is 0, 1, or 2; R2is independently for each occurrence selected from halo, cyano, —(C═O)NR5R6, —(C═O)O—R7, —SO2—R7, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, and 4-7 membered heterocycloalkyl; wherein (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6- C10)aryl, and 4-7 membered heterocycloalkyl are optionally substituted with one or more of R10; or R1and an adjacent R2taken together form a fused carbocyclic or heterocyclic ring optionally substituted with one or more of R10; X and Y are each independently a bond, —NR8—, —C(═O)—, —OC(═O)—, —SO—, —SO2—, —S—, —O—, or methylene optionally substituted with one or more (C1-C6)alkyl; where (C1-C6)alkyl is optionally substituted with one or more R11; R3is hydrogen, hydroxy, halo, cyano, or (C1-C6)alkyl optionally substituted with one or more R12, R4is (C6-C10)aryl, 5- to 10-membered heteroaryl, (C3-C8)cycloalkyl, 4- to 7-membered heterocycloalkyl, or cyano; wherein (C6-C10)aryl, 5- to 10-membered heteroaryl (C3- C8)cycloalkyl, 4- to 7-membered heterocycloalkyl, and 5- to 10-membered heteroaryl are optionally substituted with one or more R13, orwhen Y is a bond, R3and R4together with the carbon to which they are attached form a (C3-C6) spirocarbocylic ring or a 4- to 10-membered saturated heterospirocyclic ring; wherein each is optionally substituted with optionally substituted with one or more R12; R5to R7are each independently hydrogen, halogen, or (C1-C6)alkyl optionally substituted with one or more R14; R8is hydrogen or (C1-C6)alkyl optionally substituted with one or more R15; R9is independently for each occurrence selected from halo, hydroxy, (C1-C6)alkyl optionally substituted with one or more R16, (C3-C8)cycloalkyl optionally substituted with one or more R16, and (C1-C6)alkoxy optionally substituted with one or more R16; or, in the case where R1is cycloalkyl or heterocycloalkyl substituted with two R9groups, the two R9groups together with the atom or atoms to which they are attached taken together form a 3- to 8-membered carbocyclic or 3- to 8-membered heterocyclic ring, wherein each 3- to 8-membered carbocyclic or 3- to 8-membered heterocyclic ring is optionally substituted with one or more R16; R10to R15are independently for each occurrence selected from halo, hydroxy, (C1-C6)alkyl optionally substituted with one or more R16, (C3-C8)cycloalkyl optionally substituted with one or more R16, and (C1-C6)alkoxy optionally substituted with one or more R16; R16is independently for each occurrence halo, hydroxy, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkylalkyl, or (C1-C6)alkoxy; Z1is oxygen or sulfur; Z2is oxygen or —NH—; Z3is —CH—, a nitrogen, or a carbon; and represents a single bond or a double bond.
[0060] In certain embodiments, A is phenyl.
[0061] In certain embodiments, A is 5- or 6-membered heteroaryl.
[0062] In certain embodiments, the 5- or 6-membered heteroaryl is pyridyl, pyrimidinyl, pyridazinyl, or pyrazinyl.
[0063] In certain embodiments, the heterocycloalkyl is piperidinyl, piperazinyl, 1,2,3,6- tetrahydropyridine, pyrrolidinyl, azepanyl, or 1,4-diazepanyl.
[0064] In certain embodiments, R1is substituted with one or more of R9; wherein R9is independently for each occurrence fluoro, chloro, hydroxy, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1- C6)alkoxy, (C1-C4)haloalkyl, or (C3-C8)cycloalkyl)alkyl; or two R9together with the atom or atoms to which they are attached taken together form a 3- to 6-membered carbocyclic or 3- to 6- membered heterocyclic ring comprising 1 to 3 oxygen or nitrogen atoms, optionally substituted with one or more (C1-C6)alkyl. In the case where R1is cycloalkyl or heterocycloalkyl substituted with two R9groups, the two R9groups together with the atom or atoms to which they are attached taken together form a 3- to 8-membered carbocyclic or 3- to 8-membered heterocyclic ring, wherein each 3- to 8-membered carbocyclic or 3- to 8-membered heterocyclic ring is optionally substituted with one or more R16. When the two R9groups emanate from a single atom on the cycloalkyl or heterocycloalkyl ring, the interconnection of the two R9groups results in a spiro ring system. When the two R9groups emanate from two different atoms on the cycloalkyl or heterocycloalkyl ring, the interconnection of the two R9groups results in a bicyclic fused ring system. R1may also be (C6-C10)aryl substituted with two R9groups that are interconnected to result in a bicyclic fused ring system containing a (C6-C10)aryl (e.g., phenyl) as one of the rings.
[0065] In certain embodiments, at least one R9is (C1-C6)alkyl.
[0066] In certain embodiments, R1is: , ,R1independent selection of R2, R3, R4, A, X, Y, Z1, Z2, Z3, and m variables, as provided in this disclosure, to arrive at a compound within the scope of Formula (I).
[0067] In certain certain Incertain certain .
[0068] In certain is fluoro, chloro, or cyano.
[0069] In certain embodiments, R1is (C1-C4)alkyl.
[0070] In certain embodiments, R1is cyclopropyl.
[0071] In certain embodiments, R1is optionally substituted phenyl.
[0072] In certain embodiments, R1is optionally substituted heteroaryl.
[0073] In certain embodiments, R1is oxadiazole optionally substituted with one or more (C1- C4)alkyl.
[0074] In certain embodiments, n is 1 or 2.
[0075] In certain embodiments, n is 1 or 2, and R1and an adjacent R2taken together form a fused carbocyclic or heterocyclic ring of the following formula:, 0 or 1.
[0076] In certain embodiments, R1and an adjacent R2taken together form a fused heterocyclic ring of the following formula:n is 1.
[0078] In certain embodiments, at least one R2is fluoro, chloro, or cyano. In certain embodiments, n is 1 and R2is cyano.
[0079] In certain embodiments, at least one R2is optionally-substituted (C1-C6)alkyl, optionally substituted (C3-C8)cycloalkyl, or optionally substituted (C1-C6)alkoxy.
[0080] In certain embodiments, (C1-C6)alkyl, (C3-C8)cycloalkyl, or (C1-C6)alkoxy is optionally substituted with one or more fluorine.
[0081] In certain embodiments, m is 0. In other embodiments, m is 1.
[0082] In certain embodiments, X is a bond or —O—.
[0083] In certain embodiments, Y is a bond or —O—.
[0084] In certain embodiments, R3is (C1-C6)alkyl optionally substituted with one or more fluorine.
[0085] In certain embodiments, R3is methyl. In other embodiments, R3is trifluoromethyl.
[0086] In certain embodiments, R4is optionally substituted 5- to 10-membered heteroaryl.
[0087] In certain embodiments, R4is: , wherein A4is oxygen or sulfur; and R13is (C3-C8)cycloalkyl or (C3-C8)cycloalkoxy substituted with one or more substituents selected from halo, (C1-C6)alkyl, and (C1-C6)alkoxy.
[0088] In certain embodiments, A4is oxygen.
[0089] In certain embodiments, R13is (C3-C8)cycloalkyl substituted with one or more halogen.
[0090] In certain embodiments, R13.
[0091] In certain embodiments, Y is a bond or —O—.
[0092] In certain embodiments, Z1is oxygen.
[0093] In certain embodiments, Z2is —NH—.
[0094] In certain embodiments, Z3is nitrogen.
[0095] In some embodiments, Z1is oxygen, Z2is —NH—, and Z3is nitrogen.
[0096] In some embodiments, the disclosure relates to a compound of Formula (I-A), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof:
[0097] In some embodiments, the disclosure relates to a compound of Formula (I-B), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ,
[0098] In some embodiments, the disclosure relates to a compound of Formula (I-C), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ,are as defined above.
[0099] In some embodiments, the disclosure relates to a compound of Formula (I-D), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ,wherein all other variables are as defined above.
[0100] In some embodiments, the disclosure relates to a compound of Formula (I-A-1), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof:), wherein all other variables are defined as above. sclosure relates to a compound of Formula (I-B-1), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ,above.
[0102] In some embodiments, the disclosure relates to a compound of Formula (I-C-1), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ,are as above.
[0103] In some embodiments, the disclosure relates to a compound of Formula (I-D-1), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ,wherein all other variables are as defined above.
[0104] In some embodiments, the disclosure relates to a compound of Formula (I-A-2), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ,above.
[0105] In some embodiments, the disclosure relates to a compound of Formula (I-B-2), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ,above.
[0106] In some embodiments, the disclosure relates to a compound of Formula (I-C-2), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ,wherein all other variables are as defined above.
[0107] In some embodiments, the disclosure relates to a compound of Formula (I-D-2), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof:), ed above.
[0108] In some embodiments, the disclosure relates to a compound of Formula (I-A-3), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ONF R3R1X ,
[0109] In some embodiments, the disclosure relates to a compound of Formula (I-B-3), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ONF R3R1,wherein all other variables are as defined above.
[0110] In some embodiments, the disclosure relates to a compound of Formula (I-C-3), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: N R3R1,wherein all other variables are as defined above.
[0111] In some embodiments, the disclosure relates to a compound of Formula (I-D-3), or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof: ONF R3R1N X ,
[0112] In certain embodiments, for any of the above .
[0113] In some embodiments, for any of the above .
[0114] In some embodiments, for any of the aboveembodiments, for any of the above In some embodiments, for anyof the above .
[0115] In some embodiments, for any of the above formulas, R1is pyridine optionally substituted with one or more R9.
[0116] In certain embodiments, for any of the above formulas, X is a bo .
[0117] In some embodiments, for any of the above formulas, X is a .
[0118] In some embodiments, for any of the above formulas, X is a. In some embodiments, for any of the above formulas, X is a bond and R1is . In some embodiments, for any of the above formulas, X is a bond and R1is .
[0119] In some embodiments, for any of the above formulas, X is a bond and R1is pyridine optionally substituted with one or more R9.
[0120] In some embodiments, for any of the above formulas, R2is halo, cyano or (C1- C3)alkyl, wherein the (C1-C3)alkyl is optionally substituted with one or more of R10. In some embodiments, for any of the above formulas, R2is halo. In some embodiments, for any of the above formulas, R2 is chloro. In some embodiments, for any of the above formulas, R2 is cyano. In some embodiments, for any of the above formulas, R2 is (C1-C2)alkyl substituted with one or more R10, wherein R10is halo. In some embodiments, for any of the above formulas, R2is -CHF2.
[0121] In certain embodiments, the compound is selected from the following Table 1:Table 1. Exemplary compounds of the present disclosure. Compou nd #Structure IUPAC NameN-(2-chloro-6-cyanophenyl)-4-(5- 1 ((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-cyano-6-(4- 2 isopropylpiperazin-1-yl)phenyl)-4- methyl-4-(pyridin-2- yloxy)piperidine-1-carboxamideN-(2,6-dichlorophenyl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-cyclopropyl-6-(4- isopropylpiperazin-1-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-fluoro-6-(1-isopropyl-1,2,3,6- tetrahydropyridin-4-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamideN-(2-fluoro-6-(1- isopropylpiperidin-4-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-(((R)-1- (cyclopropylmethyl)pyrrolidin-3- yl)oxy)-6-fluorophenyl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-N-(2-(4- isopropylpiperazin-1-yl)pyridin-3- yl)-4-methylpiperidine-1- carboxamideN-(2,6-diisopropylphenyl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-cyano-6-isopropylphenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-cyano-6-fluorophenyl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-cyano-6-methoxyphenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-N-(2-(4- isopropylpiperazin-1-yl)-6- methylphenyl)-4-methylpiperidine- 1-carboxamide 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-N-(3-(4- isopropylpiperazin-1-yl)pyridin-4- yl)-4-methylpiperidine-1- carboxamide N-(2-chloro-6-(4- isopropylpiperazin-1-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-N-(4-(4- isopropylpiperazin-1-yl)pyridin-3- yl)-4-methylpiperidine-1- carboxamide 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-N-(2-(4- isopropylpiperazin-1-yl)-6- (trifluoromethyl)phenyl)-4- methylpiperidine-1-carboxamide N-(3-cyano-[1,1'-biphenyl]-2-yl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamideN-(2-cyano-6-(4- isopropylpiperazin-1-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-N-(2-(4- isopropylpiperazin-1-yl)phenyl)-4- methylpiperidine-1-carboxamide 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-N-(3-(4- isopropylpiperazin-1-yl)pyridin-2- yl)-4-methylpiperidine-1- carboxamideN-(2-fluoro-6-(4- isopropylpiperazin-1-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-chloro-6-(4-isopropyl-1,4- diazepan-1-yl)phenyl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-N-(2-(4- isopropylpiperazin-1-yl)-6- methoxyphenyl)-4- methylpiperidine-1-carboxamideN-(2-(difluoromethyl)-6-(4- isopropylpiperazin-1-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-cyano-6-cyclopropylphenyl)- 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(4-chloro-2-cyano-6-(4- isopropylpiperazin-1-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamideN-(2-chloro-4-(4- isopropylpiperazin-1-yl)pyridin-3- yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamide N-(2-chloro-6-(4- isopropylpiperazin-1-yl)phenyl)-4- (2-chlorophenyl)-4- methylpiperidine-1-carboxamide N-(2-chloro-6-(4- isopropylpiperazin-1-yl)phenyl)-4- (4-chlorophenyl)-4- methylpiperidine-1-carboxamide4-(4-chlorophenyl)-N-(2-cyano-6- isopropylphenyl)-4- methylpiperidine-1-carboxamide N-(2-chloro-6-cyclopropylphenyl)- 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-fluoro-6-(5-isopropyl-1,2,4- oxadiazol-3-yl)phenyl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamideN-(2-(((S)-1- (cyclopropylmethyl)pyrrolidin-3- yl)oxy)-6-fluorophenyl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(4-cyano-2-(1-isopropylpiperidin- 4-yl)pyridin-3-yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamide N-(4-cyano-2-((R)-3- isopropoxypyrrolidin-1-yl)pyridin- 3-yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamide N-(2-cyano-6-(2,3- dihydrobenzo[b][1,4]dioxin-6- yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamideMixture of 2 diastereomers N-(4-cyano-2-(1-(1,1,1- trifluoropropan-2-yl)piperidin-4- yl)pyridin-3-yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamide N-(2-cyano-4-(1-((1- (trifluoromethyl)cyclopropyl)methy l)piperidin-4-yl)pyridin-3-yl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4-methylpiperidine- 1-carboxamide N-(2-cyano-6-(6- cyclopropylpyridin-3-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-(azepan-1-yl)-4-cyanopyridin- 3-yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamideMixture of 2 diastereomers N-(2-cyano-6-(4- oxaspiro[2.5]octan-6-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-cyano-6-(1-isopropylpiperidin- 4-yl)phenyl)-3H- spiro[isobenzofuran-1,4'- piperidine]-1'-carboxamide Mixture of 2 diastereomers N-(2-cyano-6-(1,1- dioxidotetrahydro-2H-thiopyran-3- yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamide N-(2-chloro-6-((R)-3- isopropoxypyrrolidin-1-yl)phenyl)- 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamideN-(2-cyano-6-(2-ethylpyrimidin-5- yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamide N-(2-cyano-6-(5,6-dihydro-4H- pyrrolo[1,2-b]pyrazol-3-yl)phenyl)- 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-cyano-6-(7-methoxy-1H- indol-2-yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamide Mixture of 2 diastereomers N-(4-cyano-2-(6-oxa-2- azaspiro[4.5]decan-2-yl)pyridin-3- yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamideN-(2-cyano-6-(6-cyclobutylpyridin- 3-yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamide N-(2-cyano-4-(4-isopropyl-1H- 1,2,3-triazol-1-yl)pyridin-3-yl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-cyano-6-(quinolin-7- yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamide N-(2-(benzo[d]thiazol-5-yl)-6- cyanophenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamideN-(2-(5-chloro-1-methyl-1H- pyrazol-4-yl)-6-cyanophenyl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4-methylpiperidine- 1-carboxamide N-(2-cyano-6-(6- cyclopropylpyridin-3-yl)phenyl)-4- methyl-4-phenylpiperidine-1- carboxamide N-(2-cyano-6-(6- cyclopropylpyridin-3-yl)phenyl)-4- (2-methyl-2H-tetrazol-5- yl)piperidine-1-carboxamide N-(2-cyano-6-(spiro[2.5]octan-6- yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamideMixture of 2 diastereomers N-(2-(bicyclo[3.1.0]hexan-3-yl)-6- cyanophenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1- carboxamide N-(2-cyano-6-(2- oxaspiro[3.3]heptan-6-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide Mixture of 2 diastereomers N-(2-cyano-6-(5- oxaspiro[3.5]nonan-8-yl)phenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(2-cyano-6-cycloheptylphenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamideN-(2-cyano-6-(1-methyl-2-oxo-1,2- dihydropyridin-4-yl)phenyl)-4-(5- 62 ((1S,2S)-2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4-methylpiperidine- 1-carboxamide Mixture of 2 diastereomers N-(2-cyano-6-(pentan-2-yl)phenyl)- 63 4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide N-(3-cyano-3'-methoxy-2',4'- dimethyl-[1,1'-biphenyl]-2-yl)-4-(5- 64 ((1S,2S)-2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4-methylpiperidine- 1-carboxamide or a deuterated derivative, pharmaceutically acceptable salt, or prodrug of any of the compounds shown in Table 1. In some embodiments, one or more specific compounds disclosed in Table 1 may be excluded from any formula disclosed herein (e.g., Formulas I, I-A, I-B, I-C, I-D, I-A-1, I-A-2, I-A-3, I-B-1, I-B-2, I-B-3, I-C-1, I-C-2, I-C-3, I-D-1, I-D-2, and I-D-3).
[0122] In certain embodiments, the compound is selected from the following Table 2:Table 2. Exemplary compounds of the present disclosure. Compoun d#Structure IUPAC NameN-(4-cyano-2-(1- isopropylpiperidin-4- yl)pyridin-3-yl)-4-(5-((1S,2S)- 35 2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4- methylpiperidine-1- carboxamide N-(4-cyano-2-((R)-3- isopropoxypyrrolidin-1- yl)pyridin-3-yl)-4-(5-((1S,2S)- 36 2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4- methylpiperidine-1- carboxamide N-(2-cyano-6-(6- cyclopropylpyridin-3- yl)phenyl)-4-(5-((1S,2S)-2- 40 fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4- methylpiperidine-1- carboxamideN-(2-chloro-6-((R)-3- isopropoxypyrrolidin-1- yl)phenyl)-4-(5-((1S,2S)-2- 45 fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4- methylpiperidine-1- carboxamide or a deuterated derivative, pharmaceutically acceptable salt, or prodrug of any of the compounds shown in Table 2.
[0123] In certain embodiments, the compounds are atropisomers. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds produced by the replacement of a hydrogen with deuterium or tritium, or of a carbon with a13C- or14C- enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention. For example, in the case of variable R1, the (C1-C4)alkyl or the -O-(C1- C4)alkyl can be suitably deuterated (e.g., -CD3, -OCD3).
[0124] Any compound of the invention can also be radiolabeled for the preparation of a radiopharmaceutical agent.
[0125] For the avoidance of doubt, this disclosure is directed to compounds disclosed herein (e.g., Formulas (I), (I-A), (I-B), (I-C), (I-D), (I-A-1), (I-A-2), (I-A-3), (I-B-1), (I-B-2), (I-B-3), (I-C-1), (I-C-2), (I-C-3), (I-D-1), (I-D-2), and / or (I-D-3)) and the compounds described in Table 1 and Table 2, deuterated derivatives of those compounds, and pharmaceutically acceptable salts or prodrugs thereof. In some embodiments, the disclosure is directed to compounds disclosed herein (e.g., Formulas (I), (I-A), (I-B), (I-C), (I-D), (I-A-1), (I-A-2), (I-A-3), (I-B-1), (I-B-2), (I- B-3), (I-C-1), (I-C-2), (I-C-3), (I-D-1), (I-D-2), and / or (I-D-3)) and the compounds described in Table 1 and Table 2 and / or pharmaceutically acceptable salts thereof. In other embodiments, the disclosure is directed to compounds disclosed herein (e.g., Formulas (I), (I-A), (I-B), (I-C), (I-D), (I-A-1), (I-A-2), (I-A-3), (I-B-1), (I-B-2), (I-B-3), (I-C-1), (I-C-2), (I-C-3), (I-D-1), (I-D-2), and(I-D-3)) and the compounds described in Table 1 and Table 2. In yet other embodiments, the disclosure is directed to non-salt forms of the compounds disclosed herein (e.g., Formulas (I), (I- A), (I-B), (I-C), (I-D), (I-A-1), (I-A-2), (I-A-3), (I-B-1), (I-B-2), (I-B-3), (I-C-1), (I-C-2), (I-C- 3), (I-D-1), (I-D-2), and / or (I-D-3)) and the compounds described in Table 1 and Table 2.
[0126] Methods of Treatment
[0127] One aspect of the invention provides compounds, compositions, and methods useful for preventing or treating a disease which is at least partially mediated by orexin receptor 2. In certain embodiment, the compounds act as agonists of orexin receptor 2. In other embodiments, the compounds act as antagonists of orexin receptor 2.
[0128] Another aspect of the invention relates to methods of preventing or treating a disease selected from the group consisting of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptom, hypersomnia associated with Parkinson's disease, hypersomnia associated with dementia with Lewy body, hypersomnia syndrome involving daytime hypersomnia (e.g. Kleine-Levin syndrome, major depression accompanied by hypersomnia, dementia with Lewy body, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, brain contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, acute disseminated encephalomyelitis, Guillain-Barre syndrome, Rasmussen's encephalitis, Wernicke's encephalopathy, limbic encephalitis, Hashimoto encephalopathy), coma, loss of consciousness, obesity (e.g. malignant mast cell, extrinsic obesity, hyperinsulinar obesity, hyperplasmic obesity, hypophysial obesity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, childhood obesity, upper body obesity, alimentary obesity, gonadal obesity, systemic mastocytosis, primary obesity, central obesity), insulin resistance syndrome, Alzheimer, impaired consciousness such as coma, side effect or complication caused by anesthesia, sleep disturbance, sleep problem, insomnia, intermittent sleep, night myoclonus, REM sleep interruption, jet lag, jet lag syndrome, sleep disorder of shift workers, dyssomnia, sleep terror, depression, major depression, sleepwalking, enuresis, sleep disorder, Alzheimer's sundown syndrome, disease associated with circadian rhythm, fibromyalgia, condition resulting from decrease in sleeping quality, bulimia, obsessiveeating disorder, obesity-related diseases, hypertension, diabetes, elevated plasma insulin level / insulin resistance, hyperlipemia, hyperlipidaemia, endometrial cancer, breast cancer, prostate cancer, colon cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstone, heart disease, abnormal heartbeat, arrhythmia, myocardial infarction, congestive heart failure, heart failure, coronary heart disease, cardiovascular disease, sudden death, polycystic ovary, craniopharyngioma, Prader Willi syndrome, Froehlich syndrome, growth hormone deficiency, normal variant short stature, Turner syndrome, children suffering from acute lymphoblastic leukemia, syndrome X, reproductive hormone abnormality, decrease of fecundability, infertility, hypogonadism in men, sexual / reproductive-function dysfunction such as hirsutism in women, fetal defect associated with maternity obesity, gastrointestinal motility disorder such as obesity-related gastroesophageal reflux, obesity hypoventilation syndrome (Pickwickian syndrome), respiratory disease such as respiratory distress, inflammation such as vascular systemic inflammation, arteriosclerosis, hypercholesterolemia, hyperuricemia, low back pain, gallbladder disease, gout, renal cancer, secondary risk of obesity such as risk of left ventricle hypertrophy, migraine, headache, neuropathic pain, Parkinson's disease, psychosis, schizophrenia, facial flushing, night sweat, disease in genitalium / urinary system, disease associated with sexual function or fecundability, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, posttraumatic stress disorder, separation anxiety disorder, social phobia, anxiety disorder, acute neurological and psychiatric disorder such as cerebral deficiency developed after heart bypass surgery or heart transplant, stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head injury, periparturient hypoxia, cardiac arrest, hypoglycemic nerve injury, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, eye damage, retinopathy, cognitive impairment, muscle spasm, tremor, epilepsy, disorder associated with muscle spasm, delirium, amnestic disorder, age-associated cognitive decline, schizoaffective disorder, paranoia, drug addiction, movement disorder, chronic fatigue syndrome, fatigue, medication-induced parkinsonian syndrome, Gilles de la Tourette syndrome, chorea, myoclonus, tic, restless legs syndrome, dystonia, dyskinesia, attention deficit hyperactivity disorder (ADHD), conduct disorder, urinary incontinence, withdrawal symptom, trigeminal neuralgia, hearing loss, tinnitus, nerve injury, retinopathy, macular degeneration, vomiting, cerebral edema, pain, bone pain, arthralgia,toothache, cataplexy, and traumatic brain injury, in a subject in need thereof comprising administering to the subject an effective amount of any compound disclosed in this application, such as any of those within the scope of Formula I, I-A, I-B, I-C, I-D, I-A-1, I-A-2, I-A-3, I-B-1, I-B-2, I-B-3, I-C-1, I-C-2, I-C-3, I-D-1, I-D-2, or I-D-3, including deuterated derivatives, pharmaceutically acceptable salts, and prodrugs thereof.
[0129] In certain embodiments, the invention relates to methods of treating or preventing a disease selected from the group consisting of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, and hypersomnia associated with dementia with Lewy body in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I).
[0130] In certain embodiments, the disease being treated or prevented is narcolepsy, and a compound, deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof described herein is administered. In particular embodiments, the disease being treated or prevented is narcolepsy type 1.
[0131] In certain embodiments, the disease being treated or prevented is idiopathic hypersomnia, and a compound, deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof described herein is administered.
[0132] In certain embodiments, the disease being treated or prevented is narcolepsy.
[0133] In certain embodiments, the disease being treated or prevented is idiopathic hypersomnia.
[0134] In certain embodiments, the disease being treated or prevented is hypersomnia.
[0135] In certain embodiments, the disease being treated or prevented is sleep apnea syndrome.
[0136] In certain embodiments, the disease being treated or prevented is narcolepsy syndrome involving narcolepsy-like symptoms.
[0137] In certain embodiments, the disease being treated or prevented is hypersomnia associated with Parkinson's disease.
[0138] In certain embodiments, the disease being treated or prevented is hypersomnia associated with dementia with Lewy body.
[0139] In some embodiments, the compound is administered orally to the subject to treat or prevent the disease.
[0140] In some embodiments, the compound is administered parenterally to the subject to treat or prevent the disease.
[0141] In certain embodiments, the disease is prevented. In other embodiments, the disease is treated.
[0142] In some embodiments of any one of the above disclosed methods, the compound of Formula (I) is defined as: , or a deuteratedor prodrug thereof, wherein: A is phenyl or 5- or 6-membered heteroaryl; R1is halo, cyano, —(C═O)NR5R6, —NR5R6, — NR5(C═O)—R7,— (C═O)O—R7, (C1- C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, or 4-7 membered heterocycloalkyl; wherein (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, and 4-7 membered heterocycloalkyl are optionally substituted with one or more of R9; n is 0, 1, or 2; R2is independently for each occurrence selected from halo, cyano, —(C═O)NR5R6, — (C═O)O—R7, —SO2—R7, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, and 4-7 membered heterocycloalkyl; wherein (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6- C10)aryl, and 4-7 membered heterocycloalkyl are optionally substituted with one or more of R10; orR1and an adjacent R2taken together form a fused carbocyclic or heterocyclic ring optionally substituted with one or more of R10; X and Y are each independently a bond, —NR8—, —C(═O)—, —OC(═O)—, —SO—, —SO2—, —S—, —O—, or methylene optionally substituted with one or more (C1-C6)alkyl; where (C1-C6)alkyl is optionally substituted with one or more R11; R3is hydrogen, hydroxy, halo, cyano, or (C1-C6)alkyl optionally substituted with one or more R12, R4is (C6-C10)aryl, 5- to 10-membered heteroaryl, (C3-C8)cycloalkyl, 4- to 7-membered heterocycloalkyl, or cyano; wherein (C6-C10)aryl, 5- to 10-membered heteroaryl (C3- C8)cycloalkyl, 4- to 7-membered heterocycloalkyl, and 5- to 10-membered heteroaryl are optionally substituted with one or more R13, or when Y is a bond, R3and R4together with the carbon to which they are attached form a (C3-C6) spirocarbocylic ring or a 4- to 10-membered saturated heterospirocyclic ring; wherein each is optionally substituted with optionally substituted with one or more R12; R5to R7are each independently hydrogen, halogen, or (C1-C6)alkyl optionally substituted with one or more R14; R8is hydrogen or (C1-C6)alkyl optionally substituted with one or more R15; R9is independently for each occurrence selected from halo, hydroxy, (C1-C6)alkyl optionally substituted with one or more R16, (C3-C8)cycloalkyl optionally substituted with one or more R16, and (C1-C6)alkoxy optionally substituted with one or more R16; or two R9together with the atom or atoms to which they are attached taken together form a 3- to 8-membered carbocyclic or 3- to 8-membered heterocyclic ring, wherein each is optionally substituted with one or more R16; R10to R15are independently for each occurrence selected from halo, hydroxy, (C1-C6)alkyl optionally substituted with one or more R16, (C3-C8)cycloalkyl optionally substituted with one or more R16, and (C1-C6)alkoxy optionally substituted with one or more R16; R16is independently for each occurrence halo, hydroxy, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkylalkyl, or (C1-C6)alkoxy; Z1is oxygen or sulfur; Z2is oxygen or —NH—; Z3is —CH—, a nitrogen, or a carbon; andrepresents a single bond or a double bond.
[0143] In certain embodiments of any one of the disclosed methods, the compound of Formula (I), (I-A), (I-B), (I-C), (I-D), (I-A-1), (I-A-2), (I-A-3), (I-B-1), (I-B-2), (I-B-3), (I-C-1), (I-C-2), (I-C-3), (I-D-1), (I-D-2), and (I-D-3) is a compound of Table 1.
[0144] In certain embodiments, the compound of Formula (I) activates orexin receptor 2 in the subject. In some embodiments, the compound of Formula (I) is an agonist of orexin receptor 2. In other embodiments, the compound of Formula (I) inhibits orexin receptor 2 in the subject.
[0145] Pharmaceutical Compositions, Routes of Administration, and Dosing
[0146] In certain embodiments, the invention is directed to a pharmaceutical composition, comprising a compound of the invention, e.g. a compound of Formula (1), and a pharmaceutically acceptable carrier. The compound of the invention in the pharmaceutical composition may be any compound disclosed in this application or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof.
[0147] In certain embodiments, the invention is directed to a pharmaceutical composition, comprising a compound of any of the disclosed embodiments, and a pharmaceutically acceptable carrier.
[0148] In certain embodiments, the invention is directed to a pharmaceutical composition, comprising a compound of Table 1 (or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof), and a pharmaceutically acceptable carrier.
[0149] In certain embodiments, the pharmaceutical composition comprises a plurality of compounds of the invention and a pharmaceutically acceptable carrier.
[0150] In certain embodiments, a pharmaceutical composition of the invention further comprises at least one additional pharmaceutically active agent other than a compound of the invention. The at least one additional pharmaceutically active agent can be an agent useful in the treatment of ischemia-reperfusion injury.
[0151] Pharmaceutical compositions of the invention can be prepared by combining one or more compounds of the invention with a pharmaceutically acceptable carrier and, optionally, one or more additional pharmaceutically active agents.
[0152] As stated above, an “effective amount” refers to any amount that is sufficient to achieve a desired biological effect. Combined with the teachings provided herein, by choosing among the various active compounds and weighing factors such as potency, relative bioavailability, patient body weight, severity of adverse side-effects and mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial unwanted toxicity and yet is effective to treat the particular subject. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular compound of the invention being administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular compound of the invention and / or other therapeutic agent without necessitating undue experimentation. A maximum dose may be used, that is, the highest safe dose according to some medical judgment. Multiple doses per day may be contemplated to achieve appropriate systemic levels of compounds. Appropriate systemic levels can be determined by, for example, measurement of the patient’s peak or sustained plasma level of the drug. “Dose” and “dosage” are used interchangeably herein.
[0153] In certain embodiments, intravenous administration of a compound may typically be from 0.1 mg / kg / day to 20 mg / kg / day. In one embodiment, intravenous administration of a compound may typically be from 0.1 mg / kg / day to 2 mg / kg / day. In one embodiment, intravenous administration of a compound may typically be from 0.5 mg / kg / day to 5 mg / kg / day. In one embodiment, intravenous administration of a compound may typically be from 1 mg / kg / day to 20 mg / kg / day. In one embodiment, intravenous administration of a compound may typically be from 1 mg / kg / day to 10 mg / kg / day.
[0154] Generally, daily oral doses of a compound will be, for human subjects, from about 0.01 milligrams / kg per day to 1000 milligrams / kg per day. It is expected that oral doses in the range of 0.5 to 50 milligrams / kg, in one or more administrations per day, will yield therapeutic results. Dosage may be adjusted appropriately to achieve desired drug levels, local or systemic,depending upon the mode of administration. For example, it is expected that intravenous administration would be from one order to several orders of magnitude lower dose per day. In the event that the response in a subject is insufficient at such doses, even higher doses (or effective higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of the compound.
[0155] For any compound described herein the therapeutically effective amount can be initially determined from animal models. A therapeutically effective dose can also be determined from human data for compounds which have been tested in humans and for compounds which are known to exhibit similar pharmacological activities, such as other related active agents. Higher doses may be required for parenteral administration. The applied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.
[0156] The formulations of the invention can be administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.
[0157] For use in therapy, an effective amount of the compound can be administered to a subject by any mode that delivers the compound to the desired surface. Administering a pharmaceutical composition may be accomplished by any means known to the skilled artisan. Routes of administration include but are not limited to intravenous, intramuscular, intraperitoneal, intravesical (urinary bladder), oral, subcutaneous, direct injection (for example, into a tumor or abscess), mucosal (e.g., topical to eye), inhalation, and topical.
[0158] For intravenous and other parenteral routes of administration, a compound of the invention can be formulated as a lyophilized preparation, as a lyophilized preparation of liposome-intercalated or -encapsulated active compound, as a lipid complex in aqueoussuspension, or as a salt complex. Lyophilized formulations are generally reconstituted in suitable aqueous solution, e.g., in sterile water or saline, shortly prior to administration.
[0159] For oral administration, the compounds can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers, e.g., EDTA for neutralizing internal acid conditions or may be administered without any carriers.
[0160] Also specifically contemplated are oral dosage forms of the above component or components. The component or components may be chemically modified so that oral delivery of the derivative is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, where said moiety permits (a) inhibition of acid hydrolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the component or components and increase in circulation time in the body. Examples of such moieties include: polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. Abuchowski and Davis, “Soluble Polymer- Enzyme Adducts”, In: Enzymes as Drugs, Hocenberg and Roberts, eds., Wiley-Interscience, New York, N.Y., pp. 367-383 (1981); Newmark et al., J Appl Biochem 4:185-9 (1982). Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. For pharmaceutical usage, as indicated above, polyethylene glycol moieties are suitable.
[0161] For the component (or derivative) the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art has available formulations which will not dissolve in the stomach, yet will release the material in the duodenum or elsewhere in the intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the compound of the invention (or derivative) or by release of the biologically active material beyond the stomach environment, such as in the intestine.
[0162] To ensure full gastric resistance a coating impermeable to at least pH 5.0 can be employed. Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and shellac. These coatings may be used as mixed films.
[0163] A coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This can include sugar coatings, or coatings which make the tablet easier to swallow. Capsules may consist of a hard shell (such as gelatin) for delivery of dry therapeutic (e.g., powder); for liquid forms, a soft gelatin shell may be used. The shell material of cachets could be thick starch or other edible paper. For pills, lozenges, molded tablets or tablet triturates, moist massing techniques can be used.
[0164] The therapeutic can be included in the formulation as fine multi-particulates in the form of granules or pellets of particle size about 1 mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.
[0165] Colorants and flavoring agents may all be included. For example, the compound of the invention (or derivative) may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.
[0166] One may dilute or increase the volume of the therapeutic with an inert material. These diluents could include carbohydrates, especially mannitol, α-lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.
[0167] Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrates include but are not limited to starch, including the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.
[0168] Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.
[0169] An anti-frictional agent may be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.
[0170] Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.
[0171] To aid dissolution of the therapeutic into the aqueous environment a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents which can be used and can include benzalkonium chloride and benzethonium chloride. Potential non- ionic detergents that could be included in the formulation as surfactants include lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the compound of the invention or derivative either alone or as a mixture in different ratios.
[0172] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and / or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.
[0173] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
[0174] For topical administration, the compound may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art. Systemic formulations include those designed for administration by injection, e.g., subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal oral or pulmonary administration.
[0175] For administration by inhalation, compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide orother suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
[0176] Also contemplated herein is pulmonary delivery of the compounds disclosed herein (or salts thereof). The compound is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream. Other reports of inhaled molecules include Adjei et al., Pharm Res 7:565-569 (1990); Adjei et al., Int J Pharmaceutics 63:135-144 (1990) (leuprolide acetate); Braquet et al., J Cardiovasc Pharmacol 13(suppl. 5):143-146 (1989) (endothelin-1); Hubbard et al., Annal Int Med 3:206-212 (1989) (α1-antitrypsin); Smith et al., 1989, J Clin Invest 84:1145-1146 (a-1-proteinase); Oswein et al., 1990, "Aerosolization of Proteins", Proceedings of Symposium on Respiratory Drug Delivery II, Keystone, Colorado, March, (recombinant human growth hormone); Debs et al., 1988, J Immunol 140:3482-3488 (interferon-gamma and tumor necrosis factor alpha) and Platz et al., U.S. Pat. No. 5,284,656 (granulocyte colony stimulating factor; incorporated by reference). A method and composition for pulmonary delivery of drugs for systemic effect is described in U.S. Pat. No. 5,451,569 (incorporated by reference), issued Sep. 19, 1995 to Wong et al.
[0177] Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
[0178] Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Mo.; the Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colo.; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Mass.
[0179] All such devices require the use of formulations suitable for the dispensing of the compounds of the invention. Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usualdiluents, adjuvants and / or carriers useful in therapy. Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated. Chemically modified compound of the invention may also be prepared in different formulations depending on the type of chemical modification or the type of device employed.
[0180] Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise a compound of the invention (or derivative) dissolved in water at a concentration of about 0.1 to 25 mg of biologically active compound of the invention per mL of solution. The formulation may also include a buffer and a simple sugar (e.g., for inhibitor stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the compound of the invention caused by atomization of the solution in forming the aerosol.
[0181] Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the compound of the invention (or derivative) suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.
[0182] Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing compound of the invention (or derivative) and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation. The compound of the invention (or derivative) should advantageously be prepared in particulate form with an average particle size of less than 10 micrometers (µm), most preferably 0.5 to 5 µm, for most effective delivery to the deep lung.
[0183] Nasal delivery of a pharmaceutical composition of the present invention is also contemplated. Nasal delivery allows the passage of a pharmaceutical composition of the present invention to the blood stream directly after administering the therapeutic product to the nose,without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextran.
[0184] For nasal administration, a useful device is a small, hard bottle to which a metered dose sprayer is attached. In one embodiment, the metered dose is delivered by drawing the pharmaceutical composition of the present invention solution into a chamber of defined volume, which chamber has an aperture dimensioned to aerosolize and aerosol formulation by forming a spray when a liquid in the chamber is compressed. The chamber is compressed to administer the pharmaceutical composition of the present invention. In a specific embodiment, the chamber is a piston arrangement. Such devices are commercially available.
[0185] Alternatively, a plastic squeeze bottle with an aperture or opening dimensioned to aerosolize an aerosol formulation by forming a spray when squeezed is used. The opening is usually found in the top of the bottle, and the top is generally tapered to partially fit in the nasal passages for efficient administration of the aerosol formulation. Preferably, the nasal inhaler will provide a metered amount of the aerosol formulation, for administration of a measured dose of the drug.
[0186] The compounds, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi- dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents.
[0187] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also containsuitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
[0188] Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0189] The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
[0190] In addition to the formulations described above, a compound may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
[0191] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
[0192] Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and / or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer R, Science 249:1527-33 (1990).
[0193] The compound of the invention and optionally other therapeutics may be administered per se (neat) or in the form of a pharmaceutically acceptable salt or cocrystal. When used inmedicine the salts or cocrystals should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts or cocrystals may conveniently be used to prepare pharmaceutically acceptable salts or cocrystals thereof. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.
[0194] Suitable buffering agents include: acetic acid and a salt (1-2% w / v); citric acid and a salt (1-3% w / v); boric acid and a salt (0.5-2.5% w / v); and phosphoric acid and a salt (0.8-2% w / v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w / v); chlorobutanol (0.3-0.9% w / v); parabens (0.01-0.25% w / v) and thimerosal (0.004-0.02% w / v).
[0195] Pharmaceutical compositions of the invention contain an effective amount of a compound as described herein (or a deuterated derivative, pharmaceutically acceptable salt, or prodrug thereof) and optionally therapeutic agents included in a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carrier” means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a human or other vertebrate animal. The term “carrier” denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficiency.
[0196] The therapeutic agent(s), including specifically but not limited to a compound of the invention, may be provided in particles. Particles as used herein means nanoparticles or microparticles (or in some instances larger particles) which can consist in whole or in part of the compound of the invention or the other therapeutic agent(s) as described herein. The particles may contain the therapeutic agent(s) in a core surrounded by a coating, including, but not limited to, an enteric coating. The therapeutic agent(s) also may be dispersed throughout the particles. The therapeutic agent(s) also may be adsorbed into the particles. The particles may be of anyorder release kinetics, including zero-order release, first-order release, second-order release, delayed release, sustained release, immediate release, and any combination thereof, etc. The particle may include, in addition to the therapeutic agent(s), any of those materials routinely used in the art of pharmacy and medicine, including, but not limited to, erodible, nonerodible, biodegradable, or nonbiodegradable material or combinations thereof. The particles may be microcapsules which contain the compound of the invention in a solution or in a semi-solid state. The particles may be of virtually any shape.
[0197] Both non-biodegradable and biodegradable polymeric materials can be used in the manufacture of particles for delivering the therapeutic agent(s). Such polymers may be natural or synthetic polymers. The polymer is selected based on the period of time over which release is desired. Bioadhesive polymers of particular interest include bioerodible hydrogels described in Sawhney H S et al. (1993) Macromolecules 26:581-7, the teachings of which are incorporated herein. These include polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate).
[0198] The therapeutic agent(s) may be contained in controlled release systems. The term “controlled release” is intended to refer to any drug-containing formulation in which the manner and profile of drug release from the formulation are controlled. This refers to immediate as well as non-immediate release formulations, with non-immediate release formulations including but not limited to sustained release and delayed release formulations. The term “sustained release” (also referred to as “extended release”) is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period. The term “delayed release” is used in its conventional sense to refer to a drug formulation in which there is a time delay between administration of the formulation and the release of the drug there from. “Delayed release” may or may not involve gradual release of drug over an extended period of time, and thus may or may not be “sustained release.”
[0199] Use of a long-term sustained release implant may be particularly suitable for treatment of chronic conditions. “Long-term” release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for at least 7 days, and preferably 30-60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above.
[0200] It will be understood by one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the compositions and methods described herein are readily apparent from the description of the invention contained herein in view of information known to the ordinarily skilled artisan, and may be made without departing from the scope of the invention or any embodiment thereof. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included herewith for purposes of illustration only and are not intended to be limiting of the invention. EXAMPLES
[0201] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
[0202] Example 1. Synthesis of Urea Containing Compounds
[0203] Provided herein is the synthesis of Compound 1: N-(2-chloro-6-cyanophenyl)-4-{5- [(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide. Scheme 1:Synthesis of N-(2-chloro-6-cyanophenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3- yl}-4-methylpiperidine-1-carboxamide To a stirred solution of 2-amino-3-chlorobenzonitrile (100 mg, 0.655 mmol, 1 equiv) in DCM (10 mL) was added triphosgene (58.34 mg, 0.197 mmol, 0.3 equiv) inportions at 0°C. The resulting mixture was stirred for 1h at rt under nitrogen atmosphere, then triethylamine (198.96 mg, 1.965 mmol, 3 equiv) was added to the reaction at 0°C under nitrogen atmosphere and stirred for 1h at rt. After adding 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine (75 mg, 0.333 mmol, 0.51 equiv) and triethylamine (198.96 mg, 1.965 mmol, 3 equiv) at 0°C, the reaction was stirred for 1h at rt. The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC using a XBridge Prep OBD C18 Column 30 x 150 mm x 5μm column (eluent: 25% to 39% (v / v) ACN and H2O with 10 mmol / L NH4HCO3) to give the N-(2-chloro-6- cyanophenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1- carboxamide (33.3 mg, 6.02% yield) as a white solid. MS (ESI): mass calcd. for C19H19ClFN5O2: 403.12 m / z, found 404.20 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.66 – 7.79 (m, 2H), 7.31 – 7.40 (m, 1H), 7.22 (s, 1H), 4.93 – 5.17 (m, 1H), 3.79 – 3.89 (m, 2H), 3.17 – 3.28 (m, 2H), 2.41 – 2.52 (m, 1H), 2.20 – 2.30 (m, 2H), 1.70 – 1.94 (m, 3H), 1.48 – 1.62 (m, 1H), 1.35 (s, 3H).19F NMR (376 MHz, CD3CN) δ -220.46. Provided herein is the synthesis of Compound 2: N-[2-cyano-6-(4-isopropylpiperazin-1-y l)phenyl]-4-methyl-4-(pyridin-2-yloxy)piperidine-1-carboxamide.Scheme 2: SynthesisTo a solution of tert-butyl 4-hydroxy-4-methylpiperidine-1-carboxylate (500 mg, 2.322 mmol, 1 equiv) in DMF (5 mL) was added NaH (111.47 mg, 4.644 mmol, 2.0 equiv) at 0oC. After stirred for 30 min, 2-fluoropyridine (338.23 mg, 3.483 mmol, 1.5 equiv) was added to the mixture, and the reaction was stirred at 30°C for additional one hour. The reaction was quenched with water (10 mL) and extracted with EA (20 mL x 3). The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to provide the crude product, which was purified by column chromatography on silica gel with EA / PE (0-70%) to give tert-butyl 4-methyl-4-(pyridin-2-yloxy)piperidine-1-carboxylate (500 mg, 73.63% yield) as yellow solid. MS (ESI): mass calcd. for C16H24N2O3: 292.37 m / z, found 293.15 [M+H]+. Synthesis of 2-[(4-methylpiperidin-4-yl)oxy]pyridine hydrochloride To solution of tert-butyl 4-methyl-4-(pyridin-2-yloxy)piperidine-1-carboxylate (500 mg, 1.710 mmol, 1 equiv) in HCl in 1,4-dioxane (5 mL, 4M) at 0°C. The reaction was stirred at 20°C for 1 hours. The reaction was concentrated to afford 2-[(4-methylpiperidin-4-yl)oxy]pyridine hydrochloride (350 mg, 89.48% yield) as a yellow solid. MS (ESI): mass calcd. for C11H16N2O: 192.26 m / z, found 193.20 [M+H]+.Synthesis of N-[2-cyano-6-(4-isopropylpiperazin-1-yl)phenyl]-4-methyl-4-(pyridin-2-yloxy)piperi dine-1-carboxamide To a solution of 2-amino-3-(4-isopropylpiperazin-1-yl)benzonitrile (50 mg, 0.205 mmol, 1.00 equiv) in DCM (5 mL) was added triphosgene (40.08 mg, 0.135 mmol, 0.66 equiv) at 0°C under N2. After stirred for 60 min at rt, Et3N (41.41 mg, 0.410 mmol, 2.0 equiv) was added to the mixture, and the reaction was stirred at rt for additional one hour. The 2-[(4- methylpiperidin-4-yl)oxy]pyridine (78.69 mg, 0.410 mmol, 2.0 equiv) was added to the mixture, and the reaction was stirred at rt for additional one hour. Quenched with water (5 mL) and extracted with DCM (5 mL x 3). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by preparative HPLC using a Xselect CSH C18 OBD Column 150 mm x 30 mm x 5 μm column (eluent: 8% to 34% (v / v) ACN and H2O with 0.1%FA) to give the N-[2-cyano-6-(4-isopropylpiperazin-1-yl)phenyl]-4- methyl-4-(pyridin-2-yloxy)piperidine-1-carboxamide (10.3 mg, 10.73% yield) as a white solid. MS (ESI): mass calcd. for C26H34N6O2: 462.59 m / z, found 463.10 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 8.14 (dd, J = 5.2, 2.1 Hz, 1H), 7.61 – 7.73 (m, 1H), 7.37 – 7.46 (m, 2H), 7.24 (t, J = 7.9 Hz, 1H), 7.14 (s, 1H), 6.89 – 6.99 (m, 1H), 6.80 (dd, J = 8.4, 0.9 Hz, 1H), 3.83 – 3.94 (m, 2H), 3.27 – 3.42 (m, 2H), 2.87 – 2.98 (m, 5H), 2.77 – 2.85 (m, 4H), 2.49 (d, J = 13.9 Hz, 2H), 1.72 – 1.88 (m, 2H), 1.69 (s, 3H), 1.11 (d, J = 6.6 Hz, 6H). Provided herein is the synthesis of Compound 3: N-(2,6-dichlorophenyl)-4-{5-[(1S,2S)-2 -fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide.Scheme 3:Synthesis of N-(2,6-dichlorophenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine-1-carboxamideTo a stirred solution of 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine (80 mg, 0.355 mmol, 1 equiv) in DCM (15 mL) was added 1,3-dichloro-2- isocyanatobenzene (200.31 mg, 1.065 mmol, 3 equiv) and triethylamine (143.75 mg, 1.420 mmol, 4 equiv) dropwise at 0°C. The resulting mixture was stirred for 2h at rt. The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC using a XBridge Shield RP18 OBD Column 30 x 150 mm x 5μm (eluent: 33% to 53% (v / v) ACN and H2O with 10 mmol / L NH4HCO3) to give the N- (2,6-dichlorophenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine-1-carboxamide (19.2 mg, 13.07% yield) as a white solid. MS (ESI): mass calcd. for C18H19Cl2FN4O2: 412.09 m / z, found 413.05 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 7.41 – 7.49 (m, 2H), 7.18 – 7.32 (m, 1H), 6.91 (s, 1H), 4.89 – 5.21 (m, 1H), 3.72 – 3.87 (m, 2H), 3.15 – 3.31 (m, 2H), 2.39 – 2.54 (m,1H), 2.13 – 2.31 (m, 2H), 1.77 – 1.96 (m, 1H), 1.64 – 1.77 (m, 2H), 1.46 – 1.64 (m, 1H), 1.36 (s, 3H).19F NMR (282 MHz, CD3CN) δ -220.48. Provided herein is the synthesis of Compound 4: N-(2-cyclopropyl-6-(4- isopropylpiperazin-1-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide.Scheme 4: Synthesis of -( - romo- -n rop eny )- - sopropy p peraz ne To a solution of 1-bromo-3-fluoro-2-nitrobenzene (2 g, 9.091 mmol, 1 equiv) in dimethylformamide (20 mL) was added 1-isopropylpiperazine (1.40 g, 10.919 mmol, 1.20 equiv) and K2CO3 (3.77 g, 27.081 mmol, 2.98 equiv). The reaction was stirred at rt for 3h, then quenched with water (100 mL) and extracted with EA (3 x 100 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel with MeOH / DCM (0-100%) to give 1-(3- bromo-2-nitrophenyl)-4-isopropylpiperazine as a yellow oil (2.2 g,74%). LC / MS (ESI): mass calcd. for C13H18BrN3O2:327.1 m / z, found:328.20 [M+H]+. Synthesis of 1-(3-cyclopropyl-2-nitrophenyl)-4-isopropylpiperazine To a solution of 1-(3-bromo-2-nitrophenyl)-4-isopropylpiperazine (1 g, 3.047 mmol, 1 equiv) in dioxane (5 mL) and H2O (5 mL) was added cyclopropylboronic acid (0.654 g, 7.614 mmol, 2.50 equiv), Pd(dppf)Cl2 (0.25 g, 0.342 mmol, 0.11 equiv) and K2CO3 (1.05 g, 7.597 mmol, 2.49 equiv). The reaction was stirred at 90 °C under N2for 3h. Quenched with water (100 mL) and extracted with EA (3 x 100 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel with MeOH / DCM (0-100%) to give 1-(3-cyclopropyl-2-nitrophenyl)-4-isopropylpiperazine as a yellow oil (790 mg, 89 %). LC / MS (ESI): mass calcd. for C16H23N3O2: 289.2m / z, found:290.20 [M+H]+. Synthesis of 2-cyclopropyl-6-(4-isopropylpiperazin-1-yl)aniline To a solution of 1-(3-cyclopropyl-2-nitrophenyl)-4-isopropylpiperazine (400 mg, 1.382 mmol, 1 equiv) in methanol (5 mL) was added Pd / C (400 mg, 3.759 mmol, 2.72 equiv) in portions at room temperature under air atmosphere. The resulting mixture was stirred for 1 h at room temperature under hydrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was filtered, the filter cake was washed with MeOH (3x10 mL). The filtrate was concentrated under reduced pressure. This afforded 2-cyclopropyl-6-(4-isopropylpiperazin- 1-yl)aniline as a yellow oil (340 mg, 95 % ). LC / MS (ESI): mass calcd. for C16H25N3:259.2 m / z, found:260.20 [M+H]+. Synthesis of N-[2-cyclopropyl-6-(4-isopropylpiperazin-1-yl)phenyl]-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-cyclopropyl-6-(4-isopropylpiperazin-1-yl) aniline (207.24 mg, 0.799 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (94.83 mg, 0.320 mmol, 0.40 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added triethylamine (121.04 mg, 1.196 mmol, 1.50 equiv) at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-4-methylpiperidine (90 mg, 0.400 mmol, 0.50 equiv) in DCM (1 mL) and triethylamine (121.04 mg, 11.98 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-[2-cyclopropyl-6-(4-isopropylpiperazin-1-yl) phenyl]-4-{5- [(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide as a white solid (16.3 mg, 3.88 %). LC / MS (ESI): mass calcd. for C28H39FN6O2: 510.3 m / z,found:511.30 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 8.26 (s, 1H), 7.04 - 7.15 (m, 1H), 6.91 - 7.01 (m, 1H), 6.67 - 6.75 (m, 2H), 5.21 - 5.81 (m, 1H), 3.75 - 3.88 (m, 2H), 3.20 - 3.31 (m, 2H), 2.81 - 2.92 (m, 7H), 2.37 - 2.41 (m, 1H), 2.17 - 2.25 (m, 2H), 1.72 - 1.93(m, 3H), 1.68 - 1.71 (m, 2H), 1.49 - 1.57 (m, 1H), 1.27 - 1.39 (m, 3H), 1.09 - 1.19 (m, 6H), 0.79 - 0.91 (m, 2H), 0.47 - 0.58 (m, 2H).19F NMR (282 MHz, CD3CN) δ -220.44. Provided herein is the synthesis of Compound 5: N-[2-fluoro-6-(1-isopropyl-3,6-dihydro- 2H-pyridin-4-yl)phenyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine-1-carboxamide Scheme 5:Synthesis of N-[2-fluoro-6-(1-isopropyl-3,6-dihydro-2H-pyridin-4-yl)phenyl]-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide To a stirred solution of 2-fluoro-6-(1-isopropyl-3,6-dihydro-2H-pyridin-4-yl)aniline (104.02 mg, 0.444 mmol, 2 equiv) in DCM (5 mL) were added triphosgene (52.69 mg, 0.178 mmol, 0.8 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for additional 1 h at room temperature. The above mixture was added triethylamine (67.38 mg, 0.666 mmol, 3 equiv) at 0 °C under nitrogen atmosphere and stirred for 30 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (50 mg, 0.222 mmol, 1.00 equiv) and triethylamine (67.38 mg, 0.666 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3 h at room temperature under nitrogen atmosphere. Desiredproduct could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product (50 mg) was purified by Prep-HPLC with the following conditions (a XBridge Shield RP18 OBD 250 mm x 19 mm x 10 μm column (eluent: 55% to 65% (v / v) MeOH and H2O with 0.05% NH4HCO3)) to afford N-[2-fluoro-6-(1-isopropyl- 3,6-dihydro-2H-pyridin-4-yl)phenyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}- 4-methylpiperidine-1-carboxamide (6.6 mg, 5.45%) as a white solid. LC / MS: mass calcd. for C26H33F2N5O2: 485.14, found: 486.10 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.15 – 7.25 (m, 1H), 6.99 – 7.09 (m, 2H), 6.64 (s, (tt, J = 3.4, 1.6 Hz, 1H), 4.92 – 5.19 (m,1H), 3.70 – 3.81 (m, 2H), 3.13 – 3.28 (m, 4H), 2.79 – 2.90 (m, 1H), 2.68 – 2.79 (m, 2H), 2.41 – 2.53 (m, 2H), 2.32 – 2.41 (m, 3H), 1.79 – 1.93 (m, 1H), 1.62 – 1.74 (m, 2H), 1.50 – 1.62 (m, 1H), 1.35 (s, 3H), 1.09 (d, J = 6.5 Hz, 6H).19F NMR (376 MHz, CD3CN) δ -122.70, -220.35. Provided herein is the synthesis of Compound 6: N-[2-fluoro-6-(1-isopropylpiperidin-4- yl)phenyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1- carboxamide.Scheme 6: O BocSynthesis of tert-butyl 4-(3-fluoro-2-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylate To a stirred solution of 1-bromo-3-fluoro-2-nitrobenzene (2.00 g, 9.091 mmol, 1 equiv) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1- carboxylate (5.62 g, 18.182 mmol, 2 equiv) in 1,4-dioxane / H2O (10:1) were added Pd(PPh3)4 (1.05 g, 0.909 mmol, 0.1 equiv) and K2CO3(3.77 g, 27.273 mmol, 3 equiv) in portions at room temperature under air atmosphere. The resulting mixture was stirred for 3 h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. After cooling down to rt, the reaction was quenched with water (30 mL). The resulting mixture was extracted with ethyl acetate (3 x 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford tert-butyl 4-(3-fluoro-2-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylate (2.7 g, 92.14%) as a yellow oil. LC / MS: mass calcd. for C16H19FN2O4: 322.1, found: 323.05 [M+H]+. Synthesis of 4-(3-fluoro-2-nitrophenyl)-1,2,3,6-tetrahydropyridine To a stirred solution of tert-butyl 4-(3-fluoro-2-nitrophenyl)-3,6-dihydro-2H-pyridine-1- carboxylate (2.69 g, 8.345 mmol, 1 equiv) in DCM (12 mL) was added TFA (4 mL, 53.852 mmol, 6.45 equiv) in portions at room temperature under air atmosphere. The resulting mixture was stirred for 2 h at room temperature under air atmosphere. Desired product could be detected by LCMS. The resulting mixture was concentrated. This resulted in 4-(3-fluoro-2-nitrophenyl)- 1,2,3,6-tetrahydropyridine (1.70 g, 91.67%) as a yellow oil. The crude product was used in the next step directly without further purification. LC / MS: mass calcd. for C11H11FN2O2: 222.14, found: 223.10 [M+H]+. Synthesis of 4-(3-fluoro-2-nitrophenyl)-1-isopropyl-3,6-dihydro-2H-pyridine To a stirred solution of 4-(3-fluoro-2-nitrophenyl)-1,2,3,6-tetrahydropyridine (1.60 g, 7.200 mmol, 1 equiv) in MeOH were added acetone (0.84 g, 14.400 mmol, 2 equiv) at room temperature under air atmosphere. The resulting mixture was stirred for 0.5 h at room temperature under air atmosphere. Then the above solution was added NaBH3CN (2.26 g, 36.000 mmol, 5 equiv) in portions at 0 °C under air atmosphere. The resulting mixture was stirred for 3 h at room temperature under air atmosphere. Desired product could be detected by LCMS. The reaction was quenched with water (30 mL). The resulting mixture was extracted with ethyl acetate (3 x 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 4-(3-fluoro-2-nitrophenyl)-1-isopropyl-3,6-dihydro-2H-pyridine (1.70 g, 89.33%) as a yellow oil. LC / MS: mass calcd. for C14H17FN2O2: 264.14, found: 265.10 [M+H]+. Synthesis of 2-fluoro-6-(1-isopropylpiperidin-4-yl)aniline To a stirred solution of 4-(3-fluoro-2-nitrophenyl)-1-isopropyl-3,6-dihydro-2H-pyridine (500 mg, 1.892 mmol, 1 equiv) in MeOH was added Pd / C (499.28 mg, 4.692 mmol, 2.48 equiv) in portions at room temperature under air atmosphere. The resulting mixture was stirred for 4 hat room temperature under hydrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was filtered, the filter cake was washed with MeOH (3x10 mL). The filtrate was concentrated under reduced pressure. This resulted in 2-fluoro-6-(1- isopropylpiperidin-4-yl)aniline (400 mg, 89.47%) as a yellow oil. The crude product was used in the next step directly without further purification. LC / MS: mass calcd. for C14H21FN2: 236.14, found: 237.10 [M+H]+. Synthesis of N-[2-fluoro-6-(1-isopropylpiperidin-4-yl)phenyl]-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide To a stirred solution of 2-fluoro-6-(1-isopropylpiperidin-4-yl)aniline (209.83 mg, 0.888 mmol, 2 equiv) in DCM (5 mL) were added triphosgene (105.38 mg, 0.355 mmol, 0.8 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for additional 1 h at room temperature. The above mixture was added triethylamine (134.765 mg, 1.332 mmol, 2 equiv) at 0 °C under nitrogen atmosphere and was stirred for 30 min at room temperature under nitrogen atmosphere. Then the above mixture was added were added 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (100 mg, 0.444 mmol, 1.00 equiv) and triethylamine (134.765 mg, 1.332 mmol, 2 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3 h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (a XBridge Shield RP18 OBD 250 mm x 19 mm x 10 μm column (eluent: 55% to 65% (v / v) MeOH and H2O with 0.05% NH4HCO3)) to afford N-[2-fluoro-6-(1- isopropylpiperidin-4-yl)phenyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine-1-carboxamide (36.2 mg, 16.64%) as a white solid. LC / MS: mass calcd. for C26H35F2N5O2: 487.14, found: 488.25 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.15 – 7.25 (m, 1H), 7.11 – 7.20 (m, 1H), 6.99 – 7.09 (m, 1H), 6.64 (s, 1H), 4.92 – 5.18 (m, 1H), 3.71 – 3.81 (m, 2H), 3.18 – 3.30 (m, 2H), 2.90 – 2.97 (m, 2H), 2.69 – 2.81 (m, 2H), 2.40 – 2.51 (m, 1H), 2.20 – 2.30 (m, 4H), 1.81 – 1.93 (m, 1H), 1.50 – 1.78 (m, 7H), 1.35 (s, 3H), 1.09 (d, J = 6.5 Hz, 6H).19F NMR (376 MHz, CD3CN) δ -122.80, -220.43.Provided herein is the synthesis of Compound 7:N-(2-(((R)-1- (cyclopropylmethyl)pyrrolidin-3-yl)oxy)-6-fluorophenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide. Scheme 7:- To a solution of tert-butyl (3R)-3-hydroxypyrrolidine-1-carboxylate (2.35 g, 12.551 mmol, 1.00 equiv) in tetrahydrofuran (20 mL) was added sodium hydride (0.45 g, 18.752 mmol, 1.49 equiv) at 0 °C. The mixture was stirred at rt for 30 min, then 1,3-difluoro-2-nitrobenzene (2 g, 12.571 mmol, 1 equiv) was added. The reaction was stirred at rt for 2h. Quenched with water (100 mL) and extracted with EA (3 x 100 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel with MeOH / DCM (0-100%) to give tert-butyl 3-(1H-pyrrol-1-yl)-5,6,8,9-tetrahydro-7H-imidazo[1,5-d][1,4]diazepine-7-carboxylate as a yellow solid (3.1 g,76 % ). LC / MS (ESI): mass calcd. for C15H19FN2O5: 326.1 m / z, found:271.05 [M+H]+. Synthesis of (R)-3-(3-fluoro-2-nitrophenoxy)pyrrolidine To a solution of tert-butyl (3R)-3-(3-fluoro-2-nitrophenoxy)pyrrolidine-1-carboxylate (3.1 g, 9.500 mmol, 1 equiv) in DCM (3 mL) was added TFA (1 mL). The resulting mixture was stirred for 2 h at room temperature under air atmosphere. Desired product could be detected by LCMS. The resulting mixture was concentrated. This resulted in (3R)-3-(3-fluoro-2- nitrophenoxy)pyrrolidine as a yellow oil (1.87 g,89 % ). LC / MS (ESI): mass calcd. for C10H11FN2O3: 226.1 m / z, found:227.05 [M+H]+.Synthesis of (R)-1-(cyclopropylmethyl)-3-(3-fluoro-2-nitrophenoxy)pyrrolidine To a solution of (3R)-3-(3-fluoro-2-nitrophenoxy) pyrrolidine (600 mg, 2.652 mmol, 1 equiv) in methanol (6 mL) was added cyclopropanecarbaldehyde (371.83 mg, 5.305 mmol, 2.00 equiv) and NaBH3CN (500.05 mg, 7.958 mmol, 3.00 equiv). The reaction was stirred at rt for 3h. Quenched with water (100 mL) and extracted with EA (3 x 100 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel with MeOH / DCM (0-100%) to give (3R)-1- (cyclopropylmethyl)-3-(3-fluoro-2-nitrophenoxy) pyrrolidine as a white oil (195 mg, 26 %). LC / MS (ESI): mass calcd. for C14H17FN2O3: 280.1 m / z, found:281.15 [M+H]+. Synthesis of (R)-2-((1-(cyclopropylmethyl)pyrrolidin-3-yl)oxy)-6-fluoroaniline To a solution of (3R)-1-(cyclopropylmethyl)-3-(3-fluoro-2-nitrophenoxy) pyrrolidine (190 mg, 0.678 mmol, 1 equiv) in methanol (3 mL) was added Pd / C (400 mg, 3.759 mmol, 5.55 equiv) in portions at room temperature under air atmosphere. The resulting mixture was stirred for 2 h at room temperature under hydrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was filtered, the filter cake was washed with MeOH (3x10 mL). The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with MeOH / DCM (0-100%) to give 2-{[(3R)-1- (cyclopropylmethyl)pyrrolidin-3-yl]oxy}-6-fluoroaniline as a yellow oil (130 mg,76 % ). LC / MS (ESI): mass calcd. for C14H19FN2O:250.1 m / z, found:251.15 [M+H]+.Synthesis of N-(2-(((R)-1-(cyclopropylmethyl)pyrrolidin-3-yl)oxy)-6-fluorophenyl)-4-(5-((1S,2S)- 2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-{[(3R)-1-(cyclopropylmethyl) pyrrolidin-3-yl]oxy}-6- fluoroaniline (120 mg, 0.479 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (56.91 mg, 0.192 mmol, 0.40 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added Et3N (72.63 mg, 0.718 mmol, 1.50 equiv) at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (54.01 mg, 0.240 mmol, 0.50 equiv) in DCM (1 mL) and triethylamine (72.63 mg, 0.72 mmol, 3 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-(2-{[(3R)-1- (cyclopropylmethyl) pyrrolidin-3- yl]oxy }-6-fluorophenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide (34.9 mg, 14.33%) as a white solid. LC / MS (ESI): mass calcd. for C26H33F2N5O3: 501.3 m / z, found:502.25 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 7.47 - 7.59 (m, 1H), 7.22 - 7.34 (m, 2H), 7.18 (s, 1H), 4.89 - 5.22 (m, 1H), 3.77 - 3.90 (m, 2H), 3.15 - 3.30 (m, 2H), 2.35 - 2.54 (m, 1H), 2.19 - 2.30 (m, 2H), 1.97 - 2.01 (m, 1H), 1.79 - 1.95 (m, 1H), 1.70 - 1.80 (m, 2H), 1.41 - 1.60 (m, 1H), 1.30 – 1.40 (m, 3H), 0.91 - 1.01 (m, 2H), 0.59 - 0.69 (m, 2H).19F NMR (282 MHz, CD3CN) δ -220.46. Provided herein is the synthesis of Compound 8: 4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-N-[2-(4-isopropylpiperazin-1-yl) pyridin-3-yl]-4-methylpiperidine-1- carboxamide.Scheme 8:To a stirred mixture of 2-fluoro-3-nitropyridine (1000 mg, 7.038 mmol, 1.5 equiv) and 1- isopropylpiperazine (601.59 mg, 4.692 mmol, 1 equiv) in DMF was added K2CO3 (1959.52 mg, 14.076 mmol, 3 equiv) in portions at 0 °C under air atmosphere. The resulting mixture was stirred for 2h at room temperature. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with EA (3×20 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (5:1) to afford 1-isopropyl-4-(3-nitropyridin-2-yl) piperazine) (900 mg, 76.64%) as a white solid. MS (ESI): mass calcd. for C12H18N4O2: 250.1 m / z, found 251.25 [M+H]+. Synthesis of 2-(4-isopropylpiperazin-1-yl) pyridin-3-amine To a stirred mixture of 1-isopropyl-4-(3-nitropyridin-2-yl) piperazine (400 mg, 1.598 mmol, 1 equiv) and Fe (892.44 mg, 15.980 mmol, 10 equiv) in MeOH / H2O (10:1) was added NH4Cl (854.81 mg, 15.980 mmol, 10 equiv) in portions at room temperature under airatmosphere. The resulting mixture was stirred for 2h at room temperature. Desired product could be detected by LCMS. The resulting mixture was filtered the filter cake was washed with CH2Cl2 (3 x10 mL). The mixture was diluted with water (50 mL), then extracted with CH2Cl2 (3×20 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (5:1) to afford 2-(4-isopropylpiperazin-1- yl) pyridin-3-amine (250 mg, 71.01%) as a white solid. MS (ESI): mass calcd. for C12H20N4: 220.1 m / z, found 221.10 [M+H]+. Synthesis of 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[2-(4- isopropylpiperazin-1-yl) pyridin-3-yl]-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-(4-isopropylpiperazin-1-yl) pyridin-3-amine (140 mg, 0.635 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (56.57 mg, 0.191 mmol, 0.3 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added triethylamine (192.91 mg, 1.905 mmol, 3 equiv) at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-4-methylpiperidine (71.57 mg, 0.318 mmol, 0.5 equiv) in DCM (1 mL) and triethylamine (269.16 mg, 2.661mmol, 3equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with CH2Cl2 (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N- [2-(4-isopropylpiperazin-1-yl) pyridin-3-yl]-4-methylpiperidine-1-carboxamide (29.3 mg, 9.71%) as a white solid .MS (ESI): mass calcd. for C24H34FN7O2: 471.0 m / z, found 472.15 [M+H]+ 1H NMR (400 MHz, Acetonitrile-d3) δ 8.30 – 8.50 (m, 1H), 7.80 – 8.00 (m, 1H), 7.61 (s, 1H), 7.00 – 7.20 (m, 1H), 4.90 – 5.25 (m, 1H), 3.60 – 3.90 (m, 2H), 3.20 – 3.40 (m, 2H), 2.80 – 3.10 (m, 4H),2.70– 2.80 (m, 1H), 2.60 – 2.70 (m, 4H), 2.40 – 2.50 (m, 1H), 2.20 – 2.30 (m, 2H), 1.80 – 1.95(m, 1H), 1.70 – 1.80 (m, 2H), 1.50 – 1.60 (m, 1H), 1.30 – 1.40 (m, 3H), 1.00 – 1.10 (m, 6H).19F NMR (376 MHz, CD3CN) δ-75.45Provided herein is the synthesis of Compound 9: N-(2,6-diisopropylphenyl)-4-{5- [(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide. Scheme 9:Synthesis of N-(2,6-diisopropylphenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3- yl}-4-methylpiperidine-1-carboxamide To a solution of 2-isocyanato-1,3-diisopropylbenzene (80 mg, 0.394 mmol, 1 equiv) and Et3N (79.65 mg, 0.788 mmol, 2.0 equiv) in DCM (3 mL) was added 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (97.52 mg, 0.433 mmol, 1.1 equiv) at 0°C. The reaction was stirred at 25°C for additional 4 hours. The reaction was quenched with water (5 mL) and extracted with DCM (5 mL x 3). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by preparative HPLC using a Xselect CSH C18 OBD Column 150 mm x 30 mm x 5 μm column (eluent: 47% to 67% (v / v) ACN and H2O with 0.1%FA) to give the N-(2,6-diisopropylphenyl)-4- {5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide (21.9 mg, 12.95% yield) as a white solid. MS (ESI): mass calcd. for C24H33FN4O2: 428.55 m / z, found 429.25 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 7.23 – 7.31 (m, 1H), 7.18 (d, J = 6.9 Hz, 2H), 6.60 (s, 1H), 4.91 – 5.20 (m, 1H), 3.70 – 3.83 (m, 2H), 3.12 – 3.30 (m, 4H), 2.39 – 2.57 (m, 1H), 2.14 – 2.30 (m, 2H), 1.77 – 1.97 (m, 2H), 1.48 – 1.73 (m, 3H), 1.37 (s, 3H), 1.17 (d, J = 6.9 Hz, 12H).19F NMR (282 MHz, Acetonitrile-d3) δ (ppm): -220.48.Provided herein is the synthesis of Compound 10: N-(2-cyclopropyl-6-(4- isopropylpiperazin-1-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide. Scheme 10:Synthesis of N-(2-cyano-6-isopropylphenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol- 3-yl}-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-amino-3-isopropylbenzonitrile (142.21 mg, 0.888 mmol, 1 equiv) in DCM were added triphosgene (105.37 mg, 0.355 mmol, 0.40 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added triethylamine (134.49 mg, 1.329 mmol, 1.50 equiv) at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine (100 mg, 0.444 mmol, 0.50 equiv) in DCM (1 mL) and triethylamine (134.49 mg, 1.33 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-(2-cyano-6-isopropylphenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol- 3-yl}-4-methylpiperidine-1-carboxamide (22.7 mg, 6.19%) as a white solid.LC / MS (ESI): masscalcd. for C22H26FN5O2:411.2 m / z, found:412.20 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 7.62 - 7.70 (m, 1H), 7.53 - 7.61 (m, 1H), 7.34 - 7.45 (m, 1H), 7.05 (s, 1H), 4.89 - 5.21 (m, 1H), 3.75 - 3.89 (m, 2H), 3.14 - 3.33 (m, 3H), 2.27 - 2.41 (m, 1H), 2.09 - 2.19 (m, 2H), 1.70 - 1.87 (m, 1H),1.59 - 1.69 (m, 2H), 1.36 - 1.50(m, 1H), 1.23 - 1.30 (m, 3H), 1.07 - 1.13 (m, 6H).19F NMR (282 MHz, CD3CN) δ -220.47. Provided herein is the synthesis of Compound 11: methyl (cis)-N-(2-cyano-6- fluorophenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1- carboxamide. Scheme 11:Synthesis of methyl (cis)-N-(2-cyano-6-fluorophenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide A solution of 2-amino-3-fluorobenzonitrile (120.86 mg, 0.888 mmol, 2 equiv) and triphosgene (105.38 mg, 0.355 mmol, 0.8 equiv) in CH2Cl2was stirred for 1 h at 0°C under nitrogen atmosphere. To the above mixture was added triethylamine (134.76 mg, 1.332 mmol, 3 equiv) dropwise over 1 min at room temperature. The resulting mixture was stirred for additional 1 h at room temperature. To the above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-4-methylpiperidine (100 mg, 0.444 mmol, 1.00 equiv) in portions over 1 min at 0°C. The resulting mixture was stirred for additional 1 h at room temperature. The reaction was quenched with Water at room temperature. The resulting mixture was extracted with EtOAc (3 x 40 mL). The combined organic layers were dried over anhydrous Na2SO4. Afterfiltration, the filtrate was concentrated under reduced pressure. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a XBridge Prep OBD C18 Column 30 x 150mm x 5um column (eluent: 17% to 42% (v / v) ACN and H2O with 10 mmol / L NH4HCO3) to give methyl (cis)-N-(2-cyano-6-fluorophenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine-1-carboxamide (12 mg, 6.97%) .LC / MS: mass calcd. for C19H19F2N5O2: 387.20, found: 388.15.1H NMR (300 MHz, Acetonitrile-d3) δ 7.30 – 7.55 (m, 2H), 7.20 – 7.30 (m, 1H), 5.16 (td, J = 6.0, 3.5 Hz, 1H), 4.94 (td, J = 6.0, 3.5 Hz, 1H), 3.55 – 3.86 (m, 2H), 3.00 – 3.28 (m, 2H), 2.32 – 2.49 (m, 1H), 2.10 – 2.20 (m, 2H), 1.58 – 1.88 (m, 3H), 1.40 – 1.55 (m, 1H), 1.20 – 1.30 (m, 3H).19F NMR (282 MHz, CD3CN) δ 16.673, -122.057. Provided herein is the synthesis of Compound 12: N-(2-cyano-6-methoxyphenyl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide. Scheme 12:Synthesis of N-(2-cyano-6-methoxyphenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1-carboxamide To a stirred solution of 2-amino-3-methoxybenzonitrile (100 mg, 0.675 mmol, 1 equiv) in DCM (1 mL) was added triphosgene (80.11 mg, 0.270 mmol, 0.4 equiv) in DCM (1 mL) dropwise at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for additional 1 h at room temperature. The above mixture was added triethylamine (204.89 mg, 2.025 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for additional 1 h atroom temperature. To the above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-4-methylpiperidine (304.08 mg, 1.350 mmol, 2 equiv) and triethylamine (204.89 mg, 2.025 mmol, 3 equiv) dropwise at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3 h at room temperature under nitrogen atmosphere. The reaction was monitored by LCMS. Desired product could be detected by LCMS. The resulting mixture was extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC using a Xselect CSH OBD Column 30*150mm 5um column (eluent: 5% to 35% (v / v) ACN and H2O with 10 mmol / L NH4HCO3) to afford N- (2-cyano-6-methoxyphenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine-1-carboxamide (34.7 mg, 12.05%) as a white solid. LC / MS: mass calcd. for C20H22FN5O3: 399.17, found: 400.20 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 7.28 (s, 6H), 6.98 (s, 2H), 5.16 – 4.94 (m, 1H), 3.91 – 3.75 (m, 5H), 3.25 – 3.15 (m, 2H), 2.54 – 2.39 (m, 1H), 2.29 – 2.16 (m, 2H), 1.90 – 1.69 (m, 3H), 1.70 (d, J = 4.2 Hz, 1H), 1.35 (s, 3H).19F NMR (376 MHz, CDCl3) δ-220.46. Provided herein is the synthesis of Compound 13: 4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-N-[2-(4-isopropylpiperazin-1-yl)-6-methylphenyl]-4-methylpiperidine-1- carboxamide.Scheme 13:Synthesis of 1-isopropyl-4-(3-methyl-2-nitrophenyl)piperazine To a solution of 1-fluoro-3-methyl-2-nitrobenzene (3 g, 19.339 mmol, 1 equiv) in ACN (20 mL, 380.484 mmol, 19.67 equiv) were added 1-isopropylpiperazine (2.73 g, 21.273 mmol, 1.1 equiv) and K2CO3 (8.08 g, 58.017 mmol, 3 equiv) at 0°C. The resulting mixture was stirred for 3h at rt. The reaction was quenched with water. The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure to provide the crude product. The crude was purified by column chromatography on silica gel chromatography (0-100% PE / EA) to afford 1- isopropyl-4-(3-methyl-2-nitrophenyl)piperazine (1.0 g, 62.83% yield) as a white solid. MS (ESI): mass calcd for C14H21N3O2: 263.16, found: 264.10 [M+H]+. Synthesis of 2-(4-isopropylpiperazin-1-yl)-6-methylaniline To a stirred solution of 1-isopropyl-4-(3-methyl-2-nitrophenyl)piperazine (1 g, 3.797 mmol, 1 equiv) in MeOH (20 mL, 493.977 mmol) were added Pd / C (1 g, 9.397 mmol, 2.47 equiv) in portions at rt. The resulting mixture was stirred overnight at rt under hydrogen atmosphere. After filtration, the filtrate was concentrated under reduced pressure to give the 2-(4-isopropylpiperazin-1-yl)-6-methylaniline (300 mg, 68.17% yield) as a white solid. MS (ESI): mass calcd for C14H23N3: 233.19, found: 234.19 [M+H]+. Synthesis of 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[2-(4- isopropylpiperazin-1-yl)-6-methylphenyl]-4-methylpiperidine-1-carboxamide To a stirred solution of 2-(4-isopropylpiperazin-1-yl)-6-methylaniline (255 mg, 1.093 mmol, 1 equiv) in DCM (5 mL) was added triphosgene (97.27 mg, 0.328 mmol, 0.3 equiv) in portions at 0°C under nitrogen atmosphere. The resulting mixture was stirred for 1h at rt, then triethylamine (331.73 mg, 3.279 mmol, 3 equiv) was added to the reaction at 0°C and stirred for 1h at rt under nitrogen atmosphere. After adding 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine (123.08 mg, 0.546 mmol, 0.5 equiv) and triethylamine (331.73 mg, 3.279 mmol, 3 equiv) at 0°C, the reaction was stirred for 1h at rt. The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC using a XBridge Prep OBD C18 Column 30 x 150 mm x 5μm column (eluent: 17% to 42% (v / v) ACN and H2O with 10 mmol / L NH4HCO3) to give the 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[2-(4-isopropylpiperazin-1-yl)-6-methylphenyl]-4- methylpiperidine-1-carboxamide (48.2 mg, 9.06% yield) as a white solid. MS (ESI): mass calcd. for C26H37FN6O2: 484.30 m / z, found 485.30 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 6.90 – 7.02 (m, 1H), 6.80 – 6.90 (m, 2H), 6.75 (s, 1H), 4.88 – 5.21 (m, 1H), 3.76 – 3.89 (m, 2H), 3.18 – 3.35 (m, 2H), 2.72 – 2.83 (m, 4H), 2.59 – 2.68 (m, 1H), 2.39 – 2.54 (m, 4H), 2.20 – 2.31 (m, 1H), 2.13 – 2.25 (m, 3H), 2.17 (s, 1H), 1.70 – 1.86 (m, 2H), 1.60 – 1.70 (m, 2H), 1.40 – 1.60 (m, 1H), 1.01 – 1.25 (m, 3H), 0.90 – 1.01 (m, 6H).19F NMR (282 MHz, CD3CN) δ -220.47. Provided herein is the synthesis of Compound 14: 4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-N-[3-(4-isopropylpiperazin-1-yl)pyridin-4-yl]-4-methylpiperidine-1- carboxamide.F NScheme 14:Synthesis of 1-isopropyl-4-(4-nitropyridin-3-yl)piperazine To a solution of 3-chloro-4-nitropyridine (20 mg, 0.126 mmol, 1 equiv) in dimethylformamide (6 mL) was added 1-isopropylpiperazine (586.55 mg, 4.575 mmol, 1.3 equiv) and K2CO3 (1469.64 mg, 10.557 mmol, 3 equiv). The reaction was stirred at 25 °C for 16 h. Quenched with water (100 mL) and extracted with EA (3 x 100 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel with EA / PE (0-100%) to give 1-isopropyl-4- (4-nitropyridin-3-yl)piperazine (700 mg, 79.47%) as a black solid. LC / MS (ESI): mass calcd. for C12H18N4O2:250.1 m / z, found:251.1 [M+H]+.Synthesis of 3-(4-isopropylpiperazin-1-yl)pyridin-4-amine To a stirred solution of 1-isopropyl-4-(4-nitropyridin-3-yl)piperazine (700 mg, 2.797 mmol, 1 equiv) in MeOH was added Pd / C (699.40 mg, 6.573 mmol, 2.35 equiv) in portions at room temperature under air atmosphere. The resulting mixture was stirred for 2 h at room temperature under hydrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was filtered, the filter cake was washed with MeOH (3x10 mL). The filtrate was concentrated under reduced pressure. This resulted in 3-(4-isopropylpiperazin-1-yl)pyridin- 4-amine (500 mg, 81.15%) as a yellow oil. The crude product was used in the next step directly without further purification. LC / MS: mass calcd. for C12H20N4: 220.14, found: 221.10 [M+H]+. Synthesis of 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[3-(4- isopropylpiperazin-1-yl)pyridin-4-yl]-4-methylpiperidine-1-carboxamide To a stirred solution of 3-(4-isopropylpiperazin-1-yl)pyridin-4-amine (195.61 mg, 0.888 mmol, 2 equiv) in DCM (5 mL) were added triphosgene (105.38 mg, 0.355 mmol, 0.8 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for additional 1 h at room temperature. The above mixture was added triethylamine (134.76 mg, 1.332 mmol, 3 equiv) at 0 °C under nitrogen atmosphere and stirred for 30 min at room temperature under nitrogen atmosphere. Then the above mixture was added were added 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (100 mg, 0.444 mmol, 1.00 equiv) and triethylamine (134.76 mg, 1.332 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3 h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (20 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (a XBridge Shield RP18 OBD 250 mm x 19 mm x 10 μm column (eluent: 55% to 65% (v / v) MeOH and H2O with 0.05% NH4HCO3)) to afford 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[3-(4-isopropylpiperazin-1-yl)pyridin-4-yl]-4- methylpiperidine-1-carboxamide (104.9 mg, 49.87%) as a white solid. LC / MS: mass calcd. for C24H34FN7O2: 471.14, found: 472.30 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 8.32 – 8.37 (m, 2H), 8.20 (d, J = 5.5 Hz, 1H), 8.06 (d, J = 5.5 Hz, 1H), 4.93 – 5.15 (m, 1H), 3.78 – 3.87 (m,2H), 3.20 – 3.30 (m, 2H), 2.90 – 2.98 (m, 4H), 2.72 – 2.80 (m, 1H), 2.63 – 2.72 (m, 3H), 2.40 – 2.50 (m, 1H), 2.13 – 2.30 (m, 3H), 1.69 – 2.91 (m, 3H), 1.49 – 1.61 (m, 1H), 1.31 – 1.40 (m, 3H), 1.01 – 1.12 (m, 6H).19F NMR (376 MHz, CD3CN) δ -220.24. Provided herein is the synthesis of Compound 15: N-[2-chloro-6-(4-isopropylpiperazin-1- yl) phenyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-1,4-dimethyl-1lambda4- piperidine-1-carboxamide. Scheme 15:Synthesis of 1-(3-chloro-2-nitrophenyl)-4-isopropylpiperazine To a stirred mixture of 1-chloro-3-fluoro-2-nitrobenzene (1000 mg, 5.697 mmol, 1.5 equiv) and 1-isopropylpiperazine (486.95 mg, 3.798 mmol, 1 equiv) in DMF was added K2CO3(1586.11 mg, 11.394 mmol, 3 equiv) in portions at 0 °C under air atmosphere. The resulting mixture was stirred for 2h at room temperature. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with CH2Cl2(3×20 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate wasconcentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (5:1) to afford 1-(3-chloro-2-nitrophenyl)-4- isopropylpiperazine (1 g, 92.79%) as a white solid. MS (ESI): mass calcd. for C13H18ClN3O2: 283.1 m / z, found 284.20 [M+H]+. Synthesis of 2-chloro-6-(4-isopropylpiperazin-1-yl) aniline To a stirred mixture of 1-(3-chloro-2-nitrophenyl)-4-isopropylpiperazine (700 mg, 2.467 mmol, 1 equiv) and Fe (1377.63 mg, 24.670 mmol, 10 equiv) in MeOH / H2O (10:1) was added NH4Cl (1319.53 mg, 24.670 mmol, 10 equiv) in portions at room temperature under air atmosphere. The resulting mixture was stirred for 3h at 70°C. The desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with CH2Cl2(3×20 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (5:1) to afford 2-chloro-6-(4- isopropylpiperazin-1-yl) aniline (330 mg, 52.71%) as a white solid. MS (ESI): mass calcd. for C13H20ClN3: 253.7 m / z, found 254.10 [M+H]+Synthesis of N-(2-chloro-6-(4-isopropylpiperazin-1-yl) phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-chloro-6-(4-isopropylpiperazin-1-yl) aniline (225 mg, 0.887 mmol, 1 equiv) in DCM were added triphosgene (78.93 mg, 0.266 mmol, 0.3 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added triethylamine (269.16 mg, 2.661 mmol, 3 equiv) at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine (99.86 mg, 0.444 mmol, 0.5 equiv) in DCM (1 mL) and triethylamine (269.16 mg, 2.661 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with CH2Cl2 (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-(2-chloro-6-(4-isopropylpiperazin-1-yl) phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (65.3 mg, 13.74%) as a white solid. MS (ESI): mass calcd. for C25H34ClFN6O2: 504.0 m / z, found 505.15 [M+H]+1H NMR (400 MHz, Acetonitrile-d3) δ 7.10 – 7.30 (m, 2H), 7.07 (s, 1H), 6.55 – 6.70 (m, 1H), 4.90 – 5.25 (m, 1H), 3.80 – 3.90 (m, 2H), 3.20 – 3.40 (m, 2H), 2.80 – 3.00 (m, 4H), 2.70 – 2.80 (m, 1H), 2.60– 2.70 (m, 4H), 2.40 – 2.50 (m, 1H), 1.80 – 2.00 (m, 2H), 1.70 – 1.80 (m, 2H), 1.50 – 1.60 (m, 1H), 1.30 – 1.40 (m, 4H), 1.00 – 1.15 (m, 6H).19F NMR (376 MHz, CD3CN) δ- 220.45. Provided herein is the synthesis of Compound 16: 4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-N-[4-(4-isopropylpiperazin-1-yl) pyridin-3-yl]-4-methylpiperidine-1- carboxamide. Scheme 16:Synthesis of 1-isopropyl-4-(3-nitropyridin-4-yl) piperazineTo a stirred mixture of 4-chloro-3-nitropyridine (1000 mg, 6.308 mmol, 1.5 equiv) and 1- isopropylpiperazine (539.17 mg, 4.205mmol, 1equiv) in DMF was added K2CO3 (1756.19 mg, 12.616mmol, 3equiv) in portions at 0 °C under air atmosphere. The final reaction mixture was stirred for 1 h at room temperature. Desired product could be detected by LCMS. The resulting mixture was extracted with CH2Cl2 (3 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (5:1) to afford 1-isopropyl-4-(3-nitropyridin-4-yl) piperazine (920 mg, 87.41%) as a white solid. MS (ESI): mass calcd. for C12H18N4O2: 250.1 m / z, found 251.15 [M+H]+. Synthesis of 4-(4-isopropylpiperazin-1-yl) pyridin-3-amine Into a 50 mL round-bottom flask were added 1-isopropyl-4-(3-nitropyridin-4-yl) piperazine (500 mg, 1.998 mmol, 1 equiv) and Pd / C (531.46 mg, 4.995 mmol, 2.5 equiv) at room temperature. The final reaction mixture was stirred for 1h at room temperature under hydrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was filtered. The filter cake was washed with CH2Cl2 (3 x 20 mL). The filtrate was concentrated under reduced pressure. This resulted in 4-(4-isopropylpiperazin-1-yl) pyridin-3-amine (100 mg, 22.72%) as a yellow solid. The crude product was used in the next step directly without further purification. MS (ESI): mass calcd. for C12H20N4: 220.1 m / z, found 221.20 [M+H]+. Synthesis of 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[4-(4- isopropylpiperazin-1-yl) pyridin-3-yl]-4-methylpiperidine-1-carboxamide To a stirred mixture of 4-(4-isopropylpiperazin-1-yl) pyridin-3-amine (100 mg, 0.454 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (40.40 mg, 0.136 mmol, 0.3 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added triethylamine (137.79 mg, 1.362 mmol, 3 equiv) at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-4-methylpiperidine (51.12 mg, 0.227 mmol, 0.5 equiv) in DCM (1 mL) and triethylamine (137.79 mg, 1.362 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desiredproduct could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N- [4-(4-isopropylpiperazin-1-yl) pyridin-3-yl]-4-methylpiperidine-1-carboxamide (29.2 mg, 12.89%) as a white solid. MS (ESI): mass calcd. for C24H34FN7O2: 471.2 m / z, found 472.35 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 8.85 – 9.00 (m, 1H), 8.05 – 8.30 (m, 1H), 7.10 – 7.30 , 6.90 – 7.05 (m, 1H), 4.90 – 5.20 (m, 1H), 3.70 – 4.00 (m, 2H), 3.40 – 3.55 (m, 1H), 3.20 – 3.30 (m, 2H), 2.85 – 3.00 (m, 4H), 2.65 – 2.80 (m, 5H), 2.40 – 2.55 (m, 1H), 1.80 – 2.00 (m, 2H), 1.70 – 1.80 (m, 2H), 1.50 – 1.60 (m, 1H), 1.30 – 1.40 (m, 3H), 1.00 – 1.10 (m, 6H).19F NMR (376 MHz, CD3CN) δ -220.45. Provided herein is the synthesis of Compound 17: 4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-N-[2-(4-isopropylpiperazin-1-yl)-6-(trifluoromethyl)phenyl]-4- methylpiperidine-1-carboxamide. Scheme 17:Synthesis of 1-isopropyl-4-[2-nitro-3-(trifluoromethyl)phenyl]piperazine To a stirred solution of 1-chloro-2-nitro-3-(trifluoromethyl)benzene (600 mg, 2.660 mmol, 1 equiv) and 1-isopropylpiperazine (511.63 mg, 3.990 mmol, 1.5 equiv) in DMF was added K2CO3 (1110.99 mg, 7.980 mmol, 3 equiv) in portions at room temperature under air atmosphere. The resulting mixture was stirred for 3 h at 80 °C under air atmosphere. Desired product could be detected by LCMS. After cooling down to rt, the reaction was quenched with water (30 mL). The resulting mixture was extracted with ethyl acetate (3 x 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 1- isopropyl-4-[2-nitro-3-(trifluoromethyl)phenyl]piperazine (300 mg, 35.54%) as a yellow oil. LC / MS: mass calcd. for C14H18F3N3O2: 317.1, found: 318.05 [M+H]+. Synthesis of 2-(4-isopropylpiperazin-1-yl)-6-(trifluoromethyl)aniline To a stirred solution of 1-isopropyl-4-[2-nitro-3-(trifluoromethyl)phenyl]piperazine (290 mg, 0.914 mmol, 1 equiv) in MeOH were added Pd / C (289.84 mg, 2.724 mmol, 2.98 equiv) in portions at room temperature under air atmosphere. The resulting mixture was stirred for 1 h at room temperature under hydrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was filtered. The filter cake was washed with MeOH (3 x 10 mL). The filtrate was concentrated under reduced pressure. This resulted in 2-(4-isopropylpiperazin-1-yl)-6- (trifluoromethyl)aniline (240 mg, 91.39%) as a yellow oil. The crude product was used in the next step directly without further purification. LC / MS: mass calcd. for C14H20F3N3: 287.14, found: 288.10 [M+H]+. Synthesis of 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[2-(4- isopropylpiperazin-1-yl)-6-(trifluoromethyl)phenyl]-4-methylpiperidine-1-carboxamide To a stirred solution of 2-(4-isopropylpiperazin-1-yl)-6-(trifluoromethyl)aniline (255.10 mg, 0.888 mmol, 2 equiv) in DCM (5 mL) were added triphosgene (105.38 mg, 0.355 mmol, 0.8 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for additional 1 h at room temperature. The above mixture was added triethylamine (134.765 mg, 1.332 mmol, 3 equiv) at 0 °C under nitrogen atmosphere and stirred for 30 min at roomtemperature under nitrogen atmosphere. Then the above mixture were added 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (100 mg, 0.444 mmol, 1.00 equiv) and triethylamine (134.765 mg, 1.332 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The reaction was quenched with water (30 mL). The resulting mixture was extracted with DCM (3 x 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (a XBridge Shield RP18 OBD 250 mm x 19 mm x 10 μm column (eluent: 55% to 65% (v / v) MeOH and H2O with 0.05% NH4HCO3)) to afford 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[2-(4-isopropylpiperazin-1- yl)-6-(trifluoromethyl)phenyl]-4-methylpiperidine-1-carboxamide (33.2 mg, 13.59%) as a white solid. LC / MS: mass calcd. for C26H34F4N6O2: 538.14, found: 539.40 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.36 – 7.45 (m, 3H), 6.68 (s, 2H), 4.93 – 5.17 (m,3.75 – 3.83 (m, 2H), 3.19 – 3.30 (m, 2H), 2.87 – 2.96 (m, 4H), 2.71 – 2.81 (m, 1H), 2.61 – 2.60 (m, 4H), 2.41 – 2.46 (m, 1H), 2.20 – 2.30 (m, 2H), 1.80 – 1.90 (m, 1H), 1.65 – 1.79 (m, 2H), 1.50 – 1.60 (m, 1H), 1.37 (s, 6H), 1.06 (dd, J = 6.6, 1.1 Hz, 6H).19F NMR (376 MHz, CD3CN) δ -60.66, - 220.44. Provided herein is the synthesis of Compound 18: N-{3-cyano-[1,1'-biphenyl]-2-yl}-4- {5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide.Scheme 18: B(OH)2Synthesis of 2-amino-[1,1'-biphenyl]-3-carbonitrile To a stirred mixture of 2-amino-3-iodobenzonitrile (500 mg, 2.049 mmol, 1 equiv) and phenyl boronic acid (374.73 mg, 3.074 mmol, 1.5 equiv) in 1,4-dioxane / H2O (10:1) were added Pd(PPh3)4(236.77 mg, 0.205 mmol, 0.1 equiv) and K2CO3(707.92 mg, 5.122 mmol, 2.5 equiv) in portions at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 2h at 90 °C under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with EA (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (5:1) to afford 2- amino-[1,1'-biphenyl]-3-carbonitrile (150 mg, 37.69%) as a white solid. MS (ESI): mass calcd. for C13H10N2: 194.0 m / z, found 195.15 [M+H]+. Synthesis of N-{3-cyano-[1,1'-biphenyl]-2-yl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-amino-[1,1'-biphenyl]-3-carbonitrile (90 mg, 0.463 mmol, 1 equiv) in DCM were added triphosgene (41.25 mg, 0.139 mmol, 0.3 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for additional 1h at roomtemperature. The above mixture was added triethylamine (140.66 mg, 1.389 mmol, 3 equiv) at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added were added 4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-4-methylpiperidine (52.19 mg, 0.232 mmol, 0.5 equiv) in DCM (1 mL) and triethylamine (140.66 mg, 1.389 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-{3-cyano-[1,1'-biphenyl]-2-yl}-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide (29.3mg, 14.19%)as a white solid. MS (ESI): mass calcd. for C25H24FN5O2: 445.2 m / z, found 446.20 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.70 – 7.85 (m, 1H), 7.58 – 7.70 (m, 1H), 7.30 – 7.50 (m, 6H), 6.80 – 7.00 (m, 1H), 4.90 – 5.20 (m, 1H), 3.50 – 3.75 (m, 2H), 3.00 – 3.20 (m, 2H), 2.30 – 2.60 (m, 1H), 2.05 – 2.15 (m, 2H), 1.75 – 1.80 (m, 1H), 1.45 – 1.60 (m, 3H), 1.25 – 1.35 (m, 3H).19F NMR (376 MHz, CD3CN) δ-174.24 Provided herein is the synthesis of Compound 19: N-[2-cyano-6-(4-isopropylpiperazin-1- yl) phenyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1- carboxamide.Scheme 19:Synthesis of 3-(4-isopropylpiperazin-1-yl)-2-nitrobenzonitrile To a stirred mixture of 3-fluoro-2-nitrobenzonitrile (500 mg, 3.010 mmol, 1 equiv) and 1- isopropylpiperazine (385.94 mg, 3.010 mmol, 1 equiv) in DMF was added K2CO3 (1257.11 mg, 9.030 mmol, 3 equiv) in portions at room temperature under air atmosphere. The final reaction mixture was stirred for 2h at room temperature. The resulting mixture was extracted with CH2Cl2(3 x20 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 3-(4-isopropylpiperazin-1-yl)-2- nitrobenzonitrile (450 mg, 54.50%) as a white solid. MS (ESI): mass calcd. for C14H18N4O2: 274.1 m / z, found 275.15 [M+H]+. Synthesis of 2-amino-3-(4-isopropylpiperazin-1-yl) benzonitrile A mixture of 3-(4-isopropylpiperazin-1-yl)-2-nitrobenzonitrile (200 mg, 0.729 mmol, 1 equiv) and Pd / C (232.76 mg, 2.187 mmol, 3 equiv) in EA was stirred for 2 h at room temperature under hydrogen atmosphere. Desired product could be detected by LCMS. The resulting mixturewas filtered. The filter cake was washed with MeOH (3 x 30 mL). The filtrate was concentrated under reduced pressure. This resulted in crude 2-amino-3-(4-isopropylpiperazin-1-yl) benzonitrile (~200 mg) as a white solid. The crude product was purified by purified by C18 reversed-phase column (eluent: CH3CN and H2O) to give 2-amino-3-(4-isopropylpiperazin-1-yl) benzonitrile (40 mg, 22.47%). MS (ESI): mass calcd. for C14H20N4: 244.1 m / z, found 245.15 [M+H]+. Synthesis of N-[2-cyano-6-(4-isopropylpiperazin-1-yl) phenyl]-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-amino-3-(4-isopropylpiperazin-1-yl) benzonitrile (60 mg, 0.246 mmol, 1 equiv) in DCM were added triphosgene (21.86 mg, 0.074 mmol, 0.3 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added triethylamine (74.55 mg, 0.738 mmol, 3 equiv) at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. The above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine (27.66 mg, 0.123 mmol, 0.5 equiv) in DCM (1 mL) and triethylamine (74.55 mg, 0.738 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-[2-cyano-6-(4-isopropylpiperazin-1-yl) phenyl]-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide (15.3 mg, 2.97%) as a white solid. MS (ESI): mass calcd. for C26H34FN7O2: 495.3 m / z, found 496.35 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.30 –7.60 (m, 2H), 7.20 –7.30 (m, 1H), 7.00 –7.20 (m, 1H),4.90 – 5.20 (m, 1H), 3.80 –4.00 (m, 2H), 3.20 –3.40 (m, 2H), 2.80 –2.90 (m, 4H), 2.60 – 2.80 (m, 5H), 2.40 – 2.55 (m, 1H), 2.30 – 2.40 (m, 1H), 1.70 –1.90 (m,4H), 1.50 –1.60 (m, 1H), 1.30 –1.40 (m, 3H), 1.00 –1.10 (m, 6H).19F NMR (376 MHz, CD3CN) δ -200.99.Provided herein is the synthesis of Compound 20: methyl (cis)-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[2-(4-isopropylpiperazin-1-yl) phenyl]-4- methylpiperidine-1-carboxamide. Scheme 20:Synthesis of methyl (cis)- 1-isopropyl-4-(2-nitrophenyl) piperazine To a solution of o-fluoronitrobenzene (1 g, 7.087 mmol, 1 equiv) in ACN (20 mL) were added 1-isopropylpiperazine (1.00 g, 7.796 mmol, 1.1 equiv) and K2CO3 (2.96 g, 21.261 mmol, 3 equiv) in portions at 0°C. The resulting mixture was stirred for 3h at rt. The reaction was quenched with water. The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 1-isopropyl-4-(2-nitrophenyl) piperazine (1.0 g 57%) as a white oil. LC / MS: mass calcd. for C13H19N3O2: 249.15, found: 250.10 [M+H]+. Synthesis of methyl (cis)- 2-(4-isopropylpiperazin-1-yl) anilineTo a stirred solution of 1-isopropyl-4-(2-nitrophenyl)piperazine (500 mg, 2.006 mmol, 1 equiv) in MeOH (20 mL, 493.977 mmol) were added Pd / C (500 mg, 4.698 mmol, 2.34 equiv) in portions at rt. The resulting mixture was stirred overnight at rt under hydrogen atmosphere. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 2-(4-isopropylpiperazin-1-yl) aniline (300 mg, 68%) as a white oil. LC / MS: mass calcd. for C13H21N3: 219.17, found: 220.20 [M+H]+. Synthesis of methyl (cis)- 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[2-(4- isopropylpiperazin-1-yl) phenyl]-4-methylpiperidine-1-carboxamide A solution of 2-(4-isopropylpiperazin-1-yl) aniline (194.73 mg, 0.888 mmol, 2 equiv) in CH2Cl2 was treated with triphosgene (105.38 mg, 0.355 mmol, 0.8 equiv) for 1 h at 0°C under nitrogen atmosphere followed by the addition of triethylamine (134.76 mg, 1.332 mmol, 3 equiv) dropwise at 0°C. A solution of 2-(4-isopropylpiperazin-1-yl) aniline (194.73 mg, 0.888 mmol, 2 equiv) and Et3N (89.84 mg, 0.888 mmol, 2 equiv) in CH2Cl2 was stirred for 20 min at room temperature under air atmosphere. To the above mixture was added 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (100 mg, 0.444 mmol, 1.00 equiv) dropwise over 1 min at 0°C. The resulting mixture was stirred for additional 1 h at room temperature. The reaction was quenched with water at room temperature. The resulting mixture was extracted with CH2Cl2(3 x 40 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product (100 mg) was purified by preparative HPLC using a XSelect CSH Fluoro Phenyl 30 x 150 mm x 5μm column (eluent: 39% to 59% (v / v) ACN and water (10 mmol / L NH4HCO3) to afford methyl (cis)-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[2-(4- isopropylpiperazin-1-yl) phenyl]-4-methylpiperidine-1-carboxamide (18.7 mg, 8.76%). LC / MS: mass calcd. for C25H35FN6O2: 470.3, found: 471.25.1H NMR (300 MHz, Acetonitrile-d3) δ 8.25 (s, 1H), 8.11 (dd, J = 8.1, 1.5 Hz, 1H), 7.24 (dd, J = 7.8, 1.6 Hz, 1H), 7.10 (td, J = 7.8, 1.6 Hz, 1H), 6.96 (td, J = 7.6, 1.6 Hz, 1H), 4.94 (td, J = 6.0, 3.6 Hz, 1H), 3.81 (dt, J = 13.9, 4.6 Hz, 2H), 3.24 (ddt, J = 13.3, 10.2, 2.9 Hz, 2H), 2.70 - 2.83 (m, 4H), 2.50 - 2.83 (m, 5H), 2.30 - 2.43 (m, 1H), 2.10 - 2.20 (m, 2H), 1.55 - 1.85 (m, 3H), 1.36 - 1.50 (m, 1H), 1.35 (s, 3H), 0.90 - 1.03 (m, 6H).19F NMR (282 MHz, CD3CN) δ -220.452.Provided herein is the synthesis of Compound 21: 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-N-[3-(4-isopropylpiperazin-1-yl)pyridin-2-yl]-4-methylpiperidine-1- carboxamide. Scheme 21:Synthesis of 1-isopropyl-4-(2-nitropyridin-3-yl)piperazine To a solution of 3-fluoro-2-nitropyridine (1 g, 7.038 mmol, 1 equiv) in ACN (20 mL, 380.484 mmol) was added 1-isopropylpiperazine (0.99 g, 7.742 mmol, 1.1 equiv) and K2CO3 (2.94 g, 21.114 mmol, 3 equiv) at 0 °C. The resulting mixture was stirred for 3h at rt. The reaction was quenched with water. The resulting mixture was extracted with DCM (3x 30 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure to provide the crude product, which was purified by column chromatography on silica gel chromatography (0-20% DCM / MeOH) to afford 1-isopropyl-4-(2- nitropyridin-3-yl)piperazine (1.8 g, 102.18% yield) as a white solid. MS (ESI): mass calcd for C12H18N4O2: 250.14, found: 251.15 [M+H]+.Synthesis of 3-(4-isopropylpiperazin-1-yl)pyridin-2-amine To a stirred solution / mixture of 1-isopropyl-4-(2-nitropyridin-3-yl)piperazine (500 mg, 1.998 mmol, 1 equiv) in MeOH (20 mL, 493.977 mmol, 247.29 equiv) were added Pd / C (500 mg, 4.698 mmol, 2.35 equiv) in portions at rt. The resulting mixture was stirred overnight at rt under hydrogen atmosphere. After filtration, the filtrate was concentrated under reduced pressure to give the 3-(4-isopropylpiperazin-1-yl)pyridin-2-amine (300 mg, 68.17% yield) as a white solid. MS (ESI): mass calcd for C12H20N4: 220.17, found: 221.05 [M+H]+. Synthesis of 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[3-(4- isopropylpiperazin-1-yl)pyridin-2-yl]-4-methylpiperidine-1-carboxamide To a stirred solution / mixture of 23-(4-isopropylpiperazin-1-yl)pyridin-2-amine (67.5 mg, 0.306 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (36.36 mg, 0.122 mmol, 0.4 equiv) in portions at 0°C, the resulting mixture was stirred for 1h at rt under nitrogen atmosphere. triethylamine (155.01 mg, 1.530 mmol, 5 equiv) was added to the reaction at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at rt for 1h. Then 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (138.03 mg, 0.612 mmol, 2 equiv) and triethylamine (155.01 mg, 1.530 mmol, 5 equiv) was added at 0 °C. The reaction was stirred at rt for 1h. The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC using a YMC-Actus Triart C18 ExRS 30 x 150 mm x 5μm column (eluent: 27% to 45% (v / v) ACN and H2O with 10 mmol / L NH4HCO3) to give the 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[3-(4- isopropylpiperazin-1-yl)pyridin-2-yl]-4-methylpiperidine-1-carboxamide (9.5 mg, 6.43% yield) as a white solid. MS (ESI): mass calcd. for C24H34FN7O2: 471.28 m / z, found 472.25 [M+H]+. 1H NMR (300 MHz, Acetonitrile-d3) δ 8.01 (s, 1H), 7.43 – 7.54 (m, 2H), 6.95 – 7.01 (m, 1H), 4.93 – 5.15 (m, 1H), 3.80 – 3.86 (m, 2H), 3.17 – 3.31 (m, 2H), 2.88 (s, 3H), 2.74 (s, 5H), 2.34 (s, 1H), 1.72 (s, 1H), 1.52 – 1.63 (m, 2H), 1.48 – 1.57 (m, 1H), 1.27 – 1.44 (m, 6H), 0.90 – 1.06 (m, 5H), 0.91 (s, 1H). 19F NMR (282 MHz, CD3CN) δ -220.46.Provided herein is the synthesis of Compound 22: N-[2-fluoro-6-(4-isopropylpiperazin-1-yl) phenyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1- carboxamide. Scheme 22: NSynthesis of 1-(3-fluoro-2-nitrophenyl)-4-isopropylpiperazine To a stirred mixture of 1,3-difluoro-2-nitrobenzene (3000 mg, 18.857 mmol, 1 equiv) and K2CO3(7875.42 mg, 56.571 mmol, 3 equiv) in DMF was added 1-isopropylpiperazine (2417.83 mg, 18.857 mmol, 1 equiv) in portions at 0°C under air atmosphere. The resulting mixture was stirred for 2h at room temperature. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL). The resulting mixture was extracted with EA (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 1-(3-fluoro-2-nitrophenyl)-4- isopropylpiperazine (2700 mg, 53.57%) as a white solid. MS (ESI): mass calcd. for C13H18FN3O2: 267.1 m / z, found 268.15 [M +H]+.Synthesis of 2-fluoro-6-(4-isopropylpiperazin-1-yl) aniline A mixture of 1-(3-fluoro-2-nitrophenyl)-4-isopropylpiperazine (2700 mg, 10.101 mmol, 1 equiv) and Pd / C (322.48 mg, 3.030 mmol, 0.3 equiv) in MeOH was stirred for 1h at room temperature under hydrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was filtered. The filter cake was washed with MeOH (3x30 mL). The filtrate was concentrated under reduced pressure to afford 2-fluoro-6-(4-isopropylpiperazin-1-yl) aniline (1300 mg, 54.23%) as a white solid. The crude product was used in the next step directly without further purification.MS (ESI): mass calcd. for C13H20FN3: 237.1 m / z, found 238.32 [M +H]+. Synthesis of N-[2-fluoro-6-(4-isopropylpiperazin-1-yl) phenyl]-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-fluoro-6-(4-isopropylpiperazin-1-yl) aniline (730 mg, 3.076 mmol, 1 equiv) in DCM were added triphosgene (273.82 mg, 0.923 mmol, 0.3 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added triethylamine (933.81 mg, 9.228 mmol, 3 equiv) at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine (346.46 mg, 1.538 mmol, 0.5 equiv) in DCM (1 mL) and triethylamine (933.81 mg, 9.228 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-[2-fluoro-6-(4-isopropylpiperazin-1-yl) phenyl]-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide (265.4 mg, 17.29%) as a white solid. MS (ESI): mass calcd. for C25H34F2N6O2: 488.2 m / z, found 489.58[M +H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 7.10 – 7.40 (m, 1H), 6.79 – 7.00 (m, 2H), 6.49 (s, 1H), 4.90 – 5.20 (m, 1H), 3.65 – 4.00 (m, 2H), 3.05 – 3.40 (m, 2H), 2.80 – 3.00 (m, 4H), 2.50 – 2.80 (m, 5H), 2.40 – 2.50 (m, 1H), 2.20 – 2.30 (m,2H),1.80 – 2.00 (m,1H),1.60 – 1.80 (m,2H),1.50 – 1.60 (m,1H) 1.30 – 1.40 (m,3H) 1.10 – 1.00 (m,6H).19F NMR (282 MHz, CD3CN) δ 16.68, -120.63. Provided herein is the synthesis of Compound 23: N-(2-chloro-6-(4-isopropyl-1,4- diazepan-1-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide. Scheme 23:Synthesis of 2-chloro-6-(4-isopropyl-1,4-diazepan-1-yl)aniline To a solution of 1-(3-chloro-2-nitrophenyl)-4-isopropyl-1,4-diazepane (700 mg, 2.351 mmol, 1 equiv) in acetic acid (10 mL) was added zinc (1540 mg, 23.555 mmol, 10.02 equiv). The reaction was stirred at rt for 1h. The reaction was concentrated under reduced pressure. The mixture was diluted with DCM, washed with saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate, filtered and concentrated. This resulted in 2-chloro-6-(4-isopropyl- 1,4-diazepan-1-yl)aniline as a yellow oil (520 mg,83 % ). LC / MS (ESI): mass calcd. for C14H22ClN3: 267.2 m / z, found:268.15 [M+H]+Synthesis of N-(2-chloro-6-(4-isopropyl-1,4-diazepan-1-yl) phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-chloro-6-(4-isopropyl-1,4-diazepan-1-yl) aniline (166.53 mg, 0.622 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (73.76 mg, 0.249 mmol, 0.40 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added triethylamine (94.14 mg, 0.930 mmol, 1.50equiv) in portions at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added N-[2-chloro-6-(4-isopropyl-1,4- diazepan-1-yl) phenyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine-1-carboxamide (22.8 mg, 6.91%) in DCM (1 mL) and triethylamine (94.14 mg, 0.93 mmol, 3 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (30 mL), then extracted with DCM (3 × 20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18 150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-[2-chloro-6-(4-isopropyl-1,4-diazepan-1-yl) phenyl]-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide (22.8 mg, 6.91%) as a off-white solid. LC / MS (ESI): mass calcd. for C26H36ClFN6O2:518.3 m / z, found:519.25 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 6.96 - 7.13 (m, 3H), 6.73 (s, 1H), 4.80 - 5.21 (m, 1H), 3.73 - 3.87 (m, 2H), 3.16 - 3.25 (m, 2H), 3.02 - 3.15 (m, 4H), 2.83 - 2.98 (m, 1H), 2.69 - 2.79 (m, 4H), 2.39 - 2.49 (m, 1H), 2.16 - 2.23 (m, 2H), 1.61 - 1.95 (m, 5H), 1.43 - 1.60 (m, 1H), 1.26 - 1.39 (m, 3H), 0.90 - 1.03 (m, 6H).19F NMR (282 MHz, CD3CN) δ -220.43. Provided herein is the synthesis of Compound 24: 4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-N-[2-(4-isopropylpiperazin-1-yl)-6-methoxyphenyl]-4-methylpiperidine- 1-carboxamide.Scheme 24:Synthesis of 1-isopropyl-4-(3-methoxy-2-nitrophenyl)piperazine To a solution of 1-fluoro-3-methoxy-2-nitrobenzene (2 g, 11.687 mmol, 1 equiv) in ACN (20 mL) was added 1-isopropylpiperazine (1.65 g, 12.856 mmol, 1.1 equiv) and K2CO3 (4.88 g, 35.061 mmol, 3 equiv) at 0 °C. The resulting mixture was stirred for 3h at rt. The reaction was quenched with water. The resulting mixture was extracted with DCM (3x 30 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure to provide the crude product, which was purified by column chromatography on silica gel chromatography (0-100% PE / EA) to afford 1-isopropyl-4-(3-methoxy-2- nitrophenyl)piperazine (2.7 g, 82.53% yield) as a white solid. MS (ESI): mass calcd for C14H21N3O3: 279.16, found: 280.15[M+H]+. Synthesis of 2-(4-isopropylpiperazin-1-yl)-6-methoxyaniline To a stirred solution of 1-isopropyl-4-(3-methoxy-2-nitrophenyl)piperazine (600 mg, 2.148 mmol, 1 equiv) in MeOH (20 mL) was added Pd / C (600 mg) in portions at rt. The resulting mixture was stirred overnight at rt under hydrogen atmosphere. After filtration, the filtrate was concentrated under reduced pressure to give the 2-(4-isopropylpiperazin-1-yl)-6-methoxyaniline (500 mg, 91.21% yield) as a white solid. MS (ESI): mass calcd for C14H23N3O: 249.18, found: 250.20 [M+H]+. Synthesis of 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-[2-(4- isopropylpiperazin-1-yl)-6-methoxyphenyl]-4-methylpiperidine-1-carboxamide To a stirred solution of 2-(4-isopropylpiperazin-1-yl)-6-methoxyaniline (200 mg, 0.802 mmol, 1 equiv) in DCM (10 mL) were added triphosgene (71.40 mg, 0.241 mmol, 0.3 equiv) in portions at 0°C. The resulting mixture was stirred for 1h at rt under nitrogen atmosphere. Triethylamine (243.49 mg, 2.406 mmol, 3 equiv) was added to the reaction at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at rt for 1h. Then 4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (90.34 mg, 0.401 mmol, 0.5 equiv) and triethylamine (243.49 mg, 2.406 mmol, 3 equiv) was added at 0 °C. The reaction was stirred at rt for 1h. The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC using a XBridge BEH C18 OBD Prep Column 19 x 250 mm x 5μm column (eluent: 58% to 65% (v / v) ACN and H2O with 10 mmol / L NH4HCO3) to give the 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N- [2-(4-isopropylpiperazin-1-yl)-6-methoxyphenyl]-4-methylpiperidine-1-carboxamide (30.7 mg, 7.51% yield) as a white solid. MS (ESI): mass calcd. for C26H37FN6O3: 500.29 m / z, found 501.25 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 7.08 – 7.19 (m, 1H), 6.69 – 6.81 (m, 2H), 6.29 (s, 1H), 4.90 – 5.20 (m, 1H), 3.71 – 3.86 (m, 5H), 3.13 – 3.32 (m, 2H), 2.79 – 2.88 (m, 4H), 2.59 – 2.74 (m, 5H), 2.38 – 2.56 (m, 1H), 1.77 – 1.97 (m, 2H), 1.63 – 1.77 (m, 2H), 1.45 – 1.63 (m, 1H), 1.37 (s, 3H), 0.99 – 1.10 (m, 6H).19F NMR (282 MHz, CD3CN) δ -220.45 Provided herein is the synthesis of Compound 25: N-[2-(difluoromethyl)-6-(4- isopropylpiperazin-1-yl) phenyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine-1-carboxamide.Scheme 25:Synthesis of 1-(difluoromethyl)-3-fluoro-2-nitrobenzene To a stirred solution of 3-fluoro-2-nitrobenzaldehyde (1.00 g, 5.913 mmol, 1 equiv) in DCM was added DAST (657.97 mg, 17.739 mmol, 3 equiv) in portions at 0 °C under air atmosphere. The resulting mixture was stirred for 2 h at room temperature under air atmosphere. Desired product could be detected by LCMS. The reaction was quenched by the addition of water (20 mL) at room temperature. The resulting mixture was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 1-(difluoromethyl)-3-fluoro-2-nitrobenzene (900 mg, 79.64%) as a white solid. Synthesis of 1-[3-(difluoromethyl)-2-nitrophenyl]-4-isopropylpiperazine To a stirred solution of 1-(difluoromethyl)-3-fluoro-2-nitrobenzene (900 mg, 4.709 mmol, 1 equiv) and 1-isopropylpiperazine (422.68 mg, 3.296 mmol, 0.7 equiv) in DMF was added K2CO3(1311.21 mg, 9.418 mmol, 2 equiv) in portions at 0 °C under air atmosphere. Theresulting mixture was stirred for 2 h at room temperature under air atmosphere. Desired product could be detected by LCMS. The reaction was quenched with water (20 mL). The resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (5:1) to afford 1-[3-(difluoromethyl)-2-nitrophenyl]-4-isopropylpiperazine (740 mg, 52.50%) as a white solid. MS (ESI): mass calcd. for C14H19F2N3O2: 299.32 m / z, found 300.05 [M+H]+. Synthesis of 2-(difluoromethyl)-6-(4-isopropylpiperazin-1-yl) aniline The mixture of 1-[3-(difluoromethyl)-2-nitrophenyl]-4-isopropylpiperazine (350 mg, 1.169 mmol, 1 equiv) and Pd / C (349.67 mg, 3.285 mmol, 2.81 equiv) in MeOH (15 mL) was stirred for 1 h at room temperature under hydrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was filtered, the filter cake was washed with MeOH (3 x 10 mL). The filtrate was concentrated under reduced pressure. This resulted in 2- (difluoromethyl)-6-(4-isopropylpiperazin-1-yl) aniline (250 mg, 79.38%) as a yellow solid. The crude product was used in the next step directly without further purification. MS (ESI): mass calcd. for C14H21F2N3: 269.34 m / z, found 270.10[M+H]+. Synthesis of N-[2-(difluoromethyl)-6-(4-isopropylpiperazin-1-yl) phenyl]-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide To a stirred solution of 2-(difluoromethyl)-6-(4-isopropylpiperazin-1-yl) aniline (240 mg, 0.891 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (79.32 mg, 0.267 mmol, 0.3 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for additional 1h at room temperature. The above mixture was added triethylamine (450.85 mg, 4.455 mmol, 5 equiv) in portions at 0 °C under nitrogen atmosphere and was stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)- 2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (100.36 mg, 0.446 mmol, 0.5 equiv) in DCM (1 mL) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with EA (3 × 20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. Theresidue was purified by preparative HPLC using a XBridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10mmol / L NH4HCO3) to afford the N-[2-(difluoromethyl)-6-(4-isopropylpiperazin-1-yl) phenyl]-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide as white solid. (29.8 mg, 6.34%). MS (ESI): mass calcd. for C26H35F3N6O2: 520.2 m / z, found 521.25[M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.20 – 7.50 (m, 3H), 7.10 – 7.20(m, 1H), 6.80 – 7.10 (m, 1H), 4.90 – 5.20 (m, 1H), 3.87 – 4.02 (m, 2H), 3.20 – 3.40 (m, 2H), 2.60 – 2.90 (m, 9H), 2.40 – 2.50 (m, 1H), 2.20 – 2.30 (m, 1H), 1.70 – 1.90 (m, 4H), 1.50 – 1.62 (m, 1H), 1.30 – 1.42 (m, 3H), 1.00 – 1.12 (m, 6H).19F NMR (376 MHz, CD3CN) δ-113.66, -220.59. Provided herein is the synthesis of Compound 26: N-(2-cyano-6-cyclopropylphenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide. Scheme 26:Synthesis of 2-amino-3-cyclopropylbenzonitrile To a solution of 2-amino-3-bromobenzonitrile (700 mg, 3.553 mmol, 1 equiv) in dioxane (7 mL) and H2O (0.7 mL) was added cyclopropylboronic acid (457.75 mg, 5.329 mmol, 1.50 equiv), Pd(dppf)Cl2(290.12 mg, 0.396 mmol, 0.11 equiv) and K2CO3(1230 mg, 8.900 mmol, 2.51 equiv). The reaction was stirred at 90 °C for 2h under N2. Quenched with water (50 mL) and extracted with EA (3 x 50 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel with MeOH / DCM (0-100%) to give 2-amino-3-cyclopropylbenzonitrile as a yellow oil (450 mg, 80%). LC / MS (ESI): mass calcd. for C10H10N2:158.1 m / z, found:159.10 [M+H]+.Synthesis of N-(2-cyano-6-cyclopropylphenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-amino-3-cyclopropylbenzonitrile (140.43 mg, 0.888 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (105.37 mg, 0.355 mmol, 0.40 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added triethylamine (134.49 mg, 1.329 mmol, 1.50 equiv) in portions at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-4-methylpiperidine (100 mg, 0.444 mmol, 0.50 equiv) in DCM (1 mL) and triethylamine (134.49 mg, 1.33 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (30 mL), then extracted with DCM (3×20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-(2-cyano-6-cyclopropylphenyl)-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide (64.0 mg, 17.57%) as a white solid.LC / MS (ESI): mass calcd. for C22H24FN5O2: 409.2 m / z, found:410.20 [M+H] +.1H NMR (300 MHz, Acetonitrile-d3) δ 7.47 - 7.59 (m, 1H), 7.22 - 7.34 (m, 2H), 7.18 (s, 1H), 4.89 - 5.22 (m, 1H), 3.77 - 3.90 (m, 2H), 3.15 - 3.30 (m, 2H), 2.35 - 2.54 (m, 1H), 2.19 - 2.30 (m, 2H), 1.97 - 2.01 (m, 1H), 1.79 - 1.95 (m, 1H), 1.70 - 1.80 (m, 2H), 1.41 - 1.60 (m, 1H), 1.30 – 1.40 (m, 3H), 0.91 - 1.01 (m, 2H), 0.59 - 0.69 (m, 2H).19F NMR (282 MHz, CD3CN) δ -220.46. Provided herein is the synthesis of Compound 27: N-(4-chloro-2-cyano-6-(4- isopropylpiperazin-1-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide.Scheme 27:Synthesis of 5-chloro-3-fluoro-2-nitrobenzonitrile To a solution of 3-chloro-5-fluorobenzonitrile (1 g, 6.428 mmol, 1 equiv) in H2SO4 (10 mL) was added KNO3(1.30 g, 12.856 mmol, 2 equiv) at 0°C. The reaction was stirred at 0 °C for 0.5h. Quenched with water (50 mL) and extracted with DCM (3 x 30 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated to give 5- chloro-3-fluoro-2-nitrobenzonitrile (300 mg, 23.27%) as a yellow solid. Synthesis of 5-chloro-3-(4-isopropylpiperazin-1-yl)-2-nitrobenzonitrile To a solution of 5-chloro-3-fluoro-2-nitrobenzonitrile (300 mg, 1.496 mmol, 1 equiv) in dimethylformamide (5 mL) was added 1-isopropylpiperazine (230.16 mg, 1.795 mmol, 1.2 equiv) and K2CO3 (832.99 mg, 5.984 mmol, 4 equiv). The reaction was stirred at 60 °C for 16h. Quenched with water (30 mL) and extracted with EA (3 x 30 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel with EA / PE (0-100%) to give 5-chloro-3-(4- isopropylpiperazin-1-yl)-2-nitrobenzonitrile (350 mg, 75.78%) as a yellow solid. LC / MS (ESI): mass calcd. for C14H17ClN4O2: 308.1 m / z, found:309.1 [M+H]+.Synthesis of 2-amino-5-chloro-3-(4-isopropylpiperazin-1-yl)benzonitrile To a solution of 5-chloro-3-(4-isopropylpiperazin-1-yl)-2-nitrobenzonitrile (350 mg, 1.134 mmol, 1 equiv) in acetic acid (5 mL) was added zinc (741.10 mg, 11.340 mmol, 10 equiv).The reaction was stirred at 25 °C for 16h. The mixture was filtered and concentrated. Quenched with NaHCO3 water (30 mL) and extracted with EA (3 x 30 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated to give 2-amino-5-chloro-3-(4- isopropylpiperazin-1-yl)benzonitrile (70 mg, 22.15%) as a yellow oil. LC / MS (ESI): mass calcd. for C14H19ClN4:278.1 m / z, found:279.15 [M+H]+. Synthesis of N-(4-chloro-2-cyano-6-(4-isopropylpiperazin-1-yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide To a solution of 2-amino-5-chloro-3-(4-isopropylpiperazin-1-yl)benzonitrile (70 mg, 0.251 mmol, 1 equiv) in DCM (3 mL) was added triphosgene (29.80 mg, 0.100 mmol, 0.4 equiv) at 0°C under N2. The reaction was stirred at 0 °C for 1h. Then triethylamine (76.23 mg, 0.753 mmol, 3 equiv) was added at 0 °C. The reaction was stirred at 25 °C for 1h. Then to a solution of 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (62.22 mg, 0.276 mmol, 1.1 equiv) in DCM (1 mL) was added the above mixture. The reaction was stirred at 25 °C for 1h. Quenched with water (20 mL) and extracted with DCM (3 x 30 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by preparative HPLC using a YMC-Actus Triart C18 ExRS 150 mm x 30 mm x 5 μm column (eluent: 17% to 42% (v / v) CH3CN and H2O with 10mmol / L NH4HCO3) to afford the title compound N-(4-chloro-2-cyano-6-(4-isopropylpiperazin-1-yl)phenyl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (34.9 mg, 25.88%) as a white solid. LC / MS (ESI): mass calcd. for C26H33ClFN7O2: 529.2 m / z, found:430.35 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.34 – 7.43 (m, 2H), 7.05 (s, 1H), 4.92 – 5.17 (m, 1H), 3.79 – 3.90 (m, 2H), 3.20 – 3.37 (m, 2H), 2.80 – 2.86 (m, 4H), 2.68 – 2.77 (m, 1H), 2.61 – 2.68 (m, 4H), 2.41 – 2.51 (m, 1H), 2.23 – 2.29 (m, 2H), 1.79 – 1.92 (m, 1H), 1.68 – 1.78 (m, 2H), 1.48 – 1.61 (m, 1H), 1.36 (s, 3H), 1.04 (d, J = 6.6 Hz, 6H).19F NMR (376 MHz, Acetonitrile-d3) δ -220.40.Provided herein is the synthesis of Compound 28: N-(2-chloro-4-(4-isopropylpiperazin-1- yl)pyridin-3-yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1- carboxamide. Scheme 28:Synthesis of 1-(2-chloro-3-nitropyridin-4-yl)-4-isopropylpiperazine To a solution of 2,4-dichloro-3-nitropyridine (2 g, 10.364 mmol, 1 equiv) in ACN (20 mL) was added 1-isopropylpiperazine (1.33 g, 10.364 mmol, 1 equiv) and K2CO3 (4.33 g, 31.092 mmol, 3 equiv) at 0 °C. The resulting mixture was stirred for 3h at rt. The reaction was quenched with water. The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure to provide the crude product, which was purified by column chromatography on silica gel chromatography (0-100% PE / EA) to afford 1-(2-chloro-3-nitropyridin-4-yl)-4-isopropylpiperazine (2.3 g, 61.25% yield) as a white solid. MS (ESI): mass calcd for C12H17ClN4O2: 284.10, found: 285.10 [M+H]+. Synthesis of 2-chloro-4-(4-isopropylpiperazin-1-yl)pyridin-3-amine To a stirred solution of 1-(2-chloro-3-nitropyridin-4-yl)-4-isopropylpiperazine (1.9 g, 6.673 mmol, 1 equiv) in MeOH (15 mL) and H2O (1.5 mL) was added Fe (3.73 g, 66.730 mmol, 10 equiv) and NH4Cl (3.57 g, 66.730 mmol, 10 equiv) in portions at rt. The resulting mixture was stirred overnight at 70°C. The resulting mixture was filtered, the filter cake was washed with MeOH. The filtrate was concentrated under reduced pressure to provide the crude product, which was purified by column chromatography on silica gel chromatography (0-100% PE / EA) to afford 2-chloro-4-(4-isopropylpiperazin-1-yl)pyridin-3-amine (1 g, 54.55% yield) as a white solid. MS (ESI): mass calcd for C12H19ClN4: 254.13, found: 255.15 [M+H]+. Synthesis of N-(2-chloro-4-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide To a stirred solution of 2-chloro-4-(4-isopropylpiperazin-1-yl)pyridin-3-amine (350 mg, 1.374 mmol, 1 equiv) in DCM (10 mL) were added pyridine (326.01 mg, 4.122 mmol, 3 equiv) and 4-nitrophenyl carbonochloridate (415.37 mg, 2.061 mmol, 1.5 equiv) in portions at 0°C. The resulting mixture was stirred for 1h at rt. Then 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-4-methylpiperidine (154.74 mg, 0.687 mmol, 0.5 equiv) and triethylamine (417.07 mg, 4.122 mmol, 3 equiv) were added to the reaction at 0 °C. The resulting mixture was stirred at rt for 1h. The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC using a Xselect CSH C18 OBD 30 x 150 mm x 5μm column (eluent: 2% to 19% (v / v) ACN and H2O with 0.1%FA) to give N-[4-chloro-2-(4-isopropylpiperazin-1-yl)pyridin-3-yl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide formate (3.9 mg, 0.56% yield) as an off-white solid. MS (ESI): mass calcd. for C24H33ClFN7O2: 505.24 m / z, found 506.25 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 7.80 – 8.01 (m, 1H), 6.81 – 6.93 (m, 2H), 4.70 – 5.11 (m, 1H), 3.60 – 3.78 (m, 2H), 3.12 – 3.25 (m, 6H), 2.84 – 2.90 (m, 1H), 2.68 – 2.76 (m, 4H), 2.34 –2.40 (m, 1H), 2.05 – 2.18 (m, 2H), 1.71 – 1.85 (m, 1H), 1.53 – 1.68 (m, 2H), 1.39 – 1.51 (m, 1H), 1.22 – 1.31 (m, 3H), 0.99 – 1.10 (m, 6H).19F NMR (282 MHz, CD3CN) δ -220.51. Provided herein is the synthesis of Compound 29: N-(2-chloro-6-(4-isopropylpiperazin-1- yl) phenyl)-4-(2-chlorophenyl)-4-methylpiperidine-1-carboxamide. Scheme 29:Synthesis of N-(2-chloro-6-(4-isopropylpiperazin-1-yl) phenyl)-4-(2-chlorophenyl)-4- methylpiperidine-1-carboxamide To a stirred solution of 2-chloro-6-(4-isopropylpiperazin-1-yl) aniline (60 mg, 0.236 mmol, 1 equiv) in DCM were added triphosgene (42.09 mg, 0.142 mmol, 0.6 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for additional 1h at room temperature. The above mixture was added triethylamine (143.55 mg, 1.416 mmol, 6 equiv) in portions at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-(2-chlorophenyl)-4-methylpiperidine (66.11 mg, 0.315 mmol, 1 equiv) in DCM (1 mL) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (20 mL), then extracted with DCM (3 × 20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a XBridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10mmol / L NH4HCO3) to afford the N-[2-chloro-6-(4-isopropylpiperazin-1-yl)phenyl]-4-(2-chlorophenyl)-4-methylpiperidine-1-carboxamide (41.9 mg, 27.15%) as a white solid. MS (ESI): mass calcd. for C26H34Cl2N4O: 488.21 m / z, found 489.30 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.45 – 7.55 (m, 1H), 7.30 – 7.45 (m, 2H), 7.20 – 1H), 7.10– 7.20 (m, 2H), 7.00 – 7.10 (m, 1H), 6.50 – 6.70 (s, 1H), 3.50 – 3.70 (m, 4H), – 2.90 (m, 4H), 2.50 – 2.80 (m, 5H), 2.10 – 2.20 (m, 2H), 1.80 – 1.90 (m, 2H), 1.30 – 1.40 (m, 3H), 1.00 – 1.10 (m, 6H) Provided herein is the synthesis of Compound 30: N-[2-chloro-6-(4-isopropylpiperazin-1- yl) phenyl]-4-(4-chlorophenyl)-4-methylpiperidine-1-carboxamide. Scheme 30:Synthesis of 1-(3-chloro-2-nitrophenyl)-4-isopropylpiperazine To a stirred solution of 1-chloro-3-fluoro-2-nitrobenzene (500 mg, 2.848 mmol, 1.5 equiv) and 1-isopropylpiperazine (243.48 mg, 1.899 mmol, 1 equiv) in acetonitrile was added K2CO3 (793.06 mg, 5.696 mmol, 3 equiv) in portions at 0 °C under air atmosphere. The resultingmixture was stirred for 2h at room temperature under air atmosphere. Desired product could be detected by LCMS. The resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (5:1) to afford 1-(3-chloro-2-nitrophenyl)-4-isopropylpiperazine (500 mg, 92.79%) as a yellow solid. MS (ESI): mass calcd. for C13H18ClN3O2: 283.76 m / z, found 284.05 [M+H]+. Synthesis of 2-chloro-6-(4-isopropylpiperazin-1-yl) aniline To a stirred mixture of 1-(3-chloro-2-nitrophenyl)-4-isopropylpiperazine (500 mg, 1.762 mmol, 1 equiv) and Fe (984.02 mg, 17.620 mmol, 10 equiv) in MeOH / H2O (10:1, 10 mL) was added NH4Cl (942.52 mg, 17.620 mmol, 10 equiv) in portions at room temperature under air atmosphere. The resulting mixture was stirred for 2h at 70 °C. Desired product could be detected by LCMS. The reaction was quenched with water at room temperature. The resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (1:1) to afford 2- chloro-6-(4-isopropylpiperazin-1-yl) aniline (120 mg, 26.84%) as a grey solid. MS (ESI): mass calcd. for C13H20ClN3: 253.77 m / z, found 254.05[M+H]+. Synthesis of N-[2-chloro-6-(4-isopropylpiperazin-1-yl) phenyl]-4-(4-chlorophenyl)-4- methylpiperidine-1-carboxamide To a stirred solution of 2-chloro-6-(4-isopropylpiperazin-1-yl) aniline (60 mg, 0.236 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (42.09 mg, 0.142 mmol, 0.6 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for additional 1h at room temperature. The above mixture was added triethylamine (143.55 mg, 1.416 mmol, 6 equiv) in portions at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then, the above mixture was added were added 4-(4-chlorophenyl)- 4-methylpiperidine (49.59 mg, 0.236 mmol, 1 equiv) in DCM (1 mL) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water(30 mL), then extracted with DCM (3 × 20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a XBridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10mmol / L NH4HCO3) to afford the N-[2-chloro-6-(4- isopropylpiperazin-1-yl) phenyl]-4-(4-chlorophenyl)-4-methylpiperidine-1-carboxamide (12.1 mg, 10.36%) as a white solid. MS (ESI): mass calcd. for C26H34Cl2N4O: 488.21 m / z, found 489.30 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.40 – 7.60 (m, 4H), 7.10 – 7.20(m, 2H), 7.00 – 7.10 (m, 1H), 6.50 – 6.80 (s, 1H), 3.40 – 3.70 (m, 4H), 2.40 – 3.40 (m, 9H), 2.00 – 2.10 (m, 2H), 1.80 – 1.90 (m, 2H), 1.30 – 1.40 (m, 3H), 1.00 – 1.10 (m, 6H). Provided herein is the synthesis of Compound 31: 4-(4-chlorophenyl)-N-(2-cyano-6- isopropylphenyl)-4-methylpiperidine-1-carboxamide. Scheme 31:Synthesis of 1-benzyl-4-(4-chlorophenyl)-4-methylpiperidine To a solution of 1-benzyl-4-methylpiperidin-4-ol (1 g, 4.871 mmol, 1 equiv) in chlorobenzene (100 mL) was added aluminium chloride (4.22 g, 31.662 mmol, 6.5 equiv) at 0°C. The reaction was stirred at 100 °C for additional 6 hours. The reaction was cooled, quenchedwith water (50 mL) and extracted with EA (3 x 50 mL ). The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure to provide the crude product, which was purified by column chromatography on silica gel with DCM / MeOH (0-15%) to give 1-benzyl-4-(4-chlorophenyl)-4-methylpiperidine (1.1 g, 75.32% yield) as a yellow solid. MS (ESI): mass calcd. for C19H22ClN: 299.84 m / z, found 300.15 [M+H]+. Synthesis of 4-(4-chlorophenyl)-4-methylpiperidine To a solution of 1-benzyl-4-(4-chlorophenyl)-4-methylpiperidine (1 g, 3.335 mmol, 1 equiv) in DCM (100 mL) was added chloroethyl chloroformate (1.43 g, 10.005 mmol, 3.0 equiv). The reaction was stirred at 60°C for 6 hours. The reaction was cooled and concentrated. Then MeOH (100 mL) was added to the reaction and stirred at 60 °C for 1 h. The mixture was concentrated under reduced pressure to provide the crude product. The crude was purified by column chromatography on silica gel with EA / PE (0-100%) to give the 4-(4-chlorophenyl)-4- methylpiperidine (500 mg, 71.49% yield) as a yellow solid. MS (ESI): mass calcd. for C12H16ClN: 209.72 m / z, found 210.15 [M+H]+. Synthesis of 4-(4-chlorophenyl)-N-(2-cyano-6-isopropylphenyl)-4-methylpiperidine-1- carboxamide To a solution of 2-amino-3-isopropylbenzonitrile (84.04 mg, 0.525 mmol, 1.1 equiv) in DCM (10 mL) was added triphosgene (46.69 mg, 0.157 mmol, 0.33 equiv) at 0°C under N2. After stirred for 60 min at rt, Et3N (96.50 mg, 0.954 mmol, 2.0 equiv) was added to the mixture, and the reaction was stirred at rt for additional one hour. The 4-(4-chlorophenyl)-4- methylpiperidine (100 mg, 0.477 mmol, 1 equiv) was added to the mixture, and the reaction was stirred at 25 °C for additional one hour. Quenched with water (15 mL) and extracted with DCM (15 mL x 3). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by preparative HPLC using a YMC-Actus Triart C18 ExRS 150 mm x 30 mm x 5 μm column (eluent: 62% to 72% (v / v) ACN and H2O with 10 mmol / L NH4HCO3) to give the 4-(4-chlorophenyl)-N-(2-cyano-6-isopropylphenyl)-4- methylpiperidine-1-carboxamide (22.2 mg, 11.67%) as a white solid. MS (ESI): mass calcd. for C23H26ClN3O: 395.93 m / z, found 396.00 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.65(dd, J = 7.9, 1.5 Hz, 1H), 7.51 – 7.59 (m, 1H), 7.31 – 7.49 (m, 4H), 7.04 (s, 1H), 3.53 – 3.67 (m, 2H), 3.42 – 3.53 (m, 2H), 3.17 – 3.27 (m, 1H), 2.08 – 2.18 (m, 2H), 1.75 – 1.86 (m, 2H), 1.31 (s, 3H), 1.19 (d, J = 6.9 Hz, 6H). Provided herein is the synthesis of Compound 32: N-(2-chloro-6-cyclopropylphenyl)-4- (5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide. Scheme 32:Synthesis of 2-chloro-6-cyclopropylaniline To a solution of 2-chloro-6-iodoaniline (1 g, 3.945 mmol, 1 equiv) in dioxane (5 mL) and H2O (0.5 mL) was added cyclopropylboronic acid (0.847 g, 9.860 mmol, 2.50 equiv), Pd(dppf)Cl2 (0.322 g, 0.440 mmol, 0.11 equiv) and K2CO3 (1.36 g, 9.840 mmol, 2.49 equiv). The reaction was stirred at 90 °C for 3h under N2. Quenched with water (100 mL) and extracted with EA (3 x 100 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel with MeOH / DCM (0-100%) to give 2-chloro-6-cyclopropylaniline as a yellow oil (380 mg, 57 %). LC / MS (ESI): mass calcd. for C9H10ClN:167.1 m / z, found:168.15 [M+H]+. Synthesis of N-(2-chloro-6-cyclopropylphenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-chloro-6-cyclopropylaniline (133.90 mg, 0.799 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (94.83 mg, 0.320 mmol, 0.40 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. Theabove mixture was added triethylamine (121.04 mg, 1.196 mmol, 1.50 equiv) in portions at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-4-methylpiperidine (90 mg, 0.400 mmol, 0.50 equiv) in DCM (1 mL) and triethylamine (121.04 mg, 1.20 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (30 mL), then extracted with DCM (3 × 20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-(2-chloro-6-cyclopropylphenyl)-4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide (18.8 mg, 5.57%) as a white solid.LC / MS (ESI): mass calcd for C21H24ClFN4O2:418.2 m / z, found:419.15 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 7.22 - 7.31 (m, 1H), 7.08 - 7.20 (m, 1H), 6.86 - 6.95 (m, 1H), 6.79 (s, 1H), 4.87 - 5.19 (m, 1H), 3.71 - 3.85 (m, 2H), 3.15 - 3.30 (m, 2H), 2.38 - 2.41 (m, 1H), 2.19 - 2.25 (m, 2H), 1.98 - 2.02 (m, 1H), 1.77 - 1.91 (m, 1H), 1.60 - 1.75 (m, 2H), 1.42 - 1.59 (m, 1H), 1.26 - 1.39 (m, 3H), 0.81 - 0.99 (m, 2H), 0.52 - 0.66 (m, 2H).19F NMR (282 MHz, CD3CN) δ -220.49. Provided herein is the synthesis of Compound 33: N-(2-fluoro-6-(5-isopropyl-1,2,4- oxadiazol-3-yl) phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide.Scheme 33:Synthesis of methyl tert-butyl (2-cyano-6-fluorophenyl) carbamate To a stirred solution of 2-amino-3-fluorobenzonitrile (3 g, 22.038 mmol, 1 equiv) and (Boc)2O (9.62 g, 44.076 mmol, 2 equiv) in DCM (40 mL) was added DMAP (2.69 g, 22.038 mmol, 1 equiv) and Et3N (4.46 g, 44.076 mmol, 2 equiv)at rt. The mixture was stirred at rt for 3h. The reaction was quenched with water at rt. The resulting mixture was extracted with DCM (3 x 50 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE and EA (100%) to afford tert-butyl N-(2-cyano-6- fluorophenyl)carbamate (5.2 g, 99.88%) as a yellow oil. LC / MS: mass calcd. for C12H13FN2O2: 236.24, found: 237.10 [M+H]+. Synthesis of methyl tert-butyl (Z)-(2-fluoro-6-(N'-hydroxycarbamimidoyl) phenyl) carbamate To a stirred solution of tert-butyl N-(2-cyano-6-fluorophenyl) carbamate (2 g, 8.466 mmol, 1 equiv) in ethyl alcohol (20 mL) was added hydroxylamine (0.56 g, 16.932 mmol, 2equiv) at rt. The mixture was stirred at 70°C for 3h. The resulting mixture was concentrated under reduced pressure. The reaction was diluted with water (30 mL). The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in the crude product tert-butyl N-{2-fluoro-6-[(Z)-N'-hydroxycarbamimidoyl]phenyl}carbamate (1.6 g, 70.19%) as a yellow oil. The crude product was used in the next step directly without further purification. LC / MS: mass calcd. for C12H16FN3O3: 269.27, found: 270.15 [M+H]+. Synthesis of methyl tert-butyl (Z)-(2-fluoro-6-(N'-(isobutyryloxy) carbamimidoyl) phenyl) carbamate To a stirred solution of tert-butyl N-{2-fluoro-6-[(Z)-N'-hydroxycarbamimidoyl] phenyl} carbamate (1 g, 3.714 mmol, 1 equiv) and isobutyric acid (0.49 g, 5.571 mmol, 1.5 equiv) in DMF (20 mL) were added HATU (2.97 g, 7.799 mmol, 2.1 equiv) and DIEA (0.96 g, 7.428 mmol, 2 equiv) at rt. The mixture was stirred at rt for 1h. The reaction was quenched with water at rt. The resulting mixture was extracted with EA (3 x 50 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE and EA (40%) to afford (Z)-[amino({2-[(tert-butoxycarbonyl)amino]-3- fluorophenyl})methylidene]amino 2-methylpropanoate (680 mg, 53.96%) as a yellow oil. LC / MS: mass calcd. for C16H22FN3O4: 339.36, found: 340.15 [M+H]+. Synthesis of methyl tert-butyl (2-fluoro-6-(5-isopropyl-1,2,4-oxadiazol-3-yl) phenyl) carbamate To a stirred solution of (Z)-[amino({2-[(tert-butoxycarbonyl) amino]-3-fluorophenyl}) methylidene] amino 2-methylpropanoate (570 mg, 1.680 mmol, 1 equiv) in toluene (10 mL) was added DBU (383.56 mg, 2.520 mmol, 1.5 equiv) at rt. The mixture was stirred at 90oC for 2h. The reaction was quenched with water at rt. The resulting mixture was extracted with EA (3 x 25 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE and EA (30%) to afford tert-butyl N-[2-fluoro-6-(5-isopropyl- 1,2,4-oxadiazol-3-yl) phenyl] carbamate (310 mg, 57.43%) as a yellow oil. LC / MS: mass calcd. for C16H20FN3O3: 321.35, found: 322.15 [M+H]+.Synthesis of methyl 2-fluoro-6-(5-isopropyl-1,2,4-oxadiazol-3-yl) aniline To a stirred solution of tert-butyl N-[2-fluoro-6-(5-isopropyl-1,2,4-oxadiazol-3-yl) phenyl] carbamate (310 mg, 0.965 mmol, 1 equiv) in HCl in 1,4-dioxane (3 mL, 4M) at rt. The mixture was stirred at rt for 1h. The resulting mixture was concentrated under reduced pressure. This resulted in the crude product methyl 2-fluoro-6-(5-isopropyl-1,2,4-oxadiazol-3-yl) aniline (220 mg) as a yellow oil. LC / MS: mass calcd. for C11H12FN3O: 221.23, found: 222.15 [M+H]+. Synthesis of methyl N-(2-fluoro-6-(5-isopropyl-1,2,4-oxadiazol-3-yl) phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide To a stirred solution of 2-fluoro-6-(5-isopropyl-1,2,4-oxadiazol-3-yl) aniline (74 mg, 0.334 mmol, 1 equiv) in DCM (4 mL) was added triphosgene (39.70 mg, 0.134 mmol, 0.4 equiv) at 0oC under nitrogen atmosphere. The mixture was stirred at 0oC for 15 min and rt for 15min. To the above mixture was added triethylamine (169.24 mg, 1.670 mmol, 5 equiv) at 0oC. The resulting mixture was stirred for additional 0.5h at rt. To the above mixture was added 4-{5- [(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (90.42 mg, 0.401 mmol, 1.2 equiv) at rt. The resulting mixture was stirred for additional 1h at rt. The reaction was quenched with water at rt. The resulting mixture was extracted with EA (3 x 25mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC using a XBridge Prep OBD C18 Column 150 mm x 30 mm x 5 μm column (eluent: 44% to 62% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford N-[2-fluoro-6-(5-isopropyl-1,2,4- oxadiazol-3-yl) phenyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4- methylpiperidine-1-carboxamide (25 mg, 15.79%) as a white solid. LC / MS: mass calcd. for C23H26F2N6O3: 472.49, found: 473.20 [M+H]+.1H NMR (400 MHz, Acetonitrile-d3) δ 7.99 – 8.18 (m, 1H), 7.79 – 7.92 (m, 1H), 7.23 –2H), 4.88 – 5.25 (m, 1H), 3.79 – 3.92 (m, 2H), 3.29 – 3.41 (m,1H), 3.12 – 3.29 (m, 2H), 2.32 – 2.56 (m, 1H), 2.15 – 2.30 (m, 3H), 1.79 – 1.92 (m, 1H), 1.67 – 1.79 (m, 2H), 1.50 – 1.60 (m, 1H), 1.41 – 1.49 (m, 6H), 1.31 – 1.39 (m, 3H).Provided herein is the synthesis of Compound 34: N-(2-(((S)-1- (cyclopropylmethyl)pyrrolidin-3-yl)oxy)-6-fluorophenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)- 1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide. Scheme 34:Synthesis of tert-butyl (S)-3-(3-fluoro-2-nitrophenoxy)pyrrolidine-1-carboxylate To a solution of tert-butyl (3S)-3-hydroxypyrrolidine-1-carboxylate (2.35 g, 12.551 mmol, 1.00 equiv) in tetrahydrofuran (20 mL) was added sodium hydride (0.45 g, 18.752 mmol, 1.49 equiv) at 0oC. The resulting mixture was stirred at rt for 30 min, then 1,3-difluoro-2- nitrobenzene (2 g, 12.571 mmol, 1 equiv) was added. The reaction was stirred at rt for 1h. Quenched with water (100 mL) and extracted with EA (3 x 100 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue waspurified by column chromatography on silica gel with MeOH / DCM (0-100%) to give tert-butyl (3S)-3-(3-fluoro-2-nitrophenoxy)pyrrolidine-1-carboxylate as a yellow oil (3 g, 73 % ). LC / MS (ESI): mass calcd. for C15H19FN2O5: 326.1 m / z, found:227.05 [M+H]+. Synthesis of (S)-3-(3-fluoro-2-nitrophenoxy) pyrrolidine To a solution of tert-butyl (3S)-3-(3-fluoro-2-nitrophenoxy)pyrrolidine-1-carboxylate (3 g, 9.193 mmol, 1 equiv) in DCM (3 mL) was added TFA (1 mL). The reaction was concentrated under reduced pressure. The mixture was diluted with DCM, washed with saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography on silica gel with MeOH / DCM (0-100%) to give (3S)- 3-(3-fluoro-2-nitrophenoxy) pyrrolidine as a yellow (1.9 g, 90%). LC / MS (ESI): mass calcd. for C10H11FN2O3: 226.1 m / z, found:227.05 [M+H]+. Synthesis of (S)-2-((1-(cyclopropylmethyl) pyrrolidin-3-yl)oxy)-6-fluoroaniline To a solution of (3S)-3-(3-fluoro-2-nitrophenoxy) pyrrolidine (900 mg, 3.979 mmol, 1 equiv) in methanol (9 mL) was added cyclopropanecarbaldehyde (560 mg, 7.990 mmol, 2.01 equiv) and NaBH3CN (750 mg, 11.935 mmol, 3.00 equiv). The reaction was stirred at rt for 3h. Quenched with water (50 mL) and extracted with EA (3 x 50 mL). The combined extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel with MeOH / DCM (0-100%) to give (3S)-1- (cyclopropylmethyl)-3-(3-fluoro-2-nitrophenoxy)pyrrolidine as a yellow oil (350 mg, 31 % ). LC / MS (ESI): mass calcd. for C14H17FN2O3:280.1 m / z, found:281.10 [M+H]+. Synthesis of (S)-1-(cyclopropylmethyl)-3-(3-fluoro-2-nitrophenoxy)pyrrolidine To a solution of (3S)-1-(cyclopropylmethyl)-3-(3-fluoro-2-nitrophenoxy)pyrrolidine (330 mg, 1.177 mmol, 1 equiv) in methanol (3 mL) was added Pd / C (330 mg, 3.101 mmol, 2.63 equiv). The resulting mixture was stirred for 1 h at room temperature under hydrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was filtered, the filter cake was washed with MeOH (3 x 10 mL). The filtrate was concentrated under reduced pressure. This resulted in 2-{[(3S)-1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy}-6-fluoroaniline asa yellow oil (290 mg, 98 % ).LC / MS (ESI): mass calcd. for C14H19FN2O:250.1 m / z, found:251.20 [M+H]+. Synthesis of N-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-3-yl)oxy)-6-fluorophenyl)-4-(5-((1S,2S)- 2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide To a stirred mixture of 2-{[(3S)-1-(cyclopropylmethyl) pyrrolidin-3-yl] oxy}-6- fluoroaniline (133.32 mg, 0.533 mmol, 1 equiv) in DCM (5 mL) were added triphosgene (63.22 mg, 0.213 mmol, 0.40 equiv) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1h at room temperature. The above mixture was added triethylamine (80.69 mg, 0.797 mmol, 1.50 equiv) in portions at 0 °C under nitrogen atmosphere and stirred for 20 min at room temperature under nitrogen atmosphere. Then the above mixture was added 4-{5- [(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine (60 mg, 0.266 mmol, 0.50 equiv) in DCM (1 mL) and triethylamine (80.69 mg, 0.80 mmol, 3 equiv) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. Desired product could be detected by LCMS. The mixture was diluted with water (50 mL), then extracted with DCM (3 × 20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC using a X Bridge Prep OBD C18150 mm x 30 mm x 5 μm column (eluent: 39% to 69% (v / v) CH3CN and H2O with 10 mmol / L NH4HCO3) to afford the N-(2-{[(3S)-1- (cyclopropylmethyl) pyrrolidin-3-yl] oxy}-6-fluorophenyl)-4-{5-[(1S,2S)-2-fluorocyclopropyl]- 1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide (24.3 mg, 9.05%) as a white solid. LC / MS (ESI): mass calcd. for C26H33F2N5O3:501.3 m / z, found:502.20 [M+H]+.1H NMR (300 MHz, Acetonitrile-d3) δ 7.08 - 7.21 (m, 1H), 6.72 - 6.83 (m, 3H), 5.10 - 5.21 (m, 1H), 4.79 - 4.99 (m, 1H), 3.71 - 3.85 (m, 2H), 3.15 - 3.31 (m, 2H), 2.67 - 2.99 (m, 3H), 2.21 - 2.59 (m, 6H), 1.77 - 1.99 (m, 3H), 1.65 - 1.75 (m, 2H), 1.46 - 1.62 (m, 1H), 1.29 - 1.41 (m, 3H), 0.81 - 1.00 (m, 1H), 0.36 - 0.58 (m, 2H), 0.05 - 0.20 (m, 2H).19F NMR (282 MHz, CD3CN) δ -120.83, -220.49. Provided herein is the synthesis of Compound 35: N-(4-cyano-2-(1-isopropylpiperidin-4- yl)pyridin-3-yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1- carboxamide.Scheme 35: 4-methylpiperidine-1-carboxamido)pyridin-2-yl)piperidine-1-carboxylate Et3N (1.452 g, 2 mL, 14.349 mmol) and triphosgene (427 mg, 1.439 mmol) were successively added to a stirred solution of tert-butyl 4-(3-amino-4-cyanopyridin-2-yl)piperidine- 1-carboxylate (SM1, 500 mg, 1.439 mmol) in CHCl3 (20 mL) at 0 °C and the reaction mixture was stirred at 0 °C for 1 h. A solution of 5-((1S,2S)-2-fluorocyclopropyl)-3-(4-methylpiperidin- 4-yl)-1,2,4-oxadiazole hydrochloride (837 mg, 2.877 mmol) in CHCl3 (10 mL) was added dropwise at 0 °C and the mixture was stirred at ambient temperature for 16 h. The reaction was concentrated in vacuo. Purification by flash chromatography (12g SiO2, 50 to 100% EtOAc in hexanes) gave tert-butyl 4-(4-cyano-3-(4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)- 4-methylpiperidine-1-carboxamido)pyridin-2-yl)piperidine-1-carboxylate (1 g, 43%) as an off- white solid.1H NMR (400 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.61 (d, J = 4.9 Hz, 1H), 7.72 (d, J = 4.9 Hz, 1H), 5.30 - 5.10 (m, 1H), 4.10 - 4.0 (m, 2H), 3.77 - 3.74 (m, 2H), 3.27 - 3.19 (m, 3H), 2.65 - 2.55 (m, 1H),1.89 - 1.98 (m, 2H), 1.99 - 1.70 (m, 1H), 1.69 - 1.53 (m, 9H), 1.40 (s, 9H), 1.32 (s, 3H) ppm. ESI-MS m / z calc. 553.281, found 554.6 (M+1)+. Synthesis of N-[4-cyano-2-(4-piperidyl)-3-pyridyl]-4-[5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4- oxadiazol-3-yl]-4-methyl-piperidine-1-carboxamide 2,6-Lutidine (185.04 mg, 0.2 mL, 1.727 mmol) and TMSOTf (490 mg, 0.4 mL, 2.205 mmol) were added to a stirred solution of tert-butyl 4-(4-cyano-3-(4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamido)pyridin-2- yl)piperidine-1-carboxylate (500 mg, 0.623 mmol) in DCM (50 mL) at 0 °C and the reactionmixture was stirred at ambient temperature for 6 h. The reaction was quenched by addition of a saturated aqueous NaHCO3 solution (50 mL) and was extracted with 20% MeOH in DCM (4 x 75 mL). The combined organic extracts were washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. Purification by reverse phase HPLC (Sunfire C18column, 80 to 45% MeCN in water with 0.1% TFA) gave N-(4-cyano-2-(piperidin-4-yl)pyridin-3-yl)-4-(5-((1S,2S)- 2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (279.25 mg, 99%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 8.72 (s, 1H), 8.61 (d, J = 4.84 Hz, 1H), 7.7 (d, J = 4.9 Hz, 1H), 5.27 - 5.10 (m, 1H), 3.80 - 3.76 (m, 2H), 3.23 - 3.18 (m, 2H), 3.10- 3.02 (m, 1H), 3.00- 2.90 (m, 2H), 2.60 - 2.52 (m, 1H), 2.13 - 2.10 (m, 2H), 2.05 - 1.94 (m, 1H), 1.84 - 1.78 (m, 2H), 1.78-1.53 (m, 7H), 1.30 (s, 3H) 1.1 - 1.09 (m, 1H) ppm. ESI-MS m / z calc. 453.229, found 454.4 (M+1)+. Synthesis of N-[4-cyano-2-(1-isopropyl-4-piperidyl)-3-pyridyl]-4-[5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-4-methyl-piperidine-1-carboxamide Acetone (3.955 g, 5 mL, 68.097 mmol), AcOH (52.800 mg, 0.05 mL, 0.879 mmol) and NaBH3CN (67 mg, 1.066 mmol) were successively added to a stirred solution of N-(4-cyano-2- (piperidin-4-yl)pyridin-3-yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide (200 mg, 0.265 mmol) in MeOH (5 mL) and the reaction mixture was stirred at 45 °C for 1 h. The mixture was concentrated in vacuo and the residue was partitioned between a saturated aqueous NaHCO3solution (5 mL) and 25% MeOH in DCM (10 mL). The aqueous phase was separated and extracted with 25% MeOH in DCM (2 x 10 mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. Purification by reverse phase HPLC (X-Select C18 column, 70% to 30% MeCN in water with 5 mM Ammonium acetate) gave N-(4-cyano-2-(1-isopropylpiperidin-4-yl)pyridin-3-yl)-4-(5- ((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (96 mg, 72%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ 8.71 (s, 1H), 8.60 (d, J = 4.88 Hz, 1H), 7.69 (d, J = 4.88 Hz, 1H), 5.27 - 5.08 (m, 1H), 3.78 - 3.75 (m, 2H), 3.30 - 3.20 (m, 2H), 2.99 - 2.92 (m, 1H), 2.89 - 2.86 (m, 2H), 2.74 - 2.69 (m, 1H), 2.64 - 2.58 (m, 1H), 2.19 - 2.09 (m, 4H), 1.83 - 1.53 (m, 8H), 1.32 (s, 3H), 0.97 (d, J = 6.56 Hz, 6H) ppm. ESI-MS m / z calc. 495.276, found 496.3 (M+1)+.Provided herein is the synthesis of Compound 36: N-(4-cyano-2-((R)-3- isopropoxypyrrolidin-1-yl)pyridin-3-yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3- yl)-4-methylpiperidine-1-carboxamide. Scheme 36:A stirred mixture of 3-amino-2-chloroisonicotinonitrile (20 mg, 0.130 mmol) and (R)-3- isopropoxypyrrolidine (33.6 mg, 0.260 mmol) in pyridine (130 µL) was heated at 120 °C for 8 h to give a solution of (R)-3-amino-2-(3-isopropoxypyrrolidin-1-yl)isonicotinonitrile SM2, which was used without purification in the next step. Synthesis of N-(4-cyano-2-((R)-3-isopropoxypyrrolidin-1-yl)pyridin-3-yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide The above solution was diluted with pyridine (130 µL). A solution of triphosgene (27 mg, 0.091 mmol) in DCM (130 mL) was added dropwise over 1 min and the reaction mixture was stirred for 5 min. 5-((1S,2S)-2-Fluorocyclopropyl)-3-(4-methylpiperidin-4-yl)-1,2,4- oxadiazole hydrochloride (34.1 mg, 0.130 mmol) was added in one portion and the reaction was stirred for 5 min at ambient temperature. Purification by reverse phase HPLC (Atlantis T3 OBD column, MeCN in water with 0.2% formic acid) gave N-(4-cyano-2-((R)-3-isopropoxypyrrolidin- 1-yl)pyridin-3-yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (9.7 mg, 15% over 2 steps) as a brown solid.1H NMR (300 MHz, Methanol-d4) δ 8.11 (d, J = 5.0 Hz, 1H), 6.85 (d, J = 5.0 Hz, 1H), 5.03 J = 64.5, 6.0, 3.6 Hz, 1H), 4.31 -4.19 (m, 1H), 3.96 - 3.83 (m, 2H), 3.78 - 3.65 (m, 3H), - 3.48 (m, 2H), 3.20 (dddd, J = 13.8, 10.7, 7.7, 2.9 Hz, 2H), 2.56 - 2.41 (m, 1H), 2.27 (d, J = 13.7 Hz, 2H), 2.11 - 1.68 (m, 5H), 1.53 (dddd, J = 13.2, 9.9, 7.4, 5.8 Hz, 1H), 1.35 (s, 3H), 1.13 (dd, J = 8.7, 6.1 Hz, 6H) ppm; exchangeable H not observed. ESI-MS m / z calc. 497.255, found 498.4 (M+1)+. Provided herein is the synthesis of Compound 37: N-(2-cyano-6-(2,3- dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3- yl)-4-methylpiperidine-1-carboxamide. Scheme 37:- - - yl)-4-methylpiperidine-1-carboxamide Triphosgene (19.2 g, 64.701 mmol) was added to a stirred solution of 2-amino-3- bromobenzonitrile (SM3, 16 g, 81.205 mmol) and 5-((1S,2S)-2-fluorocyclopropyl)-3-(4- methylpiperidin-4-yl)-1,2,4-oxadiazole hydrochloride (21.4 g, 80.948 mmol) in pyridine (320 mL) at 0 °C and the reaction mixture was stirred at 0 °C for 30 min. The reaction was quenched by addition of a saturated aqueous NaHCO3 solution (1 L) and extracted with EtOAc (3 x 1 L). The combined organic extracts were washed with brine (2 x 500 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 3 % MeOH in DCM) gave N-(2-bromo-6-cyanophenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide (17.5 g, 46%) as light orange solid.1H NMR (400 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.01 (dd, J = 8.1,1.4 Hz, 1H), 7.85 (dd, J = 7.7, 1.3 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 5.27 - 5.10 (m, 1H), 3.79 (d, J = 13.9 Hz, 2H), 3.33 - 3.12 (m, 2H), 2.62 - 2.51(m, 1H), 2.12 (d, J = 13.9 Hz, 2H), 1.84 - 1.77 (m, 1H), 1.70 - 1.60 (m, 2H), 1.58 - 1.55 (m, 1H), 1.30 (s, 3H) ppm. ESI-MS m / z calc. 447.071, found 448.3 (M+1)+. Synthesis of N-(2-cyano-6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide K3PO4 (5 mg, 0.024 mmol) was added to a stirred mixture of N-(2-bromo-6- cyanophenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1- carboxamide (3.6 mg, 0.008 mmol), (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)boronic acid (31.38 µL, 0.5 M solution in NMP, 0.016 mmol) and PdCl2(dtbpf) (0.5 mg, 0.001 mmol) in 1,4-dioxane (60 µL) and the reaction mixture was stirred at ambient temperature for 24 h. Purification by reversed phase HPLC (C18column, MeCN in water with TFA) gave N-(2-cyano-6-(2,3- dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3- yl)-4-methylpiperidine-1-carboxamide (0.910 mg, 18%).1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 7.79 (dd, J = 7.7, 1.5 Hz, 1H), 7.62 (dd, J = 7.8, 1.5 Hz, 1H), 7.44 (t, 1H), 6.93 - 6.79 (m, 3H), 5.33 - 5.04 (m, 1H), 4.26 - 4.17 (m, 4H), 3.75 - 3.64 (m, 2H), 3.10 - 3.00 (m, 2H), 2.66 - 2.57 (m, 1H), 1.98 (d, J = 13.2 Hz, 2H), 1.89 - 1.70 (m, 1H), 1.63 - 1.44 (m, 3H), 1.25 (s, 3H) ppm. ESI-MS m / z calc. 503.197, found 504.3 (M+1)+. Provided herein is the synthesis of Compound 38: N-(4-cyano-2-(1-(1,1,1-trifluoropropan- 2-yl)piperidin-4-yl)pyridin-3-yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide. Scheme 38:((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamideA solution of 1,1,1-trifluoropropan-2-yl trifluoromethanesulfonate (80.500 mg, 0.05 mL, 0.327 mmol) in THF (0.1 mL) was added to a stirred mixture of N-(4-cyano-2-(piperidin-4- yl)pyridin-3-yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1- carboxamide (Product of Step 2 Compound 35, 100 mg, 0.111 mmol) and K2CO3(123 mg, 0.890 mmol) in THF (1 mL) and the reaction mixture was stirred at 60 °C for 16 h. The reaction was quenched by addition of a saturated aqueous NaHCO3 solution (5 mL) and extracted with 25% MeOH in DCM (3 x 10 mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. Purification by reverse phase HPLC (XSelect CSH C18 column, 45 to 55% MeCN in water with 5 mM ammonium bicarbonate) gave N-(4-cyano-2-(1-(1,1,1- trifluoropropan-2-yl)piperidin-4-yl)pyridin-3-yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (9 mg, 15%) as a mixture of 2 diastereomers and as an off-white solid.1H NMR (400 MHz, DMSO d6) δ 8.74 (s, 1H), 8.61 (d, J = 4.88 Hz, 1H), 7.71 (d, J = 4.88 Hz, 1H), 5.27- 5.11 (m, 1H), 3.80 - 3.77 (m, 2H), 3.50 - 3.40 (m, 1H), 3.25 - 3.19 (m, 2H), 3.02 - 2.95 (m, 3H), 2.65 - 2.53 (m, 1H), 2.50 - 2.41 (m, 1H), 2.12- 2.10 (m, 2H), 1.84 - 1.60 (m, 9H), 1.32 (s, 3H), 1.17 (d, J = 7.04 Hz, 3H) ppm. ESI-MS m / z calc. 549.248, found 550.4 (M+1)+. Provided herein is the synthesis of Compound 39: N-(2-cyano-4-(1-((1- (trifluoromethyl)cyclopropyl)methyl)piperidin-4-yl)pyridin-3-yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide. Scheme 39:yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide(1-Bromomethyl)-1-(trifluoromethyl)cyclopropane (18 mg, 0.089 mmol) was added to a stirred solution of N-(2-cyano-4-(piperidin-4-yl)pyridin-3-yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (prepared using the method described in Compound 35 Steps 1 and 2, except that SM4 was used as the starting material in place of SM1, 20 mg, 0.044 mmol) and DIPEA (25 µL, 0.144 mmol) in MeCN (176 µL) and the reaction mixture was stirred at 50 °C for 24 h. The reaction was cooled to ambient temperature. Purification by reverse phase HPLC (XSelect CSH C18OBD column, MeCN in water with 0.1% TFA) gave N-(2-cyano-4-(1-((1-(trifluoromethyl)cyclopropyl)methyl)piperidin- 4-yl)pyridin-3-yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine- 1-carboxamide trifluoroacetate (5.7 mg, 16%) as a white solid.1H NMR (300 MHz, Chloroform- d) δ 8.43 (dd, J = 52.0, 5.0 Hz, 1H), 7.59 (dd, J = 14.0, 4.9 Hz, 1H), 4.95 (dtd, J = 63.8, 6.0, 3.7 Hz, 1H), 3.88 - 3.73 (m, 4H), 3.51 - 3.42 (m, 2H), 3.41 - 3.27 (m, 2H), 3.05 - 2.93 (m, 2H), 2.46 - 2.19 (m, 6H), 2.18 - 2.05 (m, 1H), 2.05 - 1.91 (m, 1H), 1.89 - 1.66 (m, 2H), 1.61 - 1.45 (m, 1H), 1.43 - 1.24 (m, 8H) ppm; exchangeable H not observed. ESI-MS m / z calc. 575.263, found 576.4 (M+1)+. Provided herein is the synthesis of Compound 40: N-(2-cyano-6-(6-cyclopropylpyridin-3- yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1- carboxamide. Scheme 40:fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide Into a nitrogen filled glovebox, PdCl2(dtbpf) (14.2 mg, 0.022 mmol) and K3PO4(138.8 mg, 0.654 mmol) were successively added to N-(2-bromo-6-cyanophenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (Product of Step 1Compound 37, 100 mg, 0.218 mmol) and (6-cyclopropylpyridin-3-yl)boronic acid (71.1 mg, 0.436 mmol) in a mixture of 1,4-dioxane (1.45 mL) and NMP (727 µL) and the reaction mixture was stirred for 24 h at ambient temperature. The volatiles were removed under a stream of nitrogen. The residue was partitioned between DCM (4 mL) and water (4 mL). The organic phase was separated and the volatiles were removed under a stream of nitrogen. Purification by reversed phase chromatography (C18 column, MeCN in water with 0.2% Formic acid) gave N-(2- cyano-6-(6-cyclopropylpyridin-3-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol- 3-yl)-4-methylpiperidine-1-carboxamide (37.1 mg, 35%).1H NMR (300 MHz, Methanol-d4) δ 8.36 (s, 1H), 7.78 (dd, J = 7.7, 1.6 Hz, 1H), 7.74 - 7.61 (m, 2H), 7.51 (t, J = 7.8 Hz, 1H), 7.28 (d, J = 0.8 Hz, 1H), 5.18 - 4.91 (m, 1H), 3.77 (d, J = 13.9 Hz, 2H), 3.14 - 2.97 (m, 2H), 2.56 - 2.40 (m, 1H), 2.19 - 2.04 (m, 3H), 1.97 - 1.78 (m, 1H), 1.65 - 1.44 (m, 3H), 1.30 (s, 3H), 1.11 - 0.91 (m, 4H) ppm; exchangeable H not observed. ESI-MS m / z calc. 486.218, found 487.3 (M+1)+. Provided herein is the synthesis of Compound 41: N-(2-(azepan-1-yl)-4-cyanopyridin-3- yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide. Scheme 41:Synthesis of 3-A stirred mixture of azepane (23.25 mg, 26.42 µL, 0.234 mmol) and 3-amino-2- chloroisonicotinonitrile (12 mg, 0.078 mmol) in DIPEA was stirred at 120 °C for 2 h. The volatiles were removed under a stream of nitrogen. The residue was partitioned between DCM (1mL) and water containing 15 equivalents of pyridine hydrochloride (1 mL). The mixture was stirred for 30 min at ambient temperature and the organic phase was separated. The volatiles were removed under a stream of nitrogen to give 3-amino-2-(azepan-1-yl)isonicotinonitrile SM5 (assumed 90% yield), which was used without further purification in the next step. Synthesis of N-(2-(azepan-1-yl)-4-cyanopyridin-3-yl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide DMAP (34.35 mg, 0.281 mmol) and triphogene (6.884 mg, 0.023 mmol) were successively added to a stirred mixture of 3-amino-2-(azepan-1-yl)isonicotinonitrile (15.21 mg, 0.070 mmol) in DCM (703 µL) and the reaction mixture was stirred at 55°C for 3 h. The reaction was cooled to ambient temperature. 5-((1S,2S)-2-Fluorocyclopropyl)-3-(4-methylpiperidin-4-yl)- 1,2,4-oxadiazole hydrochloride (18.40 mg, 0.070 mmol) was added and the reaction was stirred at ambient temperature for 20 min. Water (0.5 mL) and pyridine hydrochloride (81.24 mg, 83.07 µL, 0.703 mmol) were added and the organic layer was separated. The volatiles were removed under a stream of nitrogen. Purification by reverse phase HPLC (XBridge C8 column, MeCN in water with 0.2% formic acid) gave N-(2-(azepan-1-yl)-4-cyanopyridin-3-yl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (1.1 mg, 3%).1H NMR (400 MHz, DMSO-d6) δ 8.48 (s, 1H), 8.15 (d, J = 4.9 Hz, 1H), 7.00 (d, 1H), 5.36 - 5.00 (m, 1H), 3.76 (d, J = 14.2 Hz, 2H), 3.55 (t, J = 5.9 Hz, 4H), 3.14 (t, J = 11.9 Hz, 2H), 2.65 - 2.57 (m, 1H), 2.08 (d, J = 13.4 Hz, 2H), 1.87 - 1.41 (m, 12H), 1.29 (s, 3H) ppm. ESI-MS m / z calc. 467.245, found 468.4 (M+1)+. Provided herein is the synthesis of Compound 42: N-(2-cyano-6-(4-oxaspiro[2.5]octan-6- yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1- carboxamide.Scheme 42:A solution of 2,4,6-triphenylpyrylium tetrafluoroborate (29.71 mg, 0.075 mmol) and 4- oxaspiro[2.5]octan-6-amine (14.31 mg, 0.113 mmol) in EtOH (150 µL) was stirred and heated at 70 °C for 24 h. The volatiles were removed under a stream of nitrogen to give 2,4,6-triphenyl-1- (4-oxaspiro[2.5]octan-6-yl)pyridin-1-ium tetrafluoroborate (Int-1, assumed 100% yield), which was used without further purification in the next step. ESI-MS m / z calc. 418.217, found 418.4 (M+1)+. Synthesis of N-[2-cyano-6-(4-oxaspiro[2.5]octan-6-yl)phenyl]-4-[5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4-oxadiazol-3-yl]-4-methylpiperidine-1-carboxamide In a glovebox, a solution of N-(2-cyano-6-iodophenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (prepared using the method described in Compound 37 Step 1, except that 2-amino-3-iodobenzonitrile (SM8) was used as the starting material in place of SM3, 25 mg, 0.050 mmol), (4,4′-dtbbpy)NiCl2 (7.372 mg, 0.015 mmol) and tetrakis(dimethylamino)ethylene (20.21 mg, 23.23 µL, 0.101 mmol) in DMA was stirred at ambient temperature for 10 min. The prepared mixture was added to 2,4,6- triphenyl-1-(4-oxaspiro[2.5]octan-6-yl)pyridin-1-ium tetrafluoroborate (Int-1, 38.25 mg, 0.076 mmol) and the reaction mixture was heated at 80 °C for 30 min. Purification by reverse phase HPLC (XSelect CSH C18OBD column, MeCN in water with 0.2% formic acid) gave N-(2- cyano-6-(4-oxaspiro[2.5]octan-6-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (4.5 mg, 17%) as a mixture of 2 diastereomers.1H NMR (400 MHz, DMSO-d6) δ 8.63 (s, 1H), 7.69 (t, 2H), 7.42 (t, J = 7.8 Hz, 1H), 5.33 - 5.06 (m,1H), 3.90 - 3.74 (m, 2H), 3.73 - 3.61 (m, 1H), 3.25 - 3.60 (m, 1H, overlapped with , 3.19 - 3.09 (m, 3H), 2.66 - 2.58 (m, 1H), 2.12 (d, J = 13.7 Hz, 2H), 2.07 - 1.97 (m, 1H), 1.91 - 1.75 (m, 3H), 1.74 - 1.64 (m, 2H), 1.64 - 1.50 (m, 1H), 1.30 (s, 3H), 1.21 (d, J = 13.2 Hz, 1H), 0.77 - 0.68 (m, 1H), 0.63 - 0.48 (m, 2H), 0.47 - 0.36 (m, 1H) ppm. ESI-MS m / z calc. 479.233, found 480.4 (M+1)+. Provided herein is the synthesis of Compound 43: N-(2-cyano-6-(1-isopropylpiperidin-4- yl)phenyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-1'-carboxamide. Scheme 43:Pd(dppf)Cl2.DCM (5 g, 6.123 mmol) was added to a stirred suspension of 2-amino-3- bromobenzonitrile (SM3, 25 g, 126.9 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (43 g, 139.1 mmol) and Na2CO3(27 g, 254.7 mmol) in a mixture of 1,4-dioxane (250 mL) and water (80 mL) and the reaction mixture was heated at 100 °C for 1 h. The reaction was cooled to ambient temperature and concentrated in vacuo. DCM was added to the residue and the mixture was filtered through a pad of silica, washing the filtered cake with DCM. The filtrates were concentrated in vacuo. The residue was partitioned between DCM and water and the aqueous phase was separated and extracted with DCM (2 x). The combined organic phases were dried by passing the solutionthrough a phase separator cartridge and the filtrates were concentrated in vacuo to give tert-butyl 4-(2-amino-3-cyanophenyl)-3,6-dihydropyridine-1(2H)-carboxylate (41.03 g, 95%) as a yellow semi-solid.1H NMR (300 MHz, Chloroform-d) δ 7.31 (dd, J = 7.8, 1.5 Hz, 1H), 7.14 (dd, J = 7.6, 1.6 Hz, 1H), 6.72 (t, J = 7.7 Hz, 1H), 5.80 (s, 1H), 4.51 (s, 2H), 4.06 (q, J = 2.9 Hz, 2H), 3.64 (t, J = 5.7 Hz, 2H), 2.43 - 2.26 (m, 2H), 1.50 (s, 9H) ppm. ESI-MS m / z calc. 299.163, found 299.5 (M+1)+. Synthesis of tert-butyl 4-(2-amino-3-cyanophenyl)piperidine-1-carboxylate Pd / C (12.5 g, 10 % w / w on carbon, 11.746 mmol) was added to a stirred solution of tert- butyl 4-(2-amino-3-cyanophenyl)-3,6-dihydropyridine-1(2H)-carboxylate (25 g, 71.818 mmol) in MeOH (250 mL) at ambient temperature. The mixture was degassed with nitrogen and the atmosphere was replaced with a hydrogen atmosphere. The reaction was stirred at ambient temperature for 16 h under a hydrogen atmosphere. The reaction was filtered through a pad of Celite®, washing the filtered cake with EtOAc (3 x 100 mL). The filtrates were concentrated in vacuo to give tert-butyl 4-(2-amino-3-cyanophenyl)piperidine-1-carboxylate (21 g, 96%) as a yellow oil.1H NMR (400 MHz, DMSO-d6) δ 7.26 (dd, J = 7.76 Hz, J = 1.40 Hz, 1H), 7.20 (dd, J = 7.60 = 1.24 Hz, 1H), 6.61 (t, J = 7.68 Hz, 1H),5.83 (br s, 2H), 4.06 - 4.02 (m, 2H), 2.88 - 2.80 (m, 3H), 1.70 - 1.67 (m, 2H), 1.40 (s, 9H), 1.40 - 1.30 (m, 2H) ppm. ESI-MS m / z calc. 301.179, found 300.2 (M-1)-. Synthesis of 2-amino-3-(piperidin-4-yl)benzonitrile HCl (14 mL, 4 M solution in 1,4-dioxane, 56 mmol) was added dropwise to a stirred solution of tert-butyl 4-(2-amino-3-cyanophenyl)piperidine-1-carboxylate (1.74 g, 5.613 mmol) in DCM (25 mL) at 0 °C and the reaction mixture was stirred at ambient temperature for 4 h. The mixture was concentrated in vacuo to give 2-amino-3-(piperidin-4-yl)benzonitrile dihydrochloride (1.4 g, 87%) as a white solid.1H NMR (300 MHz, DMSO-d6) δ 8.94 (d, J = 43.6 Hz, 2H), 7.32 (dd, J = 7.7, 1.5 Hz, 1H), 7.19 (dd, J = 7.7, 1.6 Hz, 1H), 6.66 (t, J = 7.7 Hz, 1H), 3.34 (d, J = 12.5 Hz,, 3.09 - 2.86 (m, 3H), 1.86 (d, J = 13.4 Hz, 2H), 1.81 - 1.64 (m, 2H) ppm; exchangeable H not observed. ESI-MS m / z calc. 201.127, found 202.1 (M+1)+.Synthesis of 2-amino-3-(1-isopropylpiperidin-4-yl)benzonitrile NaBH3CN (610 mg, 9.707 mmol) was added portionwise to a stirred solution of 2-amino- 3-(piperidin-4-yl)benzonitrile dihydrochloride (700 mg, 2.422 mmol) in a mixture of MeOH (12 mL), AcOH (550 µL, 9.672 mmol) and acetone (720 µL, 9.806 mmol) and the reaction mixture was stirred and heated at 110 °C under microwave irradiations for 60 min. The mixture was cooled to ambient temperature and concentrated in vacuo. The residue was partitioned between water and DCM. The aqueous phase was separated and extracted with DCM (3 x). The combined organic phases were passed through a phase separator cartridge and concentrated in vacuo. Purification by flash chromatography (SiO2, 0 to 50 % EtOAc:EtOH (3:1) in heptane) gave 2- amino-3-(1-isopropylpiperidin-4-yl)benzonitrile (SM9, 460 mg, 73%) as a white solid.1H NMR (300 MHz, Chloroform-d) δ 7.37 - 7.27 (m, 2H), 6.75 (t, J = 7.7 Hz, 1H), 4.42 (s, 2H), 3.21 - 2.94 (m, 2H), 2.77 (hept, J = 6.6 Hz, 1H), 2.40 (tt, J = 11.9, 3.6 Hz, 1H), 2.28 (td, J = 11.7, 2.5 Hz, 2H), 1.94 - 1.82 (m, 2H), 1.73 (qd, J = 12.2, 3.7 Hz, 2H), 1.08 (d, J = 6.6 Hz, 6H) ppm. ESI- MS m / z calc. 243.174, found 244.1 (M+1)+. Synthesis of N-(2-cyano-6-(1-isopropylpiperidin-4-yl)phenyl)-3H-spiro[isobenzofuran-1,4'- piperidine]-1'-carboxamide Triphosgene (3.116 mg, 0.011 mmol) was added to a stirred mixture of 2-amino-3-(1- isopropylpiperidin-4-yl)benzonitrile (SM9, 10.72 mg, 0.03 mmol) and DMAP (14.66 mg, 0.120 mmol) in DCM (1 mL) and the reaction mixture was stirred at ambient temperature for 20 min. 3H-spiro[isobenzofuran-1,4'-piperidine] (7.381 mg, 0.039 mmol) was added and the reaction was stirred at ambient temperature for 1 h. The reaction was diluted with pyridine hydrochloride (1 mL, 10 % w / w aqueous solution) and stirred for 5 min. The aqueous phase was separated and extracted with DCM (2 x 1 mL). The combined organic layers were concentrated in vacuo. Purification by reverse phase HPLC (Sunfire C18 column, MeCN in water with 0.2 % formic acid) gave N-(2-cyano-6-(1-isopropylpiperidin-4-yl)phenyl)-3H-spiro[isobenzofuran-1,4'- piperidine]-1'-carboxamide formate (15.3 mg, 98%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 8.63 (s, 1H), 7.70 (dd, J = 7.6, 1.5 Hz, 1H), 7.65 (dd, J = 8.0, 1.5 Hz, 1H), 7.42 (t, J = 7.8 Hz, 1H), 7.34 - 7.25 (m, 3H), 7.20 - 7.17 (m, 1H), 5.05 (s, 2H), 4.14 - 4.08 (m, 2H), 3.50- 3.15 (m, 1H, overlapped with water), 3.07 - 2.98 (m, 2H), 2.96 - 2.83 (m, 2H), 2.46 - 2.33 (m,2H), 2.01 - 1.90 (m, 2H), 1.78 - 1.60 (m, 6H), 1.06 (d, J = 6.6 Hz, 6H) ppm. ESI-MS m / z calc. 458.268, found 459.4 (M+1)+. Provided herein is the synthesis of Compound 44: N-(2-cyano-6-(1,1-dioxidotetrahydro- 2H-thiopyran-3-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide. Scheme 44:tetrafluoroborate 3-Aminotetrahydro-2H-thiopyran 1,1-dioxide (16.79 mg, 0.113 mmol) and 2,4,6- triphenylpyrylium tetrafluoroborate (29.71 mg, 0.075 mmol) were successively added to a mixture of DIPEA (14.54 mg, 19.6 µL, 0.113 mmol) and sodium pivalate (9.309 mg, 0.075 mmol) in EtOH (150 µL) and the reaction mixture was heated at 70 °C for 1 h. The volatiles were removed under a stream of nitrogen. The residue was partitioned between DCM (1 mL) and water (1 mL). The organic layer was separated by passing the biphasic solution through a phase separator cartridge. The volatiles were removed under a stream of nitrogen to give 1-(1,1- dioxidotetrahydro-2H-thiopyran-3-yl)-2,4,6-triphenylpyridin-1-ium tetrafluoroborate (assumed 100% yield).Synthesis of N-(2-cyano-6-(1,1-dioxidotetrahydro-2H-thiopyran-3-yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide In a glovebox, tetrakis(dimethylamino)ethylene (20.21 mg, 23.23 µL, 0.101 mmol) was added to a mixture of N-(2-cyano-6-iodophenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4- oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide (prepared using the method described in Compound 37 Step 1, except that SM8 was used as the starting material in place of SM3, 25 mg, 0.050 mmol) and (4,4′-dtbbpy)NiBr2(7.372 mg, 0.015 mmol) in DMA (505 µL) and the reaction mixture was stirred at ambient temperature for 15 min. This mixture was added to 1-(1,1- dioxidotetrahydro-2H-thiopyran-3-yl)-2,4,6-triphenylpyridin-1-ium tetrafluoroborate (Int-3, 39.91 mg, 0.076 mmol) and the reaction mixture was heated at 80 °C for 1 h. The reaction was cooled to ambient temperature. Purification by reverse phase HPLC (XSelect CSH Phenyl Hexyl column, MeCN in Water with 0.2% formic acid) gave N-(2-cyano-6-(1,1-dioxidotetrahydro-2H- thiopyran-3-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide (4.6 mg, 16%) as a mixture of 2 diastereomers.1H NMR (400 MHz, DMSO-d6) δ 8.67 (s, 0.5H), 8.38 (br, 0.5H), 7.74 (d, 1H), 7.57 - 7.24 (m, 2H), 5.32 - 5.06 (m, 1H), 3.93 - 3.73 (m, 2H), 3.27 - 2.85 (m, 6H), 2.63 (tm, J = 13.5, 6.7 Hz, 1H), 2.28 - 1.93 (m, 4H), 1.92 - 1.48 (m, 7H), 1.34 - 1.27 (m, 3H) ppm. ESI-MS m / z calc. 501.185, found 502.5 (M+1)+. Provided herein is the synthesis of Compound 45: N-(2-chloro-6-((R)-3- isopropoxypyrrolidin-1-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide. Scheme 45:Synthesis of tert-butyl (R)-3-isopropoxypyrrolidine-1-carboxylate A mixture of tert-butyl (R)-3-hydroxypyrrolidine-1-carboxylate (2 g, 10.682 mmol) and Ag2O (2.97 g, 12.818 mmol) iniPrI (15 mL) was stirred at 40 °C for 3 h. The reaction mixture was quenched by addition of water and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 50% EtOAc in hexanes) gave tert-butyl (R)-3-isopropoxypyrrolidine-1- carboxylate (500 mg, 20%) as a yellow solid. ESI-MS m / z calc. 229.170, found 230.2 (M+1)+. Synthesis of (R)-3-isopropoxypyrrolidine hydrochloride HCl (5 mL , 4 M solution in 1,4-dioxane) was added to a solution of tert-butyl (R)-3- isopropoxypyrrolidine-1-carboxylate (490 mg, 2.137 mmol) in 1,4-dioxane (5 mL) and the reaction mixture was stirred at ambient temperature for 1 h. The reaction was concentrated in vacuoto give (R)-3-isopropoxypyrrolidine hydrochloride (270 mg, 79%) as a yellow solid, which was used without further purification in the next step. ESI-MS m / z calc. 129.120, found 130.2 (M+1)+. Synthesis of (R)-1-(3-chloro-2-nitrophenyl)-3-isopropoxypyrrolidine 1-Chloro-3-fluoro-2-nitrobenzene (353.3 mg, 2.012 mmol) was added in portions to a stirred mixture of (R)-3-isopropoxypyrrolidine hydrochloride (260 mg, 2.012 mmol) and Cs2CO3 (1.97 g, 6.036 mmol) in MeCN (15 mL) at 0 °C and the reaction mixture was stirred at ambient temperature for 2 h. The reaction was quenched by addition of water and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 50% EtOAc in hexanes) gave (R)-1-(3- chloro-2-nitrophenyl)-3-isopropoxypyrrolidine (300 mg, 52%) as a white solid. ESI-MS m / z calc. 284.090, found 285.2 (M+1)+. Synthesis of (R)-2-chloro-6-(3-isopropoxypyrrolidin-1-yl)aniline Zn (665.9 mg, 10.180 mmol) was added portionwise to a stirred solution of (R)-1-(3- chloro-2-nitrophenyl)-3-isopropoxypyrrolidine (290 mg, 1.018 mmol) in AcOH (5 mL) and the reaction mixture was stirred at ambient temperature for 2 h. The reaction was neutralized to pH 7 by addition of a saturated aqueous NaHCO3solution and extracted with EtOAc (3 x 50 mL). Thecombined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 50% EtOAc in hexanes) gave (R)-2-chloro-6-(3- isopropoxypyrrolidin-1-yl)aniline (200 mg, 77%) as a white solid. ESI-MS m / z calc. 254.120, found 255.1 (M+1)+. Synthesis of N-(2-chloro-6-((R)-3-isopropoxypyrrolidin-1-yl)phenyl)-4-(5-((1S,2S)-2- fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide Triphosgene (79.2 mg, 0.267 mmol) was added portionwise to a stirred mixture of (R)-2- chloro-6-(3-isopropoxypyrrolidin-1-yl)aniline (170 mg, 0.667 mmol) in DCM (5 mL) at 0 °C and the reaction mixture was stirred at ambient temperature for 1 h. Et3N (270.1 mg, 2.668 mmol) was added dropwise at 0 °C and the reaction was stirred at ambient temperature for 20 min. The mixture was added dropwise to a stirred solution of 5-((1S,2S)-2-fluorocyclopropyl)-3- (4-methylpiperidin-4-yl)-1,2,4-oxadiazole (100.2 mg, 0.445 mmol) in DCM (0.5 mL) at 0 °C and the mixture was stirred at ambient temperature for 3 h. The reaction was diluted with water (15 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. Purification by reverse phase HPLC (XBridge OBD C18 column, 39 to 69% MeCN in water with 10 mM NH4HCO3) gave N-(2-chloro-6-((R)-3- isopropoxypyrrolidin-1-yl)phenyl)-4-(5-((1S,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-4- methylpiperidine-1-carboxamide (41.3 mg, 18%) as a white solid.1H NMR (400 MHz, Acetonitrile-d3) δ 7.00 - 7.20 (m, 1H), 6.82 - 6.90 (dd, 1H),(dd, 1H), 6.57 (s, 1H), 4.90 - 5.23 (m, 1H), 4.10 - 4.30 (m, 1H), 3.80 - 3.90 (m, 2H), 3.70 - 3.80 (m, 1H), 3.59 - 3.70 (m, 1H), 3.35 - 3.50 (m, 1H), 3.15 - 3.34 (m, 4H), 2.40 - 2.60 (m, 1H), 2.20 - 2.30 (m, 2H), 1.80 - 1.90 (m, 2H), 1.70 - 1.80 (m, 2H), 1.40 - 1.60 (m, 1H), 1.30 - 1.40 (m, 4H), 1.10 - 1.20 (m, 6H) ppm. ESI-MS m / z calc. 505.230, found 506.0 (M+1)+. The following compounds were made using methods analogous to those disclosed in the specification, as shown in Table 4:Table 4. Compound Boronic Cmpd Structure / Starting reagent or LC / MS NMR (shifts in ppm) No. Compound Material amine if Name applicable N-(2-cyano-6-(2- ESI-MS ethylpyrimidin-5- m / z calc. yl)ph 475.213, 46 enyl)-4-(5- SM3 ((1S,2S)-2- found fluorocyclopropy 476.4 l)-1,2,4- (M+1)+. oxadiazol-3-yl)- 4- methylpiperidine- 1-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 1H), 7.73 - 7.64 (m, N-(2-cyano-6- 2H), 7.58 (s, 1H), 7.46 - (5,6-dihydro-4H- ESI-MS 7.36 (m, 1H), 5.33 - pyrrolo[1,2- 5.02 (m, 1H), 4.15 - m / z calc. b]pyrazol-3- 475.213, 4.05 (m, 2H), 3.84 - 47 yl)phenyl)-4-(5- SM3 3.75 (m, 2H), 3.16 - found ((1S,2S)-2- 476.4 3.02 (m, 2H), 2.92 (t, J fluorocyclopropy = 7.3 Hz, 2 (M+H), 2.65 - +1) . l)-1,2,4- 2.55 (m, 3H), 2.08 (d, J oxadiazol-3-yl)- = 13.6 Hz, 2H), 1.88 - 4- 1.72 (m, 1H), 1.69 - methylpiperidine- 1.43 (m, 3H), 1.28 (s, 1-carboxamide 3H) ppm. ESI-MS N-(2-cyano-6-(7- m / z calc. 8 metho 514.213, 4 xy-1H- SM3 indol-2- found yl)phenyl)-4-(5- 515.4 ((1S,2S)-2- (M+1)+. fluorocyclopropy l)-1,2,4-Compound Boronic Cmpd Structure / Starting reagent or LC / MS NMR (shifts in ppm) No. Compound Material amine if Name applicable oxadiazol-3-yl)- 4- methylpiperidine- 1-carboxamide Mixture of 2 diastereomers 1H NMR (400 MHz, DMSO-d6) δ 8.55 (s, 1H), 8.13 (d, J = 1.0 Hz, 1H), 6.94 (d, cyano-2-(6- ESI- J = N-(4- MS 1. xa-2- m / 0 Hz, 1H), 5.35 - 5.05 o z calc. 509 (m, 1H), 3.84 - 3.66 (m, 49 aza SM6 .255, spiro[4.5]deca found 3H), 3.66 - 3.47 (m, n-2-yl)pyridin-3- 510.4 + 5H), 3.18 (br, 2H), 2.67 yl)-4-(5-((1S,2S)- (M+1) . - 2.56 (m, 1H), 2.21 - 2- 1.99 (m, 3H), 1.90 - fluorocyclopropy 1.35 (m, 11H), 1.30 (s, l)-1,2,4- 3H) ppm. oxadiazol-3-yl)- 4- methylpiperidine- 1-carboxamide N-(2-cyano-6-(6- ESI-MS cyclobutylpyridin m / z calc. -3-yl)phenyl) 500.234, 50 -4- SM3 (5-((1S,2S)-2- found fluorocyclopropy 501.4 (M++l)-1,2,4- 1) . oxadiazol-3-yl)- 4- methylpiperidine- 1-carboxamide ESI-MS1H NMR (400 MHz, m / z calc. DMSO-d6) δ 9.04 (s, 51 SM7 479.219, 1H), 8.75 (s, 1H), 8.29 found (s, 1H), 8.07 (d, J = 5.2Compound Boronic Cmpd Structure / Starting reagent or LC / MS NMR (shifts in ppm) No. Compound Material amine if Name applicable N-(2-cyano-4-(4- 480.4 Hz, 1H), 5.28 - 5.08 (m, isopropyl-1H- (M+1)+. 1H), 3.74 - 3.71 (m, 1,2,3-triazol-1- 2H), 3.13 - 3.04 (m, yl)pyridin-3-yl)- 3H), 2.63 - 2.59 (m, 4-(5-((1S,2S)-2- 1H), 2.06 - 2.03 (m, fluorocyclopropy 2H), 1.86 - 1.74 (m, l)-1,2,4- 1H), 1.65 - 1.54 (m, oxadiazol-3-yl)- 3H), 1.30 - 1.25 (m, 4- 9H) ppm. methylpiperidine- 1-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 8.93 - 8.87 (m, 1H), 8.59 (s, 1H), 8.38 (d, J = 8.1 Hz, 1H), 8.07 - 7.99 (m, 2H), 7.91 (dt, J = 7.7, N-(2-cyano-6- ESI-MS 1.7 Hz, 1H), 7.82 (dt, J (quinolin-7- m / z calc. = 7.8, 1.6 Hz, 1H), 7.57 yl)pheny 496.202, (m, 3H), 5.35 - 5.02 (m, 52 l)-4-(5- SM3 ((1S,2S)-2- found 1H), 3.63 (d, J = 14.1 fluorocyclopropy 497.4 Hz, 2H), 2.94 (t, J = l)-1,2,4- (M+1)+. 12.0 Hz, 2H), 2.61 (m, oxadiazol-3-yl)- 1H), 1.88 - 1.78 (m, 4- 2H), 1.79 - 1.71 (m, methylpiperidine- 1H), 1.61 - 1.47 (m, 1-carboxamide 1H), 1.32 (t, J = 11.2 Hz, 2H), 1.06 (s, 3H) ppm. ESI-MS N-(2- m / z calc. (benzo[d]thiazol- 502.159, 53 5-yl)-6- SM3 found cyanophenyl)-4- 503.3 (5-((1S,2S)-2- (M+1)+. fluorocyclopropy l)-1,2,4- oxadiazol-3-yl)- 4-Compound Boronic Cmpd Structure / Starting reagent or LC / MS NMR (shifts in ppm) No. Compound Material amine if Name applicable methylpiperidine- 1-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 8.80 (s, 0.5H), 8.51 (s, 0.5H), 7.95 (dd, 1H), 7.75 (dd, J = 54.9, 1.5 Hz, 1H), 7.54 (s, 1H), 7.42 (dt, J N-(2-(5-chloro-1- = 52.7, 7.9 Hz, 1H), methyl-1H- ESI-MS 5.37 - 5.01 (m, 1H), pyrazol-4-yl)-6- m / z calc. 3.91 - 3.65 (m, 3H), 54 cyanophenyl)-4- SM3 483.159, 3.48 - 3.41 (m, 2H, (5-((1S,2S)-2- found overlapped with fluorocyclopropy 484.3 l)-1,2,4- +1)+solvent), 3.15 (t, J = (M . 11.8 Hz, 1H), 3.10 - oxadiazol-3-yl)- 3.00 (m, 1H), 2.66 - 4- 2.58 (m, 1H), 2.16 - methylpiperidine- 1.98 (m, 2H), 1.89 - 1-carboxamide 1.74 (m, 1H), 1.71 - 1.50 (m, 3H), 1.28 (d, J = 11.3 Hz, 3H) ppm. 1H NMR (400 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.38 - 8.35 (m, 1H), 7.88 - 7.83 (m, 1H), 7.71 - 7.66 (m, ESI-MS 1H), 7.61 - 7.56 (m, m / z calc. 1H), 7.55 - 7.48 (m, 436.226, 1H), 7.40 - 7.33 (m, 55N-(2-cyano-6-(6-SM3 found 4H), 7.27 - 7.18 (m, cyclopropylpyridi 437.4 2H), 3.50 - 3.25 (2H, m, n-3-yl)phenyl)-4- (M+1)+. overlapped with water), methyl-4- 2.09 - 1.94 (m, 1H), phenylpiperidine- 1.93 - 1.83 (m, 2H), 1-carboxamide 1.61 - 1.53 (m, 2H), 1.21 (s, 3H), 1.00 - 0.83 (m, 4H) ppm. 1H NMR (400 MHz, ESI-MS DMSO-d6) δ 8.56 (s, m / z calc. 56 SM3 1H), 8.40 - 8.35 (m, 428.207, 1H), 7.86 (dd, J = 7.7, found 1.5 Hz, 1H), 7.70 (dd, JCompound Boronic Cmpd Structure / Starting reagent or LC / MS NMR (shifts in ppm) No. Compound Material amine if Name applicable N-(2-cyano-6-(6- 429.4 = 7.8, 1.6 Hz, 1H), 7.60 cyclopropylpyridi (M+1)+. (dd, J = 8.1, 2.3 Hz, n-3-yl)phenyl)-4- 1H), 7.52 (t, J = 7.7 Hz, (2-methyl-2H- 1H), 7.37 - 7.30 (m, tetrazol-5- 1H), 4.34 (s, 3H), 4.01 - yl)piperidine-1- 3.94 (m, 2H), 3.16 (tt, J carboxamide = 11.3, 3.8 Hz, 1H), 3.04 - 2.94 (m, 2H), 2.12 - 2.01 (m, 1H), 1.93 (dd, J = 13.5, 3.5 Hz, 2H), 1.58 - 1.43 (m, 2H), 0.95 - 0.81 (m, 4H) ppm. N-(2-cyano-6- ESI-MS (spiro[2.5]octan- m / z calc. 6-yl)phenyl)-4- 477.254, 57 (5-((1S,2S)-2- SM8 found fluorocyclopropy 478.4 l)-1,2,4- (M+1)+. oxadiazol-3-yl)- 4- methylpiperidine- 1-carboxamide Mixture of 21H NMR (400 MHz, diastereomers DMSO-d6) δ 8.49 (s, 1H), 7.65 (dd, J = 12.0, 7.8 Hz, 2H), 7.38 (t, J = 7.7 Hz, 1H), 5.35 - 4.99 ESI-MS m / z calc. (m, 1H), 3.87 - 3.68 (m, N-(2- 2H), 3.16 (t, J = 11.9 449.223, 58 (bicyclo[3.1.0]he SM8 found Hz, 2H), 3.02 - 2.87 (m, xan-3-yl)-6- 1H), 2.66 - 2.56 (m, 450.4 cyanophenyl)-4- (M+1)+. 1H), 2.09 (d, J = 13.7 (5-((1S,2S)-2- Hz, 2H), 1.98 - 1.88 (m, fluorocyclopropy 2H), 1.88 - 1.44 (m, l)-1,2,4- 6H), 1.38 - 1.25 (m, oxadiazol-3-yl)- 5H), 0.38 - 0.22 (m, 4- 2H) ppm.Compound Boronic Cmpd Structure / Starting reagent or LC / MS NMR (shifts in ppm) No. Compound Material amine if Name applicable methylpiperidine- 1-carboxamide N-(2-cyano-6-(2- ESI-MS oxaspiro[3.3]hept m / z calc. an-6-yl)phenyl)- 465.218, 59 SM8 4-(5-((1S,2S)-2- found fluorocyclopropy 466.5 l)-1,2,4- (M+1)+. oxadiazol-3-yl)- 4- methylpiperidine- 1-carboxamide Mixture of 21H NMR (400 MHz, diastereomers DMSO-d6) δ 8.58 (s, 1H), 7.69 - 7.57 (m, 2H), 7.42 (t, J = 7.8 Hz, 1H), 5.32 - 5.02 (m, ESI-MS 1H), 3.82 - 3.68 (m, N-(2-cyano-6-(5- m / z calc. 3H), 3.22 (br, J = 11.3 60 oxaspiro[3.5]non SM8 493.249, Hz, 2H), 3.13 - 3.02 (m, an-8-yl)phenyl)- found 1H), 2.66 - 2.57 (m, 4-(5-((1S,2S)-2- 494.5 1H), 2.10 (d, J = 13.9 fluorocyclopropy (M+1)+. Hz, 2H), 2.05 - 1.93 (m, l)-1,2,4- 2H), 1.93 - 1.74 (m, oxadiazol-3-yl)- 5H), 1.74 - 1.42 (m, 4- 7H), 1.38 (t, J = 12.7 methylpiperidine- Hz, 1H), 1.30 (s, 3H) 1-carboxamide ppm. 1H NMR (400 MHz, DMSO-d6) δ 8.53 (s, ESI-MS 1H), 7.61 (t, 2H), 7.38 m / z calc. (t, J = 7.8 Hz, 1H), 5.32 N-(2-cyano-6- 465.254, - 5.06 (m, 1H), 3.82 - 61 cycloheptylpheny SM8 found 3.69 (m, 2H), 3.31 - l)-4-(5-((1S,2S)- 466.5 3.17 (m, 2H), 2.91 (t, J 2- (M+1)+. = 10.5 Hz, 1H), 2.65 - fluorocyclopropy 2.57 (m, 1H), 1.87 - l)-1,2,4- 1.34 (m, 16H), 1.31 (s,Compound Boronic Cmpd Structure / Starting reagent or LC / MS NMR (shifts in ppm) No. Compound Material amine if Name applicable oxadiazol-3-yl)- 3H), 2.10 (d, J = 13.6 4- Hz, 2H) ppm. methylpiperidine- 1-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 8.61 (s, 1H), 7.90 (dd, J = 7.7, 1.5 Hz, 1H), 7.74 (d, J = 7.0 Hz, 1H), 7.68 (dd, N-(2-cyano-6-(1- J = 7.8, 1.5 Hz, 1H), methyl-2-oxo- 7.50 (t, J = 7.8 Hz, 1H), ESI-MS 1,2- 6.37 (d, J = 1.9 Hz, m / z calc. dihydropyridin-4- 1H), 6.16 (dd, J = 7.0, 62 476. yl)phenyl)-4-(5- SM3 197, 2.0 Hz, 1H), 5.33 - 5.05 found ((1S,2S)-2- (m, 1H), 3.73 (d, J = 477.4 fluorocyclopropy (M+1)+14.1 Hz, 2H), 3.42 (s, . l)-1,2,4- 3H), 3.08 - 3.00 (m, oxadiazol-3-yl)- 2H), 2.65 - 2.58 (m, 4- 1H), 2.01 (d, J = 13.7 methylpiperidine- Hz, 2H), 1.80 (dtd, J = 1-carboxamide 23.2, 7.4, 3.5 Hz, 1H), 1.64 - 1.47 (m, 3H), 1.25 (s, 3H) ppm. 1H NMR (400 MHz, Mixture of 2 DMSO-d6) δ 8.50 (s, diastereomers 1H), 7.69 - 7.56 (m, 2H), 7.45 - 7.34 (m, 1H), 5.33 - 5.06 (m, 1H), 3.77 (d, J = 14.0 ESI-MS Hz, 2H), 3.15 (t, J = N-(2-cyano-6- m / z calc. 11.7 Hz, 2H), 3.08 - 439.238, 2.96 (m, 1H), 2.67 - 63 (pentan-2- SM8 yl)phenyl)-4-(5- found 2.57 (m, 1H), 2.09 (d, J ((1S,2S)-2- 440.5 = 13.6 Hz, 2H), 1.88 - fluorocyclopropy (M+1)+. 1.71 (m, 1H), 1.71 - l)-1,2,4- 1.51 (m, 3H), 1.51 - oxadiazol-3-yl)- 1.35 (m, 2H), 1.29 (s, 4- 3H), 1.25 - 1.14 (m, methylpiperidine- 1H), 1.14 - 1.04 (m, 1-carboxamide 4H), 0.79 (t, J = 6.4 Hz, 3H) ppm.Compound Boronic Cmpd Structure / Starting reagent or LC / MS NMR (shifts in ppm) No. Compound Material amine if Name applicable 1H NMR (400 MHz, DMSO-d6) δ 8.28 (s, 1H), 7.83 (d, J = 7.2 Hz, 1H), 7.56 - 7.40 (m, N-(3-cyano-3'- 2H), 7.00 (dd, J = 7.9, methoxy-2',4'- ESI-MS 3.5 Hz, 1H), 6.72 (d, dimethyl-[1,1'- m / z calc. 1H), 5.31 - 5.07 (m, bipheny 503.233, 1H), 3.63 (s, 3H), 3.60 - 64 l]-2-yl)- SM3 4-(5-((1S,2S)-2- found 3.50 (m, 2H), 2.96 - fluorocyclopropy 504.4 2.78 (m, 2H), 2.66 - (M+1+l)-1,2,4- ) . 2.57 (m, 1H), 2.19 (s, oxadiazol-3-yl)- 3H), 1.93 (s, 3H), 1.86 - 4- 1.69 (m, 3H), 1.64 - methylpiperidine- 1.49 (m, 1H), 1.31 - 1-carboxamide 1.17 (m, 2H), 1.16 - 1.11 (m, 3H) ppm. Example 2. Synthesis of Intermediates Provided herein is the synthesis of Intermediate SM4: tert-butyl 4-(3-amino-2- cyanopyridin-4-yl)piperidine-1-carboxylate. Scheme 46:- - tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)- carboxylate (45 g, 145.53 mmol) was added to a stirred mixture of 2,4-dichloro-3-nitropyridine (25 g, 129.54 mmol) and K2CO3(36 g, 260.48 mmol) in a mixture of 1,4-dioxane (225 mL) and water (25 mL) and nitrogen gas was passed through the mixture for 1 min. Pd(dppf)Cl2.DCM (5.2 g, 6.368 mmol) was added and the reaction mixture was stirred at 60 °C for 12 h. The reaction was cooled to ambient temperature. The mixture was filtered through a pad of Celite®and the filtrates were partitioned between EtOAc (200 mL) and water (100 mL). The organic layer was separated, washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 0 to 20 % EtOAc in hexanes) gave tert-butyl 2'- chloro-3'-nitro-3,6-dihydro-[4,4'-bipyridine]-1(2H)-carboxylate (38 g, 82%) as a pale yellow solid.1H NMR (400 MHz, DMSO-d6) δ 8.63 (d, J = 1.0 Hz, 1H), 7.70 (d, J = 5.16 Hz, 1H), 5.96 (s, 3.93 (s, 2H), 3.48 (t, J = 5.24 Hz, 2H), 2.33 (br s, 2H), 1.41 (s, 9H) ppm. ESI-MS m / z calc. 339.099, found 338.2 (M-1)-. Synthesis of tert-butyl 2'-cyano-3'-nitro-3,6-dihydro-[4,4'-bipyridine]-1(2H)-carboxylate K4[Fe(CN)6]·3H2O (223.76 g, 529.760 mmol) was added to a solution of tert-butyl 2'- chloro-3'-nitro-3,6-dihydro-[4,4'-bipyridine]-1(2H)-carboxylate (45 g, 132.440 mmol) in a mixture of 1,4-dioxane (540 mL) and water (60 mL) and nitrogen gas was passed through the mixture for 15 min. XPhos Pd G3 (11.210 g, 13.244 mmol) was added and the reaction mixture was heated at 145 °C for 16 h. The reaction was poured into water (5 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (370 g SiO2, 0 to 50% EtOAc in heptane) gave tert-butyl 2'-cyano-3'-nitro-3,6-dihydro-[4,4'-bipyridine]-1(2H)-carboxylate (18.9 g, 41%) as a pale yellow solid.1H NMR (400 MHz, DMSO-d6) δ 8.94 (d, J = 5.0 Hz, 1 H), 7.97 (d, J = 5.0 Hz, 1 H), 5.96 (br s, 1 H), 3.95 (br s, 2 H), 3.51 (t, J = 5.04 Hz, 2 H), 2.33 (br s, 2 H), 1.44 (s, 9 H) ppm. ESI-MS m / z calc. 330.133, found 329.1 (M-1)-. Synthesis of tert-butyl 3'-amino-2'-cyano-3,6-dihydro-[4,4'-bipyridine]-1(2H)-carboxylate Na2S2O4 (11.596 g, 66.600 mmol) was added to a stirred solution of tert-butyl 2'-cyano- 3'-nitro-3,6-dihydro-[4,4'-bipyridine]-1(2H)-carboxylate (5.5 g, 16.650 mmol) in a mixture of THF (120 mL) and water (60 mL) at 0 °C and the reaction mixture was heated at 50°C for 1.5 h. The reaction was quenched by addition of ice cold water and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (40g SiO2, 0 to 50% EtOAc in heptane) gave tert-butyl 3'-amino-2'-cyano-3,6-dihydro-[4,4'-bipyridine]-1(2H)-carboxylate (4.05 g, 75%) as a pale yellow solid.1H NMR (400 MHz, DMSO-d6) δ 7.85 (d, J =4.4 Hz, 1 H), 7.17 (d, J =4.4 Hz,1 H), 5.90 (br s, 2 H), 5.83 (br s,1 H), 4.02 - 3.9 (m, 2 H), 3.62 - 3.5 (m, 2 H), 2.3 - 2.2 (m, 2 H), 1.42 (s, 9 H) ppm. ESI-MS m / z calc. 300.159, found 301.1 (M+1)+. Synthesis of tert-butyl 4-(3-amino-2-cyanopyridin-4-yl)piperidine-1-carboxylate Pd / C (2 g, 10 wt% on carbon, 50% wet, 18.793 mmol) and Pd(OAc)2 (271.86 mg, 1.211 mmol) were added to a solution of tert-butyl 3'-amino-2'-cyano-3,6-dihydro-[4,4'-bipyridine]- 1(2H)-carboxylate (4 g, 12.109 mmol) and Et3N (612.65 mg, 0.844 mL, 6.055 mmol) in THF (60 mL). The reaction was degassed with nitrogen gas and the atmosphere was replaced by a hydrogen atmosphere. The reaction mixture was stirred at ambient temperature for 16 h under an atmospheric pressure of hydrogen. The mixture was filtered through a pad of Celite®, washing the filtered cake with EtOAc (3 x 500 mL). The filtrates were concentrated in vacuo. Purification by flash chromatography (40 g SiO2, 0 to 40% EtOAc in heptane) gave tert-butyl 4-(3-amino-2- cyanopyridin-4-yl)piperidine-1-carboxylate (SM4, 3.4 g, 90%) as pale yellow solid.1H NMR (400 MHz, DMSO-d6) δ 7.83 (d, J = 4.6 Hz, 1H), 7.25 (d, J = 4.6 Hz, 1H), 6.152H), 4.07 - 4.04 (m, 2H), 2.94 - 2.85 (m, 3H), 1.71 (d, J = 12.3Hz, 2H), 1.43 - 1.24 (m, 11H) ppm. ESI-MS m / z calc. 302.174, found 303.2 (M+1)+. The following Intermediate was made using the method described in Intermediate SM4, except that, in Step 1, 2-chloro-3-nitroisonicotinonitrile was used as the starting material in place of 2,4-dichloro-3-nitropyridine and the reaction was carried out at 90 °C. Step 2 was omitted. Step 3 was carried out at 55 °C: Table 5. Inter media LC / MS Found te Intermediate Name (m / zMNMR (shifts in ppm)Numb calc.)+1er 1H NMR (400 MHz, DMSO-d6) δ 7.77 (d, J = 5.0 Hz, 1H), 7.23 (d, J = tert-butyl 4-(3-amino- 4-cyanopyridin-2- 5.0 Hz, 1H), 6.22 (br s, 2H), 4.04 - SM1 302.174 4.02 (m, 2H), 3.17 - ine-1- 30 3.09 (m, 1H), yl)piperid 3.4 carboxylate 2.98 - 2.75 (m, 2H), 1.69 - 1.66 (m, 2H), 1.55 - 1.51 (m, 2H), 1.40 (s, 9H) ppm.Provided herein is the synthesis of Intermediate SM6: 3-amino-2-(6-oxa-2- azaspiro[4.5]decan-2-yl)isonicotinonitrile. The following Intermediate was made using the method described in Compound 41, except that, in Step 1, 6-oxa-2-azaspiro[4.5]decane was used as the starting material amine in place of azepane. Step 2 was omitted. Table 6. Inter media LC / MS te Intermediate Name (m / z Found NMR (shifts in ppm)Numb calc.)M+1er 3-amino-2-(6-oxa-2- SM6 azaspiro[4.5]decan-2- yl)isonicotinonitrile Provided herein is the synthesis of Intermediate SM7: 3-amino-4-(4-isopropyl-1H-1,2,3- triazol-1-yl)picolinonitrile. Scheme 47:Sodium ascorbate (297.83 mg, 1.503 mmol) and CuSO4.5H2O (187.69 mg, 0.752 mmol) were added to a solution of 4-azido-2-chloro-3-nitropyridine (500 mg, 2.506 mmol) and 3- methylbut-1-yne (700 mg, 10.276 mmol) in a mixture oftBuOH (2 mL) and water (0.5 mL) and the reaction mixture was stirred at ambient temperature for 24 h. The reaction was diluted with water (15 mL) and extracted with EtOAc (50 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo to give 2-chloro-4-(4-isopropyl-1H-1,2,3-triazol-1- yl)-3-nitropyridine (300 mg, 41%) as a yellow solid. ESI-MS m / z calc. 267.052, found 268.0 (M+1)+.Synthesis of 2-chloro-4-(4-isopropyl-1H-1,2,3-triazol-1-yl)pyridin-3-amine (BOH)2 (500 mg, 5.577 mmol) and 4,4′-bipyridine (1.5 mg, 0.010 mmol) were successively added to a stirred solution of 2-chloro-4-(4-isopropyl-1H-1,2,3-triazol-1-yl)-3- nitropyridine (500 mg, 1.800 mmol) in DMF (10 mL) and the reaction mixture was stirred at ambient temperature for 10 min. Water was added (15 mL) and the reaction mixture was extracted with EtOAc (4 x 30 mL). The combined organic extracts were washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (12g SiO2, 15 to 20% EtOAc in heptane) gave 2-chloro-4-(4-isopropyl-1H-1,2,3-triazol-1-yl)pyridin-3- amine (500 mg, 100%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 8.53 (s, 1H), 7.78 (d, J = 5.1 Hz, 1H), 7.53 (d, J = 5.2 Hz, 1H), 6.13 (br s, 2H), 3.09 (quint, J = 6.9 Hz, 1H), 1.32 (s, 3H), 1.31 (s, 3H) ppm. ESI-MS m / z calc. 237.078, found 238.1 (M+1)+. Synthesis of 3-amino-4-(4-isopropyl-1H-1,2,3-triazol-1-yl)picolinonitrile 2-chloro-4-(4-isopropyl-1H-1,2,3-triazol-1-yl)pyridin-3-amine (20 mg, 0.067 mmol) was treated via the method described in Intermediate SM4 Step 2 and the reaction was carried out at 130 °C to give, after purification by flash chromatography (4g SiO2, 40% EtOAc in heptane), 3-amino- 4-(4-isopropyl-1H-1,2,3-triazol-1-yl)picolinonitrile (SM7, 10 mg, 63%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.08 (d, J = 4.96 Hz, 1H), 7.79 (d, J = 4.96 Hz, 1H), 6.73 (s, 2H), 3.13 - 3.06 (m, 1H), 1.32 (d, J = 6.92 Hz, 6H) ppm. ESI-MS m / z calc. 228.112, found 229.2 (M+1)+. Example 3. Human OX2R IP1 assay The G protein-coupled protein receptor (GPCR) OX2R signals through the Gq / 11 signaling pathway. Activation of this pathway can be readily detected by measuring the accumulation of inositol monophosphate (IP-one or IP1) in the presence of excess LiCl. This can be quantified using the commercially available cell-based IP-One Gq kit (Revvity cat #: 62IPAPEB) coupled with a cell line expressing OX2R. IP1 generated within the cell by OX2R agonism competes with the IP1 analog coupled to a d2 fluorophore (FRET acceptor) for binding to an anti-IP1 monoclonal antibody labeled with Eu cryptated (FRET donor). The measured HTRF-FRET based signal is inversely proportional to the IP1 concentration produced.Tetracycline-inducible suspension human embryonic kidney cells stably expressing tet- responsive human OX2R (2F7-hOX2R) were generated by first transfecting Expi293F Inducible cells (ThermoFisher #A39241) with pcZeo TetO DNA containing hOX2R cDNA. In this plasmid, the TET operator sequences have been inserted between the TATA box of the CMV promoter and the transcriptional start site for OX2R. These cells were induced with 4 µg / mL doxycycline at 32˚C. After 24 hours of induction, cells were harvested, aliquoted, and cryopreserved in Expi293 medium containing 10% or 7.5% DMSO. On the day of the assay, cells are thawed, washed with PBS, and resuspended in 1X Cisbio stimulation buffer. Cells were then plated at a concentration of 6,000 or 5,000 cells / well into a 384-well assay plate containing test compounds to give a final concentration of 0.5% or 0.55% DMSO. Following a one-hour incubation at 37˚C, the reaction was terminated by addition of the Cisbio detection mix containing IP1-d2 and anti-IP1-cryptate in lysis buffer. Following a one-hour incubation at room temperature, HTRF-FRET values were measured using a Envision Multilabel Plate Reader (Perkin Elmer) and the data were expressed as the standard 665nm / 620nm ratio. Orexin 2 inhibition activity of exemplary compounds is provided in Table 3 below. EC50 Bins defined as *** = 0.01-1 nM; ** = 1-100 nM; and * = 100 – 1000 nM Table 3. Orexin 2 activation activity of exemplary compounds CompoundOX2R EC501*2**3*4**5**6**7*8*9*10**11*12*13**14*15***16*17************************************ *** ** ** ** *** ** *** ** * ** *** * *** ** *** ** *** ** ** ** * *** ** ** *61 ** 62 ** 63 ** 64 ** INCORPORATION BY REFERENCE All of the U.S. patents and U.S. and PCT patent application publications cited herein are hereby incorporated by reference. EQUIVALENTS Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims
WHAT IS CLAIMED IS:
1. A compound of Formula (I): , or a deuteratedor prodrug thereof, wherein: A is phenyl or 5- or 6-membered heteroaryl; R1is halo, cyano, —(C═O)NR5R6, —NR5R6, — NR5(C═O)—R7,— (C═O)O—R7,(C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, or 4-7 membered heterocycloalkyl; wherein (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, and 4-7 membered heterocycloalkyl are optionally substituted with one or more of R9; n is 0, 1, or 2; R2is independently for each occurrence selected from halo, cyano, —(C═O)NR5R6, — (C═O)O—R7, —SO2—R7, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, and 4-7 membered heterocycloalkyl; wherein (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6- C10)aryl, and 4-7 membered heterocycloalkyl are optionally substituted with one or more of R10; or R1and an adjacent R2taken together form a fused carbocyclic or heterocyclic ring optionally substituted with one or more of R10; X and Y are each independently a bond, —NR8—, —C(═O)—, —OC(═O)—, —SO—, —SO2—, —S—, —O—, or methylene optionally substituted with one or more (C1-C6)alkyl; where (C1-C6)alkyl is optionally substituted with one or more R11; R3is hydrogen, hydroxy, halo, cyano, or (C1-C6)alkyl optionally substituted with one or more R12, R4is (C6-C10)aryl, 5- to 10-membered heteroaryl, (C3-C8)cycloalkyl, 4- to 7-membered heterocycloalkyl, or cyano; wherein (C6-C10)aryl, 5- to 10-membered heteroaryl (C3- C8)cycloalkyl, 4- to 7-membered heterocycloalkyl, and 5- to 10-membered heteroaryl are optionally substituted with one or more R13, orwhen Y is a bond, R3and R4together with the carbon to which they are attached form a (C3-C6) spirocarbocylic ring or a 4- to 10-membered saturated heterospirocyclic ring; wherein each is optionally substituted with optionally substituted with one or more R12; R5to R7are each independently hydrogen, halogen, or (C1-C6)alkyl optionally substituted with one or more R14; R8is hydrogen or (C1-C6)alkyl optionally substituted with one or more R15; R9is independently for each occurrence selected from halo, hydroxy, (C1-C6)alkyl optionally substituted with one or more R16, (C3-C8)cycloalkyl optionally substituted with one or more R16, and (C1-C6)alkoxy optionally substituted with one or more R16; or two R9together with the atom or atoms to which they are attached taken together form a 3- to 8-membered carbocyclic or 3- to 8-membered heterocyclic ring, wherein each is optionally substituted with one or more R16; R10to R15are independently for each occurrence selected from halo, hydroxy, (C1- C6)alkyl optionally substituted with one or more R16, (C3-C8)cycloalkyl optionally substituted with one or more R16, and (C1-C6)alkoxy optionally substituted with one or more R16; R16is independently for each occurrence halo, hydroxy, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkylalkyl, or (C1-C6)alkoxy; Z1is oxygen or sulfur; Z2is oxygen or —NH—; Z3is —CH—, a nitrogen, or a carbon; and represents a single bond or a double bond.
2. The compound of claim 1, wherein A is phenyl.
3. The compound of claim 1, wherein A is 5- or 6-membered heteroaryl.
4. The compound of claim 3, wherein the 5- or 6-membered heteroaryl is pyridyl, pyrimidinyl, pyridazinyl, or pyrazinyl.
5. The compound of any one of claims 1 to 4, wherein R1is heterocycloalkyl.
6. The compound of claim 5, wherein the heterocycloalkyl is piperidinyl, piperazinyl, 1,2,3,6-tetrahydropyridine, pyrrolidinyl, azepanyl,or 1,4-diazepanyl.
7. The compound of any one of claims 1 to 6, wherein R1is substituted with one or more of R9; wherein R9is independently for each occurrence fluoro, chloro, hydroxy, (C1-C6)alkyl, (C3- C8)cycloalkyl, (C1-C6)alkoxy, (C1-C4)haloalkyl, or ((C3-C8)cycloalkyl)alkyl; or two R9together with the atom or atoms to which they are attached taken together form a 3- to 6-membered carbocyclic or 3- to 6-membered heterocyclic ring comprising 1 to 3 oxygen or nitrogen atoms, optionally substituted with one or more (C1-C6)alkyl.
8. The compound of any one of claims 1 to 7, wherein at least one R9is (C1-C6)alkyl.
9. The compound of any one of claims 1 to 8, wherein R1is: , ,10. The compound of claim 10, .
11. The compound of any one of claims 1 to 4, wherein R1is fluoro, chloro, or cyano.
12. The compound of any one of claims 1 to 4, wherein R1is (C1-C4)alkyl.
13. The compound of any one of claims 1 to 4, wherein R1is cyclopropyl.
14. The compound of any one of claims 1 to 4, wherein R1is optionally substituted phenyl.
15. The compound of any one of claims 1 to 4, wherein R1is optionally substituted heteroaryl.
16. The compound of any one of claims 1 to 4, wherein R1is oxadiazole optionally substituted with one or more (C1-C4)alkyl.
17. The compound of any one of claims 1 to 16, wherein n is 1 or 2.
18. The compound of claim 17, wherein n is 1 or 2, and R1and an adjacent R2taken together form a fused carbocyclic or heterocyclic ring of the following formula: ,wherein n’ is 0 or 1.
19. The compound of claim 18, wherein R1and an adjacent R2taken together form a fused heterocyclic ring of the following formula: .
20. The compound of any one of claims 1 to 19, wherein n is 1. 21 The compound of any one of claims 1 to 20, wherein at least one R2is fluoro, chloro, or cyano.
22. The compound of any one of claims 1 to 20, wherein at least one R2is optionally- substituted (C1-C6)alkyl, or optionally-substituted (C1-C6)alkoxy.
23. The compound of any one of claims 1 to 22, wherein X is a bond or —O—.
24. The compound of any one of claims 1 to 23, wherein R3is (C1-C6)alkyl optionally substituted with one or more fluorine.
25. The compound of claim 24, wherein R3is methyl.
26. The compound of any one of claims 1 to 25, wherein R4is optionally substituted 5- to 10- membered heteroaryl.
27. The compound of claim 26, wherein R4is: , whereinoxygen or sulfur; and R13is (C3-C8)cycloalkyl or (C3-C8)cycloalkoxy optionally substituted with one or more substituents selected from halo, (C1-C6)alkyl, and (C1-C6)alkoxy.
28. The compound of claim 27, wherein A4is oxygen.
29. The compound of claim 27 or 28, wherein R13is (C3-C8)cycloalkyl substituted with one or more halogen.
30. The compound of claim 29, wherein R13is: .
31. The compound of any one of claims 1 to 30, wherein Y is a bond or —O—.
32. The compound of any one of claims 1 to 31, wherein Z1is oxygen.
33. The compound of any one of claims 1 to 32, wherein Z2is —NH—.
34. The compound of any one of claims 1 to 33, wherein Z3is nitrogen.
35. A compound selected from the compounds described in Table 1 or Table 2, or a deuterated derivative,pharmaceutically acceptable salt, or prodrug thereof.
36. A pharmaceutical composition comprising a compound of any one of claims 1 to 35; and at least one pharmaceutically acceptable excipient.
37. A method of preventing or treating a disease selected from the group consisting of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptom, hypersomnia associated with Parkinson's disease, hypersomnia associated with dementia with Lewy body, hypersomnia syndrome involving daytime hypersomnia (e.g. Kleine-Levin syndrome, major depression accompanied by hypersomnia, dementia with Lewy body, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, brain contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, acute disseminated encephalomyelitis, Guillain-Barre syndrome, Rasmussen's encephalitis, Wernicke's encephalopathy, limbic encephalitis, Hashimoto encephalopathy), coma, loss of consciousness, obesity (e.g. malignant mast cell, extrinsic obesity, hyperinsulinar obesity, hyperplasmic obesity, hypophysial obesity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, childhood obesity, upper body obesity, alimentary obesity, gonadal obesity, systemic mastocytosis, primary obesity, central obesity), insulin resistance syndrome, Alzheimer, impaired consciousness such as coma, side effect or complication caused by anesthesia, sleep disturbance, sleep problem, insomnia, intermittent sleep, night myoclonus, REM sleep interruption, jet lag, jet lag syndrome, sleep disorder of shift workers, dyssomnia, sleep terror, depression, major depression, sleepwalking, enuresis, sleep disorder, Alzheimer's sundown syndrome, disease associated with circadian rhythm, fibromyalgia, condition resulting from decrease in sleeping quality, bulimia, obsessive eating disorder, obesity-related diseases, hypertension, diabetes, elevated plasma insulin level / insulin resistance, hyperlipemia, hyperlipidaemia, endometrial cancer, breast cancer, prostate cancer, colon cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstone, heart disease, abnormal heartbeat, arrhythmia, myocardial infarction, congestive heart failure, heart failure, coronary heart disease, cardiovascular disease, sudden death, polycystic ovary, craniopharyngioma, Prader Willi syndrome, Froehlich syndrome, growth hormone deficiency,normal variant short stature, Turner syndrome, children suffering from acute lymphoblastic leukemia, syndrome X, reproductive hormone abnormality, decrease of fecundability, infertility, hypogonadism in men, sexual / reproductive-function dysfunction such as hirsutism in women, fetal defect associated with maternity obesity, gastrointestinal motility disorder such as obesity- related gastroesophageal reflux, obesity hypoventilation syndrome (Pickwickian syndrome), respiratory disease such as respiratory distress, inflammation such as vascular systemic inflammation, arteriosclerosis, hypercholesterolemia, hyperuricemia, low back pain, gallbladder disease, gout, renal cancer, secondary risk of obesity such as risk of left ventricle hypertrophy, migraine, headache, neuropathic pain, Parkinson's disease, psychosis, schizophrenia, facial flushing, night sweat, disease in genitalium / urinary system, disease associated with sexual function or fecundability, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, posttraumatic stress disorder, separation anxiety disorder, social phobia, anxiety disorder, acute neurological and psychiatric disorder such as cerebral deficiency developed after heart bypass surgery or heart transplant, stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head injury, periparturient hypoxia, cardiac arrest, hypoglycemic nerve injury, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, eye damage, retinopathy, cognitive impairment, muscle spasm, tremor, epilepsy, disorder associated with muscle spasm, delirium, amnestic disorder, age- associated cognitive decline, schizoaffective disorder, paranoia, drug addiction, movement disorder, chronic fatigue syndrome, fatigue, medication-induced parkinsonian syndrome, Gilles de la Tourette syndrome, chorea, myoclonus, tic, restless legs syndrome, dystonia, dyskinesia, attention deficit hyperactivity disorder (ADHD), conduct disorder, urinary incontinence, withdrawal symptom, trigeminal neuralgia, hearing loss, tinnitus, nerve injury, retinopathy, macular degeneration, vomiting, cerebral edema, pain, bone pain, arthralgia, toothache, cataplexy, and traumatic brain injury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-35 or a composition of claim 36.
38. A method of preventing or treating a disease selected from the group consisting of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, andhypersomnia associated with dementia with Lewy body, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-35 or a composition of claim 36.
39. The method of claim 38, wherein the disease is narcolepsy.
40. The method of claim 38, wherein the disease is idiopathic hypersomnia.
41. The method of claim 38, wherein the disease is hypersomnia.
42. The method of claim 38, wherein the disease is sleep apnea syndrome.
43. The method of claim 38, wherein the disease is narcolepsy syndrome involving narcolepsy-like symptoms.
44. The method of claim 38, wherein the disease is hypersomnia associated with Parkinson's disease.
45. The method of claim 38, wherein the disease is hypersomnia associated with dementia with Lewy body.
46. The method of any one of claims 37 to 45, wherein the compound is administered orally.
47. The method of any one of claims 37 to 45, wherein the compound is administered parenterally.
48. The method of any one of claims 37 to 47, wherein the disease is prevented.
49. The method of any one of claims 37 to 47, wherein the disease is treated.
Citation Information
Patent Citations
Pulmonary administration of granulocyte colony stimulating factor
US5284656A
Pulmonary drug delivery system
US5451569A
Cycloalkyl urea derivative
WO2021107023A1
Phenyl urea derivative
WO2022250108A1
